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Abstract 
Phosphodiesterases are key enzymes in cyclic-nucleotide signalling pathways, regulating the 
levels of cAMP and cGMP in the cell. Cyclic nucleotides play an important role in regulating 
progression of the complex parasite life cycle. There are four Plasmodium PDEs, PDEα-δ. PDEβ 
has proved refractory to deletion and is predicted to be essential in asexual blood stages. PDEs 
α, γ and δ have been successfully disrupted in previous studies, which revealed stage-specific 
roles for PDEγ and PDEδ in the mosquito. PDEβ is a promising drug target due to the proven 
ability to create specific inhibitors for individual human PDEs (e.g. Viagra inhibits human PDE5), 
the established safety record of current inhibitors and the predicted essential nature of PDEβ in 
P. falciparum blood stages. The lack of useful reagents; knockout strains, tagged lines and 
recombinant proteins, has severely limited progress in this field. 
Conditional genetic disruption (required to study essential genes) is notoriously difficult in P. 
falciparum. This project has attempted to generate a conditional knock-out using the 
destabilisation domain system and the novel DiCre system, which involves recombinase-
mediated genomic excision of the target DNA upon introduction of a drug.  A PDEβ 
haemagglutanin (HA) tagged line has been successfully generated and used to investigate the 
cellular biology of PDEβ, including, the subcellular localisation and cyclic nucleotide specificity 
of PDEβ, which until now has remained speculative.   
A small library of PDE inhibitors generated by Pfizer has been evaluated using a parasite growth 
inhibition assay and a PDE assay, with compounds active at sub-micromolar concentrations 
against the parasite and the protein. These assays have used wild type parasites and also a PDEα 
KO line which has no obvious phenotype in blood stage parasites.   
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Chapter 1: Introduction 
Malaria represents a major public health issue across the world and was responsible for an 
estimated 207 million cases and 627,000 deaths in 2012, predominantly in sub-Saharan Africa, 
but also throughout the tropics.  As of 2013, 97 countries have confirmed malaria transmission 
with in excess of 3 billion people at risk of contracting this parasitic disease (WHO, 2013).  
Despite international and domestic funding increases over the last decade, in 2013 the total 
funds committed to malaria control were an estimated 2.5 billion USD.  This figure is less than 
half the predicted 5.1 billion USD required each year to reach universal coverage of control 
interventions (WHO, 2013).   
In humans the disease can be caused by several species of apicomplexan parasites in the genus 
Plasmodium, P. falciparum, P. vivax, P. malariae, P. ovale (P. ovale curtisi and P. ovale wallikeri 
(Sutherland et al., 2010)) and P. knowlesi.  Of these, P. falciparum causes the most severe 
manifestation of malaria.  These species differ in morphology, blood stage cycle length, disease 
severity, geographical distribution, relapse patterns and in their responses to drugs.  These 
protozoan parasites have a complex life cycle, involving two hosts, human and Anopheles 
mosquito, and numerous developmental stages.   
 
1.1 The history of malaria 
Malaria is not a newly documented disease and has a history extending into antiquity.  It is 
generally believed that human malaria originated in our primate ancestors and has been co-
evolving with us since.  In ancient writings from many regions of the globe, recurring fevers, 
characteristic of malarial infection, have been documented in many early civilisations including 
in China, the Roman Empire and the Arab world (Reviewed in Cox 2002).  The word malaria 
originated from Medieval Italian for ‘bad air’ from the association between the disease and 
marshes.  It was long thought malaria was caused by miasmas rising from the swamps.  In the 
19th century, after the advent of germ theory there was a race to find the causative agent of 
different infectious diseases.  In 1880, Alphonse Laveran, a French army surgeon, was the first 
to visualise parasites in the blood of infected patients using microscopy.  Subsequently in 1897, 
Ronald Ross, a British army surgeon, discovered that Anopheles mosquitoes were responsible 
for transmitting the disease and that the association with marshes was due to their habitat 
range.  In the same year the mosquito developmental stages were described by the Italian 
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scientists Giovanni Grassi, Amico Bignami, and Giuseppe Bastianelli.  The life cycles of P. 
falciparum, P. vivax and P. malariae were described a year later.  It was not until 1947 that 
London based Henry Shortt and Cyril Garnham described the liver stages of malaria, thereby 
explaining why parasites were not observed in the blood until 10 days post infection (Reviewed 
in Cox 2002).  In 1980, Krotoski et al. described a putative latent form of P. cynomolgi in rhesus 
monkey liver cells (Krotoski et al., 1980), later termed hypnozoites and their existence was 
confirmed in the human malaria P. vivax (Krotoski et al., 1982). 
 
1.2 Life cycle of Plasmodium species 
Malaria parasites are transmitted to humans through the saliva associated with the bite of an 
infected Anopheles mosquito.  There are at least 30 documented species of Anopheles that are 
of major importance in malaria spread, with a further 30 capable of transmission (Tuteja, 2007).  
Of the Plasmodium species that infect humans, P. falciparum causes the majority of fatalities 
worldwide and is most associated with drug resistance.  It is mostly found in sub-Saharan Africa, 
but is also prevalent in areas of Southeast Asia and South America.  P. vivax is the most common 
and is globally distributed.  P. malariae, P. ovale and P. knowlesi are the least common.  Whilst 
P. malariae is also found throughout the globe, P. ovale is restricted to West Africa and P. 
knowlesi is restricted to Southeast Asia (Singh et al., 2004).   P. vivax and P. ovale are able to 
form dormant liver stages, called hypnozoites, which can lead to relapses in disease from weeks 
to even years after the initial infection.  P. malariae can remain in the blood for decades as a low 
level asymptomatic infection (Tuteja, 2007). 
1.2.1 Exo-erythrocytic liver stages 
Human infection begins when an infected Anopheles mosquito takes a blood meal and injects 
motile infectious sporozoites into the skin.  The parasites are injected into the extracellular 
matrix of the skin as the mosquitoes probe for a blood vessel (Sidjanski and Vanderberg, 1997; 
Vanderberg and Frevert, 2004).  The sporozoites then invade blood or lymphatic vessels via 
which they are passively conveyed to the liver.  A parasite surface protein, circumsporozoite 
protein (CSP), binds to highly sulphated glycosamino glycan chains in liver heparan sulphate 
proteoglycans (HSPGs) on the host cell surface (Pradel et al., 2002) to invade hepatocytes inside 
a parasitophorous vacuole (PV).  Once inside a liver cell, the elongated sporozoite rounds up and 
undergoes schizogony, generating tens of thousands of liver merozoites.  The parasite is able to 
19 
 
control host cell death in such a way that the host cell membrane is preserved (Graewe et al., 
2011), forming vesicles called merosomes full of hundreds of merozoites and surrounded by the 
host cell membrane.  The merosomes then detach from the cell and bud off.  This is thought to 
immunologically protect the merozoites from the host’s immune system surveillance (Sturm et 
al., 2006).  Merosomes are transported by the blood into the narrow vessels in the lungs where 
they rupture, releasing merozoites which are able to initiate the blood stage infection (Baer et 
al., 2007).  From the initial bite to a blood stage infection, the entire process takes about 8-30 
days for human malaria, depending on the infecting species and only 2 days for rodent malaria 
(Hollingdale and Leland, 1982).  This is termed the prepatent period.   
1.2.2 Asexual erythrocytic stages 
Invasion of red blood cells (RBCs) by merozoites is a highly complex process that involves; initial 
recognition and attachment to the RBC membrane, tight junction formation, rhoptry and 
microneme secretion inducing formation of the PV, host cell invagination to enclose the 
merozoite and resealing of both the PV and the RBC membranes.   As one of the few extracellular 
life cycle stages, merozoites are attractive vaccine targets.  Asexual blood stage replication takes 
48 hours for P. falciparum, P. ovale, and P. vivax, 72 hours for P. malariae and 24 hours for P. 
knowlesi, as the parasites grow from early trophozoites, called ring-stages due to their 
distinctive morphology, through trophozoites to schizonts (figure 1.1).   
 
Figure 1.1 Giemsa staining of the major erythrocytic asexual stages of P. falciparum 
The image on the left shows a ring-stage parasite, the middle image is a trophozoites and a late 
stage schizont is shown on the right.    
 
The trophozoite phase is highly metabolically active, notably in the glycolysis of imported 
glucose, RBC cytoplasm ingestion and scavenging of amino acids from haemoglobin (Tuteja, 
2007).  Free haem is liberated during haemoglobin digestion which is toxic to the parasite via 
oxidative stress.  To combat this, haem is polymerised into crystalline haemozoin (malaria 
pigment) and stored in the food vacuole (Coronado et al., 2014).    
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Schizonts are formed as the parasite undergoes DNA replication and multiple rounds of nuclear 
division with no cytokinesis.  The schizonts undergo cytokinesis to form a number of merozoites 
(around 20, depending on the species), which are liberated on parasite egress, reinvade new 
RBCs and perpetuate the infection.  The molecular process of egress and invasion is discussed in 
more detail below.   
1.2.3 Sexual and mosquito stages 
A small percentage of parasites differentiate into sexual stage gametocytes, macro- and 
microgametocytes (female and male, respectively).  Whilst gametocytes are a dead end within 
the human host, they are essential for onward transmission.  Gametocytes are taken up by the 
Anopheles mosquito when they take a blood meal from an infected host.  Once inside the 
insect’s midgut, the drop in temperature and the mosquito factor xanthurenic acid (XA) triggers 
a change in morphology of the gametocytes, from crescent shaped to spherical with an 
accompanying loss of erythrocyte membrane (Billker et al., 1998).  This process is termed 
rounding up.  Whilst the female parasite does not undergo many morphological changes to form 
a macrogamete, the male parasite rapidly undergoes three rounds of replication, leading to the 
formation and release of eight highly motile microgametes in a process called exflagellation.  
The microgamete then penetrates the macrogamete, fusion and fertilisation occurs to form a 
zygote.  Within about 24 hours, the zygote transforms into a motile ookinete that is capable of 
moving by gliding motility which subsequently penetrates the midgut wall.  From there the 
ookinetes migrate to the basal sub-epithelial space and form replicating oocysts (Sinden, 2002; 
Vlachou et al., 2004).    
As the oocyst develops it becomes spherical, produces a thick cyst wall and proceeds to undergo 
many rounds of replication leading to the development of several thousand sporozoites within 
12-18 days.  As the oocyst ruptures, it liberates the motile sporozoites which migrate to the 
insects salivary glands (Sinden, 2002).  Once the sporozoites have reached the salivary glands 
the mosquito infects new vertebrate hosts upon each blood meal (Tuteja, 2007).   
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Figure 1.2 Life cycle of P. falciparum 
The main phases of the life cycle of Plasmodium falciparum parasites within the human host and 
insect vector (Bannister and Mitchell, 2003). 
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1.3 Pathogenesis 
The asexual blood stage replication of the malaria parasite is the cause of pathology within the 
vertebrate host.  Malaria symptoms can appear from around day six after a bite by an infected 
mosquito, to several months later, depending on the species of Plasmodium.  Infections can 
range from asymptomatic to life threatening, with clinical outcome dependent on numerous 
factors, many of which are currently unknown (Miller et al., 2002).  Symptoms of malaria are 
varying and include; fever, headache, shivering, sweating, cough, joint pain, vomiting, diarrhoea, 
with severe malaria symptoms of respiratory distress, convulsions, kidney failure, jaundice, 
coma and anaemia (Miller et al., 2002; Tuteja, 2007).  Progression to severe malaria is very 
poorly understood and involves three overlapping syndromes; severe anaemia, cerebral malaria 
and metabolic acidosis.  With severe malaria there is a mortality rate of up to 20%, and those 
that recover may still suffer from neurological sequelae after the infection is cleared (Miller et 
al., 2013).   
A major factor in the pathogenesis of P. falciparum is the ability of the infected RBCs (iRBCs) to 
adhere to small blood vessel linings, termed sequestration.  In particular, sequestration is a 
principle feature in cerebral malaria and pregnancy associated malaria with parasites binding to 
vascular endothelial cells in the brain and placenta, respectively.  Sequestration leads to 
blockage of blood flow and reduced tissue perfusion.  P. falciparum late trophozoites and 
schizonts and express the parasite ligand erythrocyte membrane protein 1 (PfEMP1) which is 
able to bind to various host cell receptors including CD36 and intracellular adhesion molecule 1 
(ICAM1) (Franke-Fayard et al., 2010; Roberts et al., 1992; Scherf et al., 2001).  Gametocytes are 
also sequestered in internal organs, however it is though that mechanical rather than adhesion 
properties regulate this interaction (Tibúrcio et al., 2012).    
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1.4 Treatment and control 
The treatment and control of malaria has a history spanning centuries rather than decades.  Prior 
to the development of germ theory in the mid-19th century, fevers (malarial or otherwise) were 
often treated with various different and usually ineffective approaches such as blood-letting or 
consuming large amounts of garlic (Meshnick and Dobson, 2001).  However, two herbal 
remedies utilised for fever treatment for hundreds of years are still greatly important in malaria 
control today, cinchona bark (quinine) and qinghao (artemisinin).  Whilst the story of the 
‘discovery’ of quinine is debated, whether it was a Spanish Countess in Peru who was cured 
using the bark or observations of a Jesuit missionary in South America, ground cinchona bark 
was certainly used to treat fever in Europeans by the late 17th Century, and possibly by the 
indigenous population before this (reviewed in Achan et al. 2011).  Quinine remained the 
principal treatment until the 1930s when synthetic malaria drugs were developed, chiefly 
chloroquine in 1934 by Hans Andersay, for the German pharmaceutical company Bayer AG.  
Chloroquine was hugely effective and was used extensively in the WHO Global Eradication 
Programme of the 1950s and 60s, until drug resistance in P. falciparum developed in South East 
Asia and spread to the majority of the malaria endemic world, rendering it ineffective.   However 
chloroquine is still commonly used to treat P. vivax malaria, often in combination with 
primaquine to target the liver hypnozoites (Thomé et al., 2013).  Many other antimalarials were 
discovered in the period from 1940-1970, including pyrimethamine-sulphadoxine combination, 
marketed as Fansidar and atovaquone-proguanil, sold as Malarone (Meshnick and Dobson, 
2001).  Artemisinin, from the qinghao herb (Artemisia annua, also called sweet wormwood) was 
used for thousands of years in Chinese herbal medicine, originally for haemorrhoids.  In 1596, a 
Chinese herbalist wrote about its use as a treatment for fever (Klayman, 1985).  In the People’s 
Republic of China, in the late 1960s, qinghaosu (qinghao essence) was found to be extremely 
effective as an antimalarial (Meshnick and Dobson, 2001), and with the opening up of China in 
the late 1970s to early 1980s, the artemisinins were soon in clinical trials and they have been 
the frontline treatment for P. falciparum malaria since the 1990s (Miller and Su, 2011).   
Antimalarial drugs cover only a few unique classes, with many of the compounds acting on the 
parasites ability to degrade haemoglobin.  Resistance is therefore a major problem and generally 
develops within a short time from drug introduction.  Resistance has developed in P. falciparum 
to every major class of antimalarial so far introduced, with the possible exception of artemisinin 
combination therapy (ACTs) where delayed clearance times have been recorded, but with no 
full treatment failure as yet (Noedl et al., 2008).   
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1.4.1 Amino alcohols 
Quinine is an alkaloid, belonging in the aryl amino alcohol group of drugs, with schizonticidal 
activity against blood stages of all species of human malaria.  The mechanism of action remains 
unknown, although it seems likely to interfere with haem metabolism (Hoppe et al., 2004).  
Quinine resistance occurs mostly in Southeast Asia, and is associated with amplification of the 
pfmdr1 (Plasmodium falciparum multidrug resistance gene 1) locus, a transporter in the food 
vacuole membrane (Schlitzer, 2008).  There are significant side effects of quinine, including 
tinnitus, vomiting and hypoglycaemia.  However it remains an important drug in treatment 
during the first trimester of pregnancy and as a second line treatment for severe malaria (Achan 
et al., 2011).  Other aryl amino alcohols used for antimalarial therapy include mefloquine, 
lumefantrine and halofantrine.    
1.4.2 4-Aminoquinolines  
The 4-Aminoquinolines include chloroquine and its derivatives (e.g. amodiaquine, piperaquine) 
which act on the asexual blood stages of malaria.  The mechanism of action has not been 
conclusively proven, but current consensus is that the drugs prevent polymerisation of toxic 
haem products into inert haemozoin in the digestive vacuole of the developing parasite, 
although via a different mechanism to quinine derivatives (Griffin et al., 2012; Hoppe et al., 
2004).  Chloroquine is known to accumulate in the digestive vacuole and raise the internal pH 
(Homewood et al., 1972).  However, in chloroquine resistant P. falciparum, this accumulation is 
much less in comparison to chloroquine sensitive strains, suggesting an efflux based resistance 
mechanism.  The two genes, pfcrt (Plasmodium falciparum chloroquine resistance transporter) 
and pfmdr1 have been implicated in chloroquine resistance (Krogstad et al., 1987; Peel, 2001).  
Amodiaquine can be used against chloroquine tolerant, but not highly-resistant P. falciparum.  
However, it has serious adverse effects when used over a prolonged period of time, but is still 
used in endemic regions (Schlitzer, 2008).   
1.4.3 8-Aminoquinolines 
 Primaquine and tafenoquine (still in development), among others are examples of 8-
aminoquinolines.  Primaquine is currently the only drug available that can clear hepatocyte and 
sexual stages of the parasite.  It is used to kill liver stage hypnozoites in P. vivax infections (Wells 
et al., 2010).  However, primaquine is contraindicated in people with G6PD (glucose-6-
phosphate-dehydrogenase) deficiency, in whom it can cause life-threatening haemolysis of 
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RBCs.  Unfortunately G6PD deficiency is relatively common in much of Africa and parts of Asia 
(Taylor and White, 2004).    
1.4.4 Endoperoxides 
The current WHO recommended treatment is artemisinin combination therapy (ACT) (WHO, 
2013).  The most commonly used artemisinin derivatives are artemether and artesunate.  These 
compounds are hemisynthetic, initially dihydroartemisinin is obtained from the Artemisia annua 
plant and methylated or acylated to the commercial prodrug form.  When administered, the 
compounds are rapidly reverted to dihydroartemisinin which is extremely potent, but has a very 
short half-life of approximately 40-60 minutes (Haynes, 2001).  Artemisinins kill asexual parasites 
and gametocytes, thereby providing some transmission blocking potential (Abay, 2013).  
However, they are not effective at killing liver stages of the parasites (Meshnick et al., 1996).  
The exact mode of action of artemisinins is still under debate, although it appears to rely on the 
endoperoxide bridge structure.  Studies have shown various effects of artemisinins on the 
parasites including haem alkylation, inhibition of sarcoplasmic/endoplasmic reticulum Ca2+ 
ATPase, interference with transporter proteins, depolarisation of the mitochondrial membrane 
and increased levels of reactive oxygen species (Golenser et al., 2006; Müller and Hyde, 2010), 
however no overall consensus has emerged.   
Although there has been no clinically relevant resistance reported, delayed parasite clearance 
times have been described in P. falciparum infections at the Thai-Cambodian border (Noedl et 
al., 2008).  Studies have shown that delayed parasite clearance times are associated with 
reduced susceptibility of ring-stages to artemisinin derivatives.  A combination of stage-specific 
lag time and the short half-life of artemisinins could be a mechanism for developing resistance 
(Klonis et al., 2013).  Until recently there was no obvious candidate for a molecular marker of 
resistance to artemisinin, however, a recent study has shown that kelch (K13-) propeller 
polymorphisms are linked to resistance both in vitro and in vivo.  A drug sensitive strain of P. 
falciparum was grown in culture for five years with intermittent exposure to artemisinin, after 
which the proportion of parasites surviving a treatment increased from 0.01 to over 10%.  Whole 
genome sequencing of this strain and the non-treated control strain was compared to the 
sequences of Cambodian isolates and this single K13 gene was identified.   (Ariey et al., 2014).   
1.4.5 Antifolates 
Pyrimethamine and proguanil (metabolised to active drug cycloguanil) inhibit parasite 
dihydrofolate reductase (DHFR) activity of the bifuctional DHFR-thymidylate synthetase (TS) 
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enzyme.  DHFR is found in both the host and the parasite and is essential in almost all organisms 
to reduce dihydrofolate to tetrahydrofolate to provide folates for many essential one-carbon 
transfer reactions, including DNA synthesis (Hyde, 2005).  DHFR inhibitors must therefore be 
highly specific to the parasite protein, but not the human DHFR to minimise collateral effects.  
Sulpha drugs, such as sulphadoxin and sulphonamide, affect dihydropteroate synthetase (DHPS) 
activity of the hydroxymethylpterin pyrophosphokinase (HPPK)-DHPS protein, which is 
responsible for de novo synthesis of folate coenzymes in the parasite (Müller and Hyde, 2010).  
If monotherapy is used, then parasites can quickly develop resistance, however combination 
therapy of DHFR and DHPS inhibitors proves synergistic and is much less prone to resistance.  
The combination of sulphadoxin-pyrimethamine (SP, Fansidar™), introduced in the 1960s, has 
been of long-term use (Hyde, 2007).  It is most widely used in intermittent preventive treatment 
(IPT) for pregnant women and children.  IPT is a curative dose of SP to all individuals in a cohort 
(pregnant women or infants) in areas of high transmission, regardless of whether they are 
infected with malaria or not (Warsame et al., 2010).   
1.4.6 Antibiotics 
The apicoplast is a prokaryotic derived organelle, biochemically similar to bacteria cells, that is 
essential to Plasmodium spp. ((Goodman and McFadden, 2013) and described further in chapter 
1.6).  This allows use of some antibiotics, notably doxycyclin and clindamycin, that inhibit 
proteins present in both organisms (Schlitzer, 2008).  Doxycyclin is a member of the tetracycline 
class of antibiotics, and in prokaryotes it inhibits protein synthesis.  In Plasmodia spp., doxycyclin 
specifically blocks expression of apicoplast genes, with non-functional apicoplasts dispensed 
into the dividing merozoites (Dahl et al., 2006).  Clindamycin is a lincosamide antibiotic, derived 
from lincomycin, that is also a translation blocker in bacteria.  Studies in the related 
apicomplexan parasite Toxoplasma gondii have also identified the apicoplast 70S ribosome as 
the target of clindamycin (Camps et al., 2002).  In vitro assays with both doxycyclin and 
clindamycin have shown that they produce a ‘delayed-death phenotype’.  Parasites that have 
been treated with these compounds are able to develop normally, produce daughter 
merozoites, egress and invade new RBCs, however these daughter cells are unable to maintain 
growth and die shortly after invasion.  This phenomenon is apparent even if the drug is removed 
prior to egress (Dahl and Rosenthal, 2008).  The apicoplast appears morphologically normal for 
the first replication cycle, but is unable to elongate into the typical branching pattern seen in 
healthy cells (Dahl et al., 2006).   
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Due to the slow parasite killing nature of these apicoplast inhibitors, both doxycyclin and 
clindamycin must be used in combination with faster acting antimalarials such as quinine or 
artesunate for treatment.  Doxycyclin is widely used as prophylaxis especially in areas where, for 
example, resistance to mefloquine is prevalent (Shanks and Edstein, 2005).  Unfortunately, it is 
contra-indicated in young children and pregnant women as it can be incorporated into 
developing teeth and bones, in such cases clindamycin can be used.  Clindamycin is unsuitable 
for use as a prophylactic due to its short half-life (Schlitzer, 2008).   
1.4.7 Others drugs 
Atovaquone is a broad spectrum antiparasitic that is used clinically with proguanil, an antifolate, 
under the brand name Malarone™, often used as chemoprophylaxis for travellers.  Atovaquone 
inhibits electron transfer in the mitochondria by acting as a structural analogue to coenzyme Q 
in the respiratory chain, leading to loss of membrane potential and preventing pyrimidine 
biosynthesis (Srivastava et al., 1997).  Specifically, atovaquone stops movement of the iron-
sulphur protein subunit from cytochrome b, preventing electron transfer from cytochrome b-
bound ubihydroquinone to cytochrome c1 of the cytochrome bc1 complex (Mather et al., 2005).  
A single nucleotide point mutation in the cytochrome b gene can confer complete resistance to 
atovaquone (Srivastava et al., 1999).  Although this should not be a problem clinically as 
atovaquone is always used as a prophylactic.   
The chemical family of spiroindolones are an example of new antimalarial agents that were 
developed from phenotypic screening by Novartis.  The compound NITD609 was generated after 
lead compound optimisation from a natural product library of 12,000 molecules.  NITD609 has 
strong in vitro and in vivo potency and is potentially suitable for single-dose cure (Rottmann et 
al., 2010).  The vacuolar proton pump PfATP4 has been identified as the molecular target.  
PfATP4 regulates sodium homeostasis which is essential to parasite survival (Spillman et al., 
2013).  NITD609 is currently in Phase II clinical trials (Gamo, 2014).   
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1.4.8 Vector control 
Vector control is currently the most effective form of malaria prevention worldwide, particularly 
in regions with endemic high transmission.  Interventions such as distribution of long-lasting 
insecticide treated nets (LLINs), indoor residual spraying (IRS) and larval source management, 
amongst others, have contributed to large reductions in the incidence of malaria cases over the 
past decade (Hemingway, 2014).  Although 12 WHO approved insecticides exist in four different 
chemical classes (organochlorines, organophosphates, carbamates and pyrethroids), currently 
pyrethroids are used in all LLINs and the majority of IRS operations (WHO).  As with the 
antimalarial drugs, huge selection pressure has driven the development of insecticide resistant 
mosquitoes thereby generating a major threat to vector control, particularly in Africa where 
resistance is widespread (Ranson et al., 2011).   Whilst there are several new compounds in 
various chemical classes in the pipeline, it will be some years before they reach the market 
(Hemingway, 2014).   
1.4.9 Vaccines 
Since the demonstration of the protective immunity of attenuated sporozoites inoculated into 
mice (Nussenzweig et al., 1967) and humans (Clyde et al., 1973) in the late 1960s to early 1970s, 
the promise of a protective vaccine seemed high.  However, despite decades of research, there 
is still no effective vaccine.  The complex life cycle and huge genetic variability of Plasmodium 
parasites has seriously impeded development (Thera and Plowe, 2012).   
In endemic moderate to high transmission regions, natural protective immunity to disease 
develops with repeated exposure to the parasites.  Newborns and very young infants are initially 
protected by maternal antibodies (Hviid and Staalsoe, 2004).   The highest at risk population 
tends to be children who are in the process of developing acquired immunity.  Adults are 
generally semi-immune, whilst they do not acquire sterilising immunity (infection and a 
detectable parasitaemia can be frequently observed), they are protected from clinical symptoms 
(Doolan et al., 2009).  Another at risk population is women pregnant with their first child as they 
lack antibodies to placenta-specific cytoadherance antigens (Menendez, 2006).    
There are several approaches that are being attempted in order to develop a useful vaccine, pre-
erythrocyctic, blood stage and transmission blocking.  Pre-erythrocytic vaccines could target the 
sporozoite or liver stages, and if 100% effective could prevent both clinical disease and 
transmission.  The vaccine candidate RTS,S/AS01,the most advanced vaccine candidate to date 
for P. falciparum, is predicted to give a protective efficacy of around 30-50% (Agnandji et al., 
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2011, 2012).  A recent study has found that at 18 months post-immunisation, vaccine efficiency 
against clinical malaria in children after three doses of the vaccine was 46% (2014).  The RTS,S 
vaccine is comprised of a C-terminal section of the P. falciparum circumsporozoite protein (CSP), 
a sporozoite surface protein, conjugated to  a hepatitis B virus S antigen, which forms virus-like 
particles (Riley and Stewart, 2013).  As RTS,S is only partially effective, it is not a useful 
transmission blocking strategy.  The use of live attenuated sporozoites has been studied 
extensively.  However huge hurdles exist in using this approach, including intravenous injection, 
safety, production and storage of live parasites, and not least that protection is often strain 
specific (Epstein and Richie, 2013).   
Blood stage vaccines could be used to prevent clinical disease by targeting merozoites or iRBCs.  
Whilst it is unlikely sterilising immunity can be achieved, these vaccines could still be useful in 
preventing morbidity and mortality (Riley and Stewart, 2013).  Potential merozoite candidate 
proteins include merozoite surface protein 1 (MSP-1), merozoite surface protein 2 (MSP-2) and 
apical membrane antigen 1 (AMA-1), although trials so far have only produced allele specific 
protection, with no cross reactivity (Genton et al., 2002; Thera et al., 2011).  However, since the 
discovery of the RBC antigen basigin as an essential invasion receptor for P. falciparum 
merozoites, its ligand, reticulocyte-binding protein homolog 5 (PfRh5) has been under the 
spotlight (Crosnier et al., 2011).  PfRh5 has been shown to be highly susceptible to cross-strain 
neutralizing vaccine-induced antibodies (Douglas et al., 2011)by blocking the tight attachment 
of merozoites to the RBC surface by inhibiting its interaction with basigin (Douglas et al., 2014).  
A recent study has identified P. falciparum schizont egress antigen-1 (PfSEA-1) as a parasite 
antigen expressed on the surface of the iRBC that has potential as a vaccine candidate.  In vitro, 
antibodies against PfSEA-1 are able to prevent schizont rupture.  Vaccination of mice with 
recombinant P. berghei SEA-1 demonstrated longer survival and reduced parasitaemia when 
challenged with a lethal dose of P. berghei parasites.  In addition, in two cohorts of individuals 
from malaria endemic regions in east Africa, presence of antibodies against PfSEA-1 were 
associated with protection against parasitaemia and severe disease (Raj et al., 2014).  These data 
suggests that PfSEA-1 might be a good target for vaccine development for erythrocytic stages of 
the life cycle.    
Vaccines specifically preventing transmission are somewhat of a controversial idea, but would 
have a huge positive impact on global public health.  Targeting the sexual stages of the parasite 
lifecycle would reduce transmission and ultimately prevent disease by providing herd immunity 
to a population, but would not provide clinical protection to the immunised individuals.  This 
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could make regulation and acceptance of the vaccine more complex (malERA Consultative 
Group on Vaccines., 2011).  Gamete surface proteins are significantly more conserved than 
erythrocytic and pre-erythrocytic stages, and therefore more likely to give broader immunity 
than strain specific merozoite surface proteins, for example.  Unquestionably, a multistage 
vaccine to prevent clinical disease and transmission, with no potential for breakthrough would 
be ideal.   
 
 
1.5 Overview of Plasmodium genomics 
Plasmodium parasites are single-celled eukaryotic protozoa of the Apicomplexa phylum which 
also includes the causative agents of, babesiosis (Babesia sp.), cryptosporidiosis 
(Cryptosporidium parvum), coccidiosis (Eimeria sp.), East Coast fever (Theileria parva), tropical 
theileriosis (Theileria annulata) and toxoplasmosis (T. gondii). 
The first draft of a malaria genome (P. falciparum) was published in 2002, using a whole 
chromosome shotgun sequencing approach (Gardner et al., 2002).   Human malaria genomes 
are haploid with 14 nuclear chromosomes, an approximately 6- kilobase (kb) mitochondrial and 
a 35-kb apicoplast genome (Gardner et al., 2002).   The P. falciparum 3D7 genome is currently 
estimated to contain 23.33 megabase pairs, with 5398 protein coding genes.  The P. vivax Sal-1 
genome is 27.01 megabases with 5530 protein coding genes (genome version: 2013-03-01, 
http://plasmodb.org/plasmo/).  Approximately half of the genome has no sequence homology 
with other studied model organisms, with many coding regions annotated as hypothetical 
proteins.  At present, the genome of P. falciparum remains the most AT-rich discovered at over 
80% on average and rising to 95% in intergenic regions and introns (Le Roch et al., 2012).  About 
31% of the genome is predicted to encode membrane spanning proteins, with a lower 
percentage of multispanning membrane proteins compared with other eukaryotes (Gardner et 
al., 2002).  Gene regulation in Plasmodium species is only beginning to be elucidated.  It appears 
to be complex and with little homology to other known eukaryote systems.   
The centromeres of all P. falciparum chromosomes have been mapped and generally correspond 
to a roughly 2 kb, highly repetitive and AT-rich, length of sequence (Kelly et al., 2006).  P. 
falciparum chromosomes show considerable variation in length and polymorphism between 
isolates, presumably due to a combination of frequent chromosome breakage and healing 
(Scherf et al., 1992) and meiotic recombination in the mosquito (Hinterberg et al., 1994).  
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Epigenetic regulation by chromosome architecture changes is extremely important in the 
transcriptional regulation of Plasmodium parasites.  Throughout the erythrocytic stage of its 
lifecycle, the parasite’s genome is mostly retained as open, unstructured eucharomatin.  There 
are stretches of heterochromatin dispersed throughout the genome, regulating expression of 
various genes involved in crucial pathogenic processes such as invasion, antigenic variation and 
environmental stress responses (Duffy et al., 2013).  Many of the genes involved in antigenic 
variation are located in the telomeric and subtelomeric regions of the chromosomes, and are 
regulated epigenetically.  P. falciparum contains three highly variable gene families, stevor , rifin 
and var, coding for proteins known as, sub-telomeric variable open reading frame (stevor), 
repetitive interspersed family (rifin) and erythrocyte membrane protein 1 (PfEMP1) (Wickstead 
et al., 2003).  In each parasite, only one PfEMP1 variant is active at any time (Scherf et al., 1998).  
Infrequently, a reversible switch to an alternative antigen will occur, leading to evasion of the 
adaptive immune response allowing the parasite to persist within the host (Deitsch et al., 2009).  
The histone modifications H3K36me3 and H3K9me3 are primarily responsible for maintaining 
heterochromatin mediated silencing around the virulence genes (Duraisingh et al., 2005; Jiang 
et al., 2013).  The ApiAP2 transcription factor PfSIP2 is implicated in this process (Flueck et al., 
2010).  Two recent studies have highlighted a link between the epigenetic machinery of var gene 
switching and the commitment to sexual stages.  Conditional knockdowns of two components 
of P. falciparum epigenetic machinery, heterochromatin protein 1 (PfHP1) (Brancucci et al., 
2014)and histone deacetylase 2 (PfHda2) (Coleman et al., 2014), leads to derepression of var 
genes and other virulence associated genes.  Additionally there is derepression of the AP2-G 
transcription factor (see next paragraph) leading to a three-fold increase in the gametocyte 
switching rate (Flueck and Baker, 2014).   
When the P. falciparum genome was first published in 2002, about 60% of the genes had 
insufficient similarity to those in other sequenced species to be able to assign a function.  In 
addition, there were comparatively few genes that could be assigned to the categories ‘cell 
organisation and biogenesis’, ‘transcription factors’ and ‘cell cycle’ proteins (Gardner et al., 
2002).  Rather than this being a result of fewer genes, it is likely to be a result of substantial 
evolutionary divergence from other sequenced species.  Indeed, apicomplexan AP2 (ApiAP2) 
transcription factors in Plasmodium have recently been identified as major regulators of 
Plasmodium gene expression (Campbell et al., 2010).  They are related to plant transcription 
factors (Jofuku et al., 1994).  P. falciparum is predicted to contain 27 ApiAP2 factors, containing 
1-3 AP2 DNA binding domains (Balaji et al., 2005; Campbell et al., 2010).  Expression of the 
ApiAP2 genes is developmentally regulated, with different genes active at different stages of the 
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parasite’s erythrocytic lifecycle.  In addition, they appear to be able to regulate their own 
expression, forming an interaction network throughout the developmental stages (Campbell et 
al., 2010).  The DNA binding motifs of each ApiAP2 protein have been predicted and the function 
of each protein is beginning to be elucidated.  One such transcription factor, AP2-G (PFL1085w), 
has recently been found to be essential in the switch from asexual blood stages to gametocyte 
stages (Kafsack et al., 2014; Sinha et al., 2014).   
All of the currently identified transcription factors in P. falciparum account for less than 2% of 
the total genome, which is approximately half the number predicted to be required for a classical 
transcription factor-mediated model of gene regulation (Coulson et al., 2004; Le Roch et al., 
2012).  Therefore there are either elusive transcription factors yet to be found or gene regulation 
in Plasmodium is mediated via alternative means (Le Roch et al., 2012).   
Studies have indicated that post-transcriptional and post-translational modifications are 
widespread in P. falciparum (Foth et al., 2008).  mRNA to protein production analysis shows a 
substantial delay for some genes, suggesting that post-transcriptional modification may be 
crucial for parasite development (Hall et al., 2005; Le Roch et al., 2004).  One particular example 
is the repression of female blood stage gametocyte mRNA, which forms a complex with the 
DDX6-class RNA helicase, DOZI (development of zygote inhibited).  These translationally 
repressed complexes are stored in cytoplasmic bodies for translation post-fertilisation (Mair et 
al., 2006).  Post-translational modifications including proteolytic cleavage, phosphorylation, 
myristoylation, acetylation, glycosylation and ubiquitination, are prevalent in the regulation of 
protein activity in Plasmodium species (Foth et al., 2008).  One major example is the proteolytic 
cleavage of various merozoite surface antigens, an essential step in RBC invasion (Blackman et 
al., 1994).  This will be discussed in greater detail in chapter 1.8.    
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1.6 Cellular organisation in erythrocyte stages of P. falciparum 
During the asexual blood stage of the life cycle, the parasite resides within an erythrocyte.  
Erythrocytes are terminally differentiated cells, lacking all intracellular organelles, unable to 
perform protein or lipid synthesis and lacking endocytic machinery (Haldar et al., 2002). In some 
respects this is an advantage for the parasite, RBCs are unable to present antigens on their 
plasma membrane due to a lack of MHC molecules, reducing the chance of T-cell recognition by 
the immune system, and have a ready supply of protein in the form of haemoglobin. However, 
the parasite needs to invade, survive and prevent splenic clearance of RBCs with altered 
deformability and antigenicity.     
Merozoite stages have been extensively studied for many years.  They are the only extracellular 
blood stage and therefore have been a major target for vaccine development.  Merozoites are 
amongst the smallest known eukaryotic cells at about 1.6 µm long, similar dimensions to a large 
bacterium, oval shaped with a flat apical projection (Langreth et al., 1978).  The apex contains 
many secretory organelles for invasion (rhoptries, micronemes, and exonemes), and 
cytoskeletal elements (polar rings).  The merozoite is surrounded by three membranes, the 
outer plasma membrane (PM) and two inner membranes (the inner membrane complex, IMC), 
forming the pellicle, onto which microtubules are attached.  The nucleus is at the basal side and 
there is a single mitochondrion and an apicoplast plastid (Bannister and Mitchell, 2009) (figure 
1.3, image A).     
The rhoptries, micronemes, dense granules and exonemes are vesicles that discharge their 
contents prior to and during invasion to prime the parasite cell and the RBC for entry.  There are 
two rhoptries that contain host cell recognition and invasion proteins, as well as lipids to help 
establish the parasitophorous vacuole that the parasite will reside in (Kats et al., 2006).  
Micronemes have overlapping functions with rhoptries, but contain distinct additional adhesins 
for host cell identification and attachment, as well as proteins involved in gliding and invasion 
(Dowse and Soldati, 2004).  Exonemes have been more recently identified as vesicles involved 
in RBC egress and invasion, distinct from the previously mentioned dense granules.  Exonemes 
discharge PfSUB1 protease leading to destruction of the parasitophorous vacuole and RBC 
membrane, in addition to priming merozoite surface proteins for invasion (Janse and Waters, 
2007; Yeoh et al., 2007).  The precise mechanism of egress and invasion is discussed in chapters 
1.7 and 1.8. 
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Post-invasion, the parasite flattens into a cup-shaped early trophozoite, called a ring-stage due 
to the ring-like structural appearance visible in Giemsa stained blood smears.  The ring-stage is 
typically formed of a thick outer periphery, containing the majority of the organelles, and a thin 
central portion.  The endoplasmic reticulum is close to the nucleus, with small clusters of rough 
and smooth ER and a Golgi body (Bannister et al., 2000) (figure 1.3, image B).   
The parasite will begin to consume the host cell haemoglobin, with degradation mostly occurring 
within the digestive vacuole of the parasite.  The digestive vacuole is an acidic environment, with 
a pH of between 5.0-5.4, maintained by a ATPase pump induced proton gradient (Klonis et al., 
2007).  Haemoglobin is digested not only for a source of amino acids, but also potentially for 
lysis prevention or to facilitate the increase in parasite cell volume (Ginsburg, 1990).  The 
aspartic proteases plasmepsin I and plasmepsin II, along with a cysteine protease falcipain, have 
been implicated in haemoglobin degradation (Coronado et al., 2014; Gluzman et al., 1994).  How 
the toxic product of haemoglobin degradation, haem, is converted to the inert haemozoin is, at 
present, unknown (Coronado et al., 2014).   
As the parasite grows, it loses its ring-like structure and begins to take up more of the volume 
of the host cell, becoming a trophozoite.  Haemoglobin degradation is most active during 
trophozoites stages, forming a large brown vacuole full of haemozoin.  The number of ribosomes 
and size of the ER increases markedly and the mitochondrion and apicoplast lengthen.  As the 
parasite ages, there is increased protein export into the RBC cytosol and surface, often to 
membranous clefts on the cell plasma membrane (figure 1.3, image C).  Some of these proteins 
are associated with parasite sequestration (Bannister et al., 2000).   
Parasites are defined as schizonts after the initiation of nuclear division, roughly 36 hours post 
invasion.  Plasmodium spp. divide by schizogony, firstly the nuclei replicate asynchronously in 
several rounds of mitosis, with the last round synchronous for all nuclei coinciding with assembly 
of the daughter merozoites (Francia and Striepen, 2014).  During schizogony, the amount of 
ribosomes and rough ER increases greatly, the mitochondria and apicoplast multiply and large 
lipid vacuoles accumulate (figure 1.3, image D).  The merozoites assemble in an ordered manner, 
beginning with the apical organelles.  The cytoskeleton assembles and a single nucleus, 
mitochondrion and apicoplast move into each merozoite.  A constriction ring segregates each 
merozoite from the schizont residual body.  Finally the PV membrane and the RBC membranes 
rupture and the merozoites are liberated into the blood stream, ready to infect new 
erythrocytes and perpetuate the infection (Bannister et al., 2000).   
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Figure 1.3 The main stages of the asexual blood cycle of Plasmodium falciparum.  
Drawings depicting the ultrastructure of P. falciparum asexual blood stages.  A. Merozoite stage 
B. Ring stage trophozoites C. Mid-trophozoite D. Late stage schizont with budding merozoites 
(Bannister et al., 2000) 
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Apicomplexan mitochondria are highly divergent in terms of both the organisation and their 
genomic content (Vaidya and Mather, 2009).  The mtDNA of malaria parasites is just 6 kb in 
length and encodes only three genes, cytochrome c oxidase subunit 1 (cox1), cytochrome c 
oxidase subunit 3 (cox3) and cytochrome b (cytb), along with several rRNA subunits (Suplick et 
al., 1990).  However, many nuclear encoded genes are trafficked to the mitochondrion.  It was 
long thought that the mitochondrion in asexual stages was not a source of ATP, the parasites 
instead relying on glycolysis for energy generation (Suplick et al., 1990).  However, a recent study 
has shown that Apicomplexa are able to perform a full TCA cycle to catabolise glucose.  Unlike 
classical systems which utilise pyruvate dehydrogenase (PDH) to convert of pyruvate to acetyl-
CoA, P. berghei mitochondrial branched chain ketoacid dehydrogenase (BCKDH) can perform 
this function.  Plasmodium mitochondria are also essential for various biosynthetic processes 
including haem biosynthesis, pyrimidine biosynthesis, ubiquinone biosynthesis and iron-sulphur 
cluster biosynthesis (Mather et al., 2007; Vaidya and Mather, 2009).   
A defining characteristic of the apicomplexan phylum is the presence of an apicoplast, a relict 
plastid originating from a photosynthetic eukaryote (Oborník et al., 2009).  Virtual proteome 
studies have identified approximately 500 nuclear-encoded apicoplast-targeted proteins and 35 
proteins encoded within the apicoplast itself (Ralph et al., 2004).  As well as various 
‘housekeeping’ functions (such as genome replication, transcription, translation etc.), the 
apicoplast has been confirmed to be involved in several metabolic pathways including 
haemozoin synthesis, iron-sulphur cluster biogenesis, fatty acid synthesis and isoprenoid 
precursor synthesis.  Less well defined roles may include import and export of metabolites and 
energy generation, which are, in addition to the organelle growth and division, are poorly 
understood (Goodman and McFadden, 2013).   
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1.7 Invasion of RBCs by P. falciparum merozoites 
The exterior of the merozoite is covered with abundant surface proteins that function in both 
immune evasion and RBC invasion.  P. falciparum can invade erythrocytes via various molecular 
mechanisms, leading to redundancy in the invasion pathway.  It has been known for some time 
that culture adapted P. falciparum, and more recently clinical isolates, have differential invasion 
efficiencies into enzyme treated (neuraminidase, trypsin, chymotrypsin) RBCs.  These protease 
treatments specifically cleave different receptors on the RBC surface.  None of the treatments 
block invasion entirely in all strains (Bei et al., 2007; Mitchell et al., 1986), indicating various 
mechanisms for cell entry.   
Over 50 parasite proteins have been hypothesised to have a function in invasion, however, the 
precise role is known for very few of them (Wright and Rayner, 2014).  Some of these proteins 
have been classed into functional groups, MSPs (merozoite surface proteins), PfEBAs (P. 
falciparum erythrocyte binding antigens) and PfRHs (P. falciparum reticulocyte binding protein 
homologues).  MSPs are the most abundant proteins on the merozoite surface and are thought 
to act early in the initial cell contact phase of invasion.  PfRHs and PfEBAs are stored in the 
merozoite secretory organelles and have functions later in invasion (Wright and Rayner, 2014).  
Invasion of erythrocytes by merozoites is extremely rapid and is concluded, on average, within 
two minutes of egress (Gilson and Crabb, 2009).  This is presumably another method of immune 
evasion by reducing the length of time that the merozoite is extracellular.      
Merozoite invasion is a tightly regulated stepwise process that begins with initial attachment to 
the RBC surface.  A process of reorientation then occurs to align the apex of the merozoite with 
the RBC membrane, there is also major buckling of the erythrocyte membrane, possibly as the 
merozoite manipulates the host cytoskeleton (Zuccala and Baum, 2011).   
There is a great variety of parasite proteins that are predicted to be involved in erythrocyte initial 
contact.  These proteins are not evenly distributed on the surface and some are concentrated at 
the merozoite apex, indicating a role in invasion (Sanders et al., 2005).  In addition, many have 
domains involved in protein-protein interactions including the Duffy binding-like (DBL) domains 
which are specific to Plasmodium spp. (Peterson et al., 1995).  Some of the families implicated 
in initial contact, whether directly or indirectly are MSPs and serine repeat antigens (SERAs) 
protease like family.  Although functions are not fully understood, some members of these 
families are essential and specific antibodies can inhibit invasion, including MSP-1 (Blackman et 
al., 1994).  Many of these proteins are also important vaccine candidates.   
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Parasite reorientation and active invasion involves multiple proteins that are released from 
apical organelles in a highly coordinated manner.  The differential localisation of proteins into 
separate organelles, and even within organelles (especially rhoptries), presumably plays a role 
in this regulation (Riglar et al., 2011).  Invasion proteins can be divided into adhesins, which 
function as binding ligands to host cell receptors, and invasins, which are involved in invasion 
but not binding directly to host receptors (Cowman and Crabb, 2006).   The major adhesins can 
be grouped into two families, EBL and reticulocyte binding-like homologues (PfRh), examples 
include EBA-175 which binds to glycophorin A (Sim et al., 1994), PfRH4 which binds to 
complement receptor 1 (Tham et al., 2010) and PfRh5 which binds basigin (CD147) (Crosnier et 
al., 2011). Apical membrane antigen-1 (AMA-1), an important vaccine candidate, is the most 
studied invasin to date.  It forms a complex with a group of rhoptry neck proteins called the RON 
complex, at the moving junction during invasion (Richard et al., 2010).   
Formation of the moving junction (also termed tight junction) may be the trigger for the release 
of proteins from the rhoptry bulbs, providing the lipids and proteins needed to form the PV.  The 
exact functional components of the moving junction are still under investigation, but it is known 
to link the parasite, erythrocyte membrane and the internal actomyosin motor.  AMA-1 forms a 
ring, and with the RON complex, follows the moving junction (Riglar et al., 2011).  A single-
headed myosin is thought to provide the force that drives invasion (and gliding motility) of the 
merozoites (Baum et al., 2006).  It is attached to the IMC by a number of proteins, including 
GAP45 (Frénal et al., 2010).  Filaments of actin are also concentrated in this region, and form a 
ring-like distribution at the moving junction (Angrisano et al., 2012).  The parasite is then pushed 
through into the PV created by rhoptry protein release, and the cell membrane is sealed behind 
it (Riglar et al., 2011).    
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1.8 Egress of P. falciparum merozoites from infected RBCs 
Merozoite egress from infected red blood cells is a complex process, and must be tightly 
regulated by the parasite, premature or late egress results in non-invasive merozoites (Collins 
et al., 2013a).  To escape the RBC, the parasites must rupture two membranes, the PV and the 
RBC membrane.  For many years the order of rupture of these membranes was contested.  
However it is now known that the parasites are released by an ‘inside-out’ egress mechanism, 
where the PV membrane ruptures prior to the RBC membrane (Sologub et al., 2011; Wickham 
et al., 2003).  The cysteine protease inhibitor E64 can inhibit the rupture of the host cell 
membrane when the PV has already ruptured (Chandramohanadas et al., 2011).  A further study 
observed that the PV swells a few minutes prior to egress, with the RBC compartment shrinking, 
suggesting that the parasites draw in water from the host cell cytoplasm to the PV to create 
space for parasite separation and then the PV ruptures once it reaches critical expansion 
(Glushakova et al., 2010).  Before the parasite can break down the host cell membrane, it must 
destabilise the RBC cytoskeleton.  The progressive loss of α/β-adducin by host calpain-1 
proteolysis has been implicated as a major factor in this process (Millholland et al., 2011).  
Parasite proteases are also essential for egress, examples include the cysteine protease 
falcipain-2 and the aspartic protease plasmepsin II, which both act to degrade the host 
cytoskeleton, and a subtilisin-like serine protease PfSUB1.  PfSUB1 is secreted from the 
exonemes into the PV just prior to egress, where it specifically cleaves a range of substrates 
including MSP proteins and members of the cysteine-like protease SERA (serine repeat antigen) 
family.  While the precise involvement in egress is unknown, activation of PfSUB1 is thought to 
lead to a proteolytic cascade resulting in egress and the priming of merozoites to make them 
ready for invasion (Blackman and Carruthers, 2013).  Less is known about the related PfSUB2.  
PfSUB2 is considered the primary merozoite surface sheddase which is secreted onto the 
merozoite surface where it cleaves MSP1 and AMA1 on the surface of the parasite (Harris et al., 
2005).     
Recently it has been shown that perforin-like proteins are essential for host cell egress in both 
T. gondii and P. falciparum.  Perforin-like protein 1 (PLP-1) is released from the micronemes and 
disrupts host cell membranes to allow the parasite to escape (Garg et al., 2013; Roiko and 
Carruthers, 2013).    
Parasites must also escape host RBCs at the gametocyte stage of their life cycle, the RBC 
membrane is lost as the parasites form gametes inside the mosquito midgut.  Gametocyte 
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emergence has many similarities to schizont rupture.  The parasites also use an ‘inside-out’ 
egress mechanism, with the PV rupturing before the host cell membrane (Sologub et al., 2011), 
although there is an approximately 15 minute delay between the two, and utilises proteases and 
perforins (Wirth and Pradel, 2012).  Osmiophilic bodies are thought to play a somewhat 
analogous role to exonemes in asexual stage egress, with the contents, including proteins that 
have egress phenotypes such as Pfg377 and GEST (gametocyte egress and sporozoite traversal), 
released into the PV just prior to rupture (de Koning-Ward et al., 2008; Talman et al., 2011).  
Cyclic nucleotide and calcium signalling are thought to be key regulators in parasite egress.  This 
is described in more detail below.   
 
1.9 Secondary messenger signal transduction 
All cells must be able to sense the environment around them and respond appropriately.  Signal-
transduction cascades are responsible for processing the stimuli and moderating the cellular 
response.  Diverse signals can be detected and amplified leading to activation of an appropriate 
reaction.   There are some small, non-polar molecules, such as steroid hormones, that are able 
to act as direct messengers by diffusing through the cell membrane to the nucleus and binding 
to proteins that interact with DNA to modulate gene expression.  However, most signal 
messenger molecules are too large or polar to cross the membrane and transport mechanisms 
do not exist.  Therefore, the signal must be passed across the membrane without the messenger 
molecule entering the cell.  Commonly a membrane bound receptor detects the messenger by 
binding to it and transmits the message.  This leads to changes in the concentration of secondary 
messenger molecules such as calcium ions (Ca2+), inositol 1,4,5-trisphosphate (IP3), 
diacylglycerol (DAG) and the cyclic nucleotides cyclic adenosine monophosphate (cAMP) and 
cyclic guanosine monophosphate (cGMP).  Generation of a large number of second messengers 
leads to amplification of the initial signal.   
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Figure 1.4 Common second messenger molecules 
The most abundant second messenger signalling molecules involved in cellular signal 
transduction.  Clockwise, from the top left shows, the cyclic nucleotides, cAMP and cGMP (for a 
more detailed image see figure 1.5), a calcium ion (Ca2+), inositol 1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG).  From (Berg JM, Tymoczko JL, 2002) 
 
Second messengers often convey the signal via activation of protein kinases, which transfer 
gamma phosphate of ATP phosphoryl groups to specific threonine, tyrosine and serine amino 
acids in targeted proteins.  Protein phosphatases can remove the phosphoryl groups, making 
protein phosphorylation a reversible reaction (Berg JM, Tymoczko JL, 2002).   
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1.10 Secondary messenger signal transduction in P. falciparum  
Malaria parasites utilise several secondary messenger signalling pathways, which are likely to be 
inextricably linked.  Calcium signalling and cyclic nucleotide signalling are of particular 
importance and regulate many pathways in Plasmodium parasites, with an array of conserved 
and unique component parts when compared to other organisms (Budu and Garcia, 2012).     
1.10.1 Calcium signalling in P. falciparum  
The importance of calcium ions in Plasmodium growth and replication has been known since the 
1980s.  Invasion of RBCs and asexual stage development was found to be dependent on both 
extracellular and intracellular Ca2+ (Wasserman et al., 1982).   
Calcium signalling requires the movement of Ca2+ from intracellular stores and the extracellular 
environment.  This mobilization and removal of calcium in the cytoplasm is controlled by a series 
of buffers, pumps and exchangers.  Ca2+ binds to effectors, such as kinases, that then leads to 
the stimulation of a number of Ca2+ -dependent processes (Verkhratsky and Parpura, 2013).   
The erythrocytic cytoplasm calcium concentration is very low (<100 nM), in order to combat the 
problem of obtaining sufficient calcium ions the malaria parasite maintains a high concentration 
of Ca2+ in the PV (approx. 40 µM) (Gazarini et al., 2003).  In addition, the parasite stores Ca2+ in 
the mitochondrion, an acidic store and the endoplasmic reticulum (Gazarini and Garcia, 2004; 
Marchesini et al., 2000; Passos and Garcia, 1997).   
In comparison with other eukaryotic organisms, apicomplexans have fewer calcium related 
genes, although as with most systems, the genetic information in these organisms is so divergent 
that others may remain uncharacterised (Moreno et al., 2011).  There are at least two calcium 
pumps acting in the parasite, an apicomplexan unique P-type ATPase, PfATP4 (Krishna et al., 
2001), and a sarco/endoplasmic reticulum Ca2+ -ATPase (SERCA) orthologue, PfATP6 (Eckstein-
Ludwig et al., 2003).   
In most mammalian cells, a receptor is coupled to a phospholipase C protein, leading to 
hydrolysis of phosphatidylinositol 4,5-disphosphate (PIP2), giving inositol 1,4,5-trisphosphate 
(IP3) and diacylglycerol.  IP3 then interacts with the IP3 receptors on the ER membrane, leading 
to calcium release through IP3 gated calcium channel (Ma et al., 2000).  There is experimental 
evidence for inositol 1,4,5-trisphosphate (IP3)-dependent calcium signalling in Plasmodia (Alves 
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et al., 2011), however no receptors have been identified.  Phosphoinositide phospholipase C (PI-
PLC) has been identified in T. gondii (Fang et al., 2006).   
Free calcium ions in the cell interact with calcium binding proteins, generally classed in three 
main categories, the calcineurin B-like (CBL), calmodulins (CaM) and the calcium-dependent 
protein kinases (CDPKs).  Calcium binding proteins are characterised by the presence of a 
conserved helix-loop-helix motif, called the EF-hand, which are usually in dimerised pairs and 
facilitate the binding of two Ca2+ ions to each domain.  Based on sequence homology, it has been 
predicted that P. falciparum encodes around 70 proteins with an EF-hand domain, currently 
most of these remain hypothetical with no known function (Moreno et al., 2011).  Most 
apicomplexan genomes encode a putative CaM gene, however only in T. gondii has it been 
cloned and proven to bind Ca2+ (Seeber et al., 1999).  The CaM inhibitors calmidazolium and 
trifluoperazine have been shown to inhibit host cell entry by T. gondii tachyzoites (Pezzella-
D’Alessandro et al., 2001) and parasite development and RBC invasion on P. falciparum (Geary 
et al., 1986; Vaid et al., 2008).   
There are seven known CDPKs encoded by malaria parasites (12 in T. gondii), related to plant 
CDPKs (Harper and Harmon, 2005), that regulate many varied processes including stress 
responses and cell cycle progression.  Typically the CDPKs have an amino-terminal 
serine/threonine kinase domain, then an autoinhibitory domain connecting to a calmodulin-like 
domain (usually with multiple Ca2+ binding domains) at the carboxy terminus (Moreno et al., 
2011).  In P. berghei, CDPK3 is critical for ookinete motility and penetration of the mosquito mid-
gut wall, targeted disruption of the PbCDPK3 gene prevented the formation of oocysts (Ishino 
et al., 2006).  Plasmodium CDPK4 has been shown to be essential for male-specific events in 
gametogenesis, particularly genome replication, in P. berghei (Billker et al., 2004).  T. gondii 
CDPK1 (closest homolog of PfCDPK4) downregulation leads to a reduction in parasite motility, 
host cell invasion and host cell egress (Lourido et al., 2010).  TgCDPK3 (the closest homolog of 
PfCDPK1) genetic disruption results in a defect in calcium induced egress which can be rescued 
by complementation with the PfCDPK1 gene (Gaji et al., 2014).  PfCDPK5 is essential for RBC 
egress in asexual blood stages (Dvorin et al., 2010).  Recently, it has been shown that PfCDPK7 
has a PH (pleckstrin homology) domain which can interact with a PIP2, and is involved in asexual 
stage growth.  Genetic ablation of PfCDPK7 results in severe asexual growth defects (Kumar et 
al., 2014).   
Calcium signalling is critical for microneme secretion in both Toxoplasma and Plasmodia.  The 
contents of micronemes can be artificially released with the addition of calcium ionophores, 
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which can be blocked with the addition of the calcium chelator BAPTA-AM (Carruthers and 
Sibley, 1999; Gantt et al., 2000).  In addition, T. gondii egress can be stimulated by addition of 
calcium ionophores (Endo et al., 1982).    
Motility is a key theme in apicomplexan calcium signalling.  As mentioned previously, PbCDPK3 
is involved in ookinete motility (Ishino et al., 2006; Siden-Kiamos et al., 2006) and TgCDPK1 
downregulation reduces motility in tachyzoites (Lourido et al., 2010).  In addition, increased 
cytosolic Ca2+ levels have been linked to sporozoite motility in P. berghei (Carey et al., 2014).  
PfCDPK1 is essential in asexual blood stages, and is known to phosphorylate at least two 
merozoite motor complex components (Green et al., 2008). 
As soon as the merozoite is released from the host RBC, it is exposed to low potassium levels, 
triggering calcium release that activates secretion of invasion proteins onto the merozoite 
surface (Singh et al., 2010). 
1.10.2 Cyclic nucleotide signalling 
The cyclic nucleotides 3′-5′-cyclic adenosine monophosphate (cAMP) and 3′-5′-cyclic guanosine 
monophosphate (cGMP) are ubiquitous signalling molecules found in all eukaryotes, regulating 
processes as diverse as water reabsorption in the kidney, vision in mammals and chemotaxis in 
Dictyostelium (Baker, 2011).   
In mammalian cells, cyclic nucleotide signalling is frequently activated by membrane bound G-
protein coupled receptors (GPCRs).  GPCRs that stimulate the increase of cNMPs are termed 
stimulatory G proteins (Gs), there are also inhibitory G proteins (Gi) that act by preventing the 
formation of cNMPs.  GPCRs frequently act in combination with heterotrimeric G proteins.  
cAMP and cGMP are synthesised by adenylyl cyclase (AC) and guanylyl cyclase (GC), respectively, 
and hydrolysed by cyclic nucleotide phosphodiesterases (PDEs).  By the action of these opposing 
enzymes, levels of cNMPs can jump over 20-fold from resting state (approximately 10-7 M 
(Bacskai et al., 1993)) in seconds.  The primary effector molecule of cAMP is protein kinase A 
(PKA), and protein kinase G (PKG) for cGMP (Alberts et al., 2002).   
PKA and PKG are serine/threonine kinases, they act by phosphorylating specific serine or 
threonine residues in target proteins, thereby regulating their activity.  PKA has both a 
regulatory and a catalytic subunit.  When inactive (in higher eukaryotes at least) PKA is a complex 
containing two regulatory and two catalytic domains.  When cAMP binds to the regulatory 
domain, the complex dissociates and the active catalytic domains are released, leading to kinase 
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activity (Reimann et al., 1971; Taylor et al., 2012).  The regulatory domains are also responsible 
for protein localisation within the cell via association with A-kinase anchoring proteins (AKAPs).  
AKAPs bind the regulatory domain to other components, including membrane associated 
proteins, the cytoskeleton and other signalling associated molecules, thereby forming a 
signalling complex called a signalosome (Wong and Scott, 2004).  For example, around the 
nuclear membrane of heart muscle cells, AKAP binds PKA and a phosphodiesterase together.  
When the cell is unstimulated, the PDE will keep levels of cAMP low locally around the PKA, then 
becoming saturated when stimulated leading to PKA activity.  As soon as the signal stops, the 
PDE will then rapidly reduce the level of cyclic nucleotide and PKA activity will cease.  This 
arrangement leads to an extremely rapid response to the signal (Röder et al., 2009).  In some 
cases, activation of PKA can lead to a (slower) transcriptional response.  Some transcriptional 
activating proteins contain a cAMP response element (CRE), that is activated by the CRE-binding 
protein (CREB), a substrate of PKA.  For example, in brain cells, the hormone somatostatin 
initiates a cAMP signalling cascade leading to activation of CREB and upregulation of genes 
thought to be involved in memory and learning (Brunelli et al., 1976; Kandel, 2012).   
cGMP signalling is less ubiquitous than that of cAMP and, unlike PKA, the regulatory and catalytic 
domains of PKG are contained within the same polypeptide. In humans, there are two PKG 
families, PKGI and PKGII, encoded by separate genes.  In addition, PKGI exists as two different 
splice variants, PKGIα/β which differ in the N-terminus by roughly 100 amino acids (Francis et 
al., 2010; Wernet et al., 1989).  The catalytic domain is found at the C-terminus of the protein, 
with the regulatory domain at the N-terminus, containing a leucine zipper motif (for 
dimerisation and localisation), overlapping autoinhibitory and autophosphorylation domains 
and cGMP binding domains (Francis et al., 2010).  PKG interacting partners (GKIPs) share some 
analogous features with AKAPs in that they can localise PKG to certain cellular locations, 
however the characteristics are significantly different.  Most GKIPs are PKG substrates, requiring 
activation by PKG for association (Reger et al., 2014).  Example of GKIPs include myosin-binding 
subunit of myosin light-chain phosphatase (Surks, 1999) and PDE-5 (Thomas et al., 1990).  Nitric 
oxide (NO) signalling is primarily cGMP dependent.  NO binds directly to the NO-activated GC, 
leading to phosphorylation of proteins involved in smooth muscle contraction, cardiac function 
and platelet activation (Francis et al., 2010).     
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1.10.3 Cyclic nucleotide signalling proteins in Plasmodium 
All currently sequenced species of malaria contain homologues of many of the major genes 
involved in cyclic nucleotide signalling.  There are two ACs and two GCs, PKG, catalytic and 
regulatory subunits of PKA and four PDEs.  No receptor proteins have yet been discovered, and 
there are no recognisable heterotrimeric G proteins in the Plasmodium genome.    
In the 1990s, it was determined that P. falciparum parasites contained AC activity with distinct 
biochemical properties from that of the erythrocyte.  A notable property of PfAC activity was 
that it was insensitive to the mammalian AC activator forskolin and heterotrimeric G protein 
activators AlF4- and GTPγS (Read and Mikkelsen, 1991a).  In Plasmodia, cAMP is synthesised by 
two ACs, PfACα (PF3D7_1404600) and PfACβ (PF3D7_0802600), that are structurally divergent 
from mammalian ACs and each other.  Full length PfACα contains six predicted transmembrane 
(TM) domains, and a single C-terminal catalytic domain (CD), however mRNA analysis has shown 
that  PfACα exists as multiple splicing variants, potentially giving rise to proteins with differing 
numbers of TM domains (Muhia et al., 2003).  Structural studies have shown that motifs for 
catalytic activity and substrate binding are present within the CD.  However a homodimer is 
necessary for activity (Muhia et al., 2003).  PfACα has dual predicted functions, in addition to 
the C-terminal AC catalytic domain there is also an N-terminal potassium channel (Salazar et al., 
2012).  PfACβ has no predicted TM domains and has two catalytic domains, with substrate 
binding and catalytic sites spread over the two, implying the need for intramolecular 
heterodimerisation.  Uniquely for P. falciparum, the two CDs of PfACβ are broken up by low 
complexity regions consisting of blocks of highly charged residues, the function of which remains 
unknown (Salazar et al., 2012).   Illumina-based sequencing of P. falciparum 3D7 mRNA suggests 
that PfACα is upregulated in gametocytes and ookinetes and PfACβ in schizonts (López-Barragán 
et al., 2011).    In ACα deficient P. berghei, there was more than a 50% reduction in hepatocyte 
infectivity by sporozoites in vivo (Ono et al., 2008).  ACβ is homologous to mammalian soluble, 
bicarbonate sensitive ACs, and has proved refactory to genetic disruption and recombinant 
expression, however in P. falciparum asexual stage culture, addition of specific AC inhibitors 
resulted in parasite death before completion of schizogony, suggesting an essential asexual 
function of ACβ.   (Salazar et al., 2012).    
The two GCs, PfGCα (PF3D7_1138400) and PfGCβ (PF3D7_1360500), are closely related to each 
other, but have an unusual predicted bifunctional topology, unique to alveolates.  The N-
terminus is similar to a P-type ATPase, but its function is unknown. The C-terminal end resembles 
mammalian heterotrimeric G protein-dependent ACs.  Notably it is cGMP, not cAMP that is 
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synthesised however (Carucci et al., 2000; Linder et al., 1999).  Each of the domains contains 
many putative TM domains, giving a predicted 22 overall.  Illumina-based sequencing of P. 
falciparum 3D7 mRNA suggests PfGCα is relatively consistently expressed, but somewhat 
upregulated in late trophozoites.  PfGCβ is upregulated in stage V gametocytes (PlasmoDB).  
Microscopy studies using antibodies against the C-terminus of PfGCα localise to the PV of 
gametocytes, with little staining in the asexual stages (Carucci et al., 2000), which is unexpected 
considering the mRNA data.  It could be that, like some other Plasmodium proteins, the mRNA 
is transcribed and then suppressed to be translated later in the life cycle (Hall et al., 2005), or 
that the antibody used lacked specificity.  GCβ deficient P. berghei parasites were found to have 
a motility deficiency in ookinetes (Hirai et al., 2006), which will be discussed in more detail in 
chapter 1.12.9.   
PfPKG (PF3D7_1436600), like mammalian PKG, is encoded by a single polypeptide and consists 
of a C-terminal catalytic domain and a N-terminal regulatory domain (Gurnett et al., 2002).  
Whilst mammalian PKG proteins have two cGMP binding domains, PfPKG has four (of which 
three bind cGMP, the fourth is degenerate) (Deng et al., 2003).  Studies on the orthologous 
Eimeria PKG have shown that for full activation of the kinase, cGMP must be bound to all three 
functional cGMP binding domains (Salowe et al., 2002).  In other apicomplexan parasites 
(Toxoplasma and Eimeria), PKG is found as both a membrane bound and a cytosolic isoform.  
The membrane attachment is facilitated by dual acylation (Donald and Liberator, 2002), the 
signatures of which are absent from PfPKG (Diaz et al., 2006).  PfPKG does not have any 
recognisable leucine zipper motif or dimerization domains.  mRNA transcript data suggests that 
PKG is upregulated in trophozoites, schizonts and ookinetes (PlasmoDB).      
PfPKA has both a regulatory (PKA-R, PF3D7_1223100) and catalytic subunit (PKA-C, 
PF3D7_0934800), similar to PKA in higher eukaryotes, that are encoded by separate genes on 
different chromosomes.  PfPKA-R, unlike its mammalian counterpart, is predicted to be a 
monomer as the N-terminus of PfPKA-R does not contain a similar dimerisation domain.  
However, it does contain predicted myristylation and palmitylation sites, which presumably 
localises PKA to a cellular membrane.  Therefore, if AKAP binding is involved in P. falciparum, a 
novel mechanism must be present (Haste et al., 2012).  There are eleven different 
experimentally verified phosphorylation sites within PfPKA-R, mostly towards the N-terminus 
(Lasonder et al., 2012).  One of these sites appears to be PKG specific, indicating some degree 
of crosstalk between the cAMP and cGMP signalling pathways (Christine Hopp, Thesis).  PKA-R 
overexpression has been shown to lead to reduced PKA activity and was detrimental to parasite 
49 
 
growth (Merckx et al., 2008).  PKA-C has considerable homology with its mammalian 
counterparts, however there are disparities in key domains, including domains involved in 
phosphorylation mechanisms, ATP anchoring, substrate recognition and inhibitor sensitivity 
(Wurtz et al., 2011).       
Plasmodium species encode four PDEs, that have six predicted TM domains at the N-terminal 
end and a C-terminal catalytic domain.  PDEα (PF3D7_1209500) is cGMP specific and is the only 
PfPDE to have been active when expressed in recombinant form (Wentzinger et al., 2008).  
Deletion of PfPDEδ (PF3D7_1470500) gave reduced levels of cellular cGMP-PDE activity in 
gametocytes and a corresponding increase in cellular cGMP levels, strongly suggesting that PDEδ 
is cGMP specific (Taylor et al., 2008).  The cyclic nucleotide specificities of PDEβ 
(PF3D7_1321500) and PDEγ (PF3D7_1321600) have yet to be proven experimentally.  PDEs are 
discussed in more detail below.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 
 
1.11 Cyclic nucleotide phosphodiesterases 
Cyclic nucleotide phosphodiesterases (PDEs) have an opposing action to the cyclases, catalysing 
the hydrolysis of the cyclic nucleotides (figure 1.5), thereby controlling the intracellular 
concentrations of cAMP and cGMP.  Dysregulation of cyclic nucleotide signalling is responsible 
for many human disorders, including chronic obstructive pulmonary disorder (COPD), acute 
refractory cardiac failure and erectile dysfunction, amongst many others (Maurice et al., 2014).    
 
 
 
 
 
 
 
Figure 1.5 Cyclic nucleotide hydrolysis by PDEs 
PDEs catalyse the hydrolysis of the cyclic phosphate bond between carbons 3 and 5 of the ribose 
group (left hand structure) in cAMP and cGMP, in the presence of a divalent cation (such as 
magnesium).  This results in the production of AMP or GMP (right hand structure).  The box 
shows the differences between adenine-based and guanine-based structures (Lugnier, 2006). 
 
The therapeutic potential of targeting PDEs has been long investigated.  Shortly after the 
discovery of the cAMP hydrolytic activity of PDEs, caffeine was shown to be an effective inhibitor 
(Rall and West, 1963).  Indeed, before they were identified as non-selective PDE inhibitors, 
caffeine and other xanthine derivatives were used clinically in the treatment of asthma, as 
bronchodilators.  However, the broad specificity of these therapies lead to unfavourable side-
effects (Schudt et al., 2011).  Later studies in the 1970s and 80s identified that there were 
multiple molecular forms of PDEs, that had the potential to be selectively targeted (Weishaar et 
al., 1985).     
The mammalian superfamily of PDEs can be subdivided into 11 structurally similar, but 
functionally divergent gene families (PDEs 1-11), most containing several different PDE genes 
(e.g. PDE1A, PDE1B and PDE1C), that can each be spliced or transcriptionally processed to give 
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over 100 PDE isoenzymes in total (Maurice et al., 2014).  The individual PDEs differ in structure, 
cyclic nucleotide specificity, function, catalytic properties, regulatory mechanisms and 
responses to activators, inhibitors and effectors (Conti and Beavo, 2007; Francis et al., 2011).   
PDEs are modular proteins that contain a conserved C-terminal catalytic domain and divergent 
N-terminal regulatory domains.  Different PDE families can hydrolyse different cyclic 
nucleotides.  There are cAMP specific PDEs, (PDEs 4, 7 and 8) cGMP specific PDEs (PDEs 5, 6 and 
9) and some that are dual specific (PDEs 1, 2, 3, 10 and 11).  The amino terminal domains are 
responsible for subcellular location targeting, post-translational modifications, responses to 
regulatory molecules and signals, dimerisation domains, autoinhibitory regulation, allosteric 
ligand binding, phosphorylation sites, protein-protein interaction sites etc. (figure 1.6) (Kritzer 
et al., 2012; Maurice et al., 2014). 
 
Figure 1.6 Structure and domain organisation of the 11 mammalian PDE families. 
The catalytic domain of all mammalian PDEs is conserved at the C-terminus, and many contain 
N-terminal subdomains and phosphorylation sites.  (Maurice et al., 2014) 
 
The mammalian PDE family is extremely complex, and although there is likely to be some 
redundancy most of the PDE isozymes have been demonstrated to have specific physiological 
roles (Bender and Beavo, 2006).  A brief overview of each PDE family is described below.  The 
PDE1 family are calcium and calmodulin (CaM)-dependent.  The binding of a Ca+2/CaM complex 
to N-terminus stimulates cyclic nucleotide hydrolysis.  There are three PDE1 isoforms, PDE1A, 
PDE1B and PDE1C that have dual-specific cyclic nucleotide activity, although specific affinities 
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vary (Goraya and Cooper, 2005).  PDE1A is involved in regulation of vascular smooth muscle 
contraction and possibly sperm function.  PDE1B is important for immune cell activation and 
survival as well as dopaminergic signalling.  PDE1C has been implicated in sperm function and 
neuronal signalling and is essential for vascular smooth muscle cell proliferation (Bender and 
Beavo, 2006).  PDE2 is also dual specific and often is involved in cross-talk between cAMP and 
cGMP pathways.  Examples include in adrenal gland aldosterone secretion, phosphorylation of 
Ca+2 channels in the heart and long-term memory function (Bender and Beavo, 2006; Gomez 
and Breitenbucher, 2013).  The two isoforms of PDE3 (PDE3A and PDE3B) are dual specific, 
however, in vivo cAMP hydrolysis can be inhibited by the presence of cGMP.  They are activated 
by phosphorylation by numerous kinases, including PKA.  PDE3A has many functions, including 
cardiac muscle contraction and platelet aggregation.  PDE3B is involved in insulin signalling and 
cell cycle regulation (Ahmad et al., 2012).  PDE4 comprises a large family, with four genes 
(PDE4A-D) each with multiple splicing variants.  All PDE4 enzymes are cAMP specific are involved 
in a large number of functions, including vascular smooth muscle proliferation, immune cell 
activation and neutrophil infiltration (Bender and Beavo, 2006; Gavaldà and Roberts, 2013).  
Only one PDE5 gene has been discovered (PDE5A), although several spice variants exist.  
Amongst other potential functions, PDE5 is involved in NO-cGMP signalling, particularly in the 
penis and the lungs (Sung et al., 2003).  Members of the PDE6 family are involved in cGMP 
signalling in photoreceptors in the eye and are important in vision (Kerr and Danesh-Meyer, 
2009).  PDE7A and PDE7B are cAMP specific enzymes, expressed in immune and 
proinflammatory cells and are implicated in T cell activation (Safavi et al., 2013).  The PDE8 family 
comprises PDE8A and PDE8B which are cAMP specific.  Although limited studies exist on PDE8, 
it is known to regulate Leydig cell steroid production (Shimizu-Albergine et al., 2012).  PDE9A, 
the only member of the PDE9 family, although multiple splice variants exist, is involved in NO-
cGMP signalling in the brain (Zhihui, 2013).  PDE10 can hydrolyse both cAMP and cGMP in vitro, 
however the in vivo specificity is still under investigation.  PDE10 is involved in cGMP signalling 
in the brain and has been implicated in neurodegenerative disorders (Bollen and Prickaerts, 
2012).  PDE11, described in 2000, is the most recently reported PDE enzyme family (Fawcett et 
al., 2000).  Little is known about PDE11, it is dual specific but can be stimulated by cAMP.  It has 
been implicated in sperm development and dysregulation is associated with major depressive 
disorder (Bollen and Prickaerts, 2012; Makhlouf et al., 2006).    
X-ray crystallography has determined the structures for the catalytic domains of nine of the PDE 
families, exhibiting a shared topography, roughly 350 amino acids folded into 16 helices.  The 
active site forms a highly conserved, histidine containing, hydrophobic pocket with the PDE-
53 
 
specific signature motif HD(X2) H(X4)N, and two divalent metal ion binding sites which are 
essential for catalytic activity (Ke et al., 2011).  The catalytic site can be divided into four sub-
sites, the metal binding site, core pocket, hydrophobic pocket and the lid region (Sung et al., 
2003).  The active site pocket contains 11 of the 17 PDE conserved residues (Jin et al., 1992).  
Two metal ions are necessary for PDE activity, a zinc ion and (usually) a magnesium ion (Conti 
and Beavo, 2007).   
Most of the current PDE inhibitors were generated using classical medicinal chemistry 
approaches, involving ‘black-box’ screening, generation of a lead compound and then systematic 
chemical modification to produce an inhibitor with the desired attributes, such as selectivity, 
potency and pharmacokinetic properties.  Recently, the field is moving towards a more 
structure-based design approach, using crystal structures of the catalytic sites and PDE-inhibitor 
complexes for lead optimisation (Card et al., 2005).    
At present there are limited PDE inhibitors in widespread clinical use, these include inhibitors 
against PDEs in three different PDE families (PDE3, PDE4 and PDE5 inhibitors).  However there 
are many more currently in clinical trials.  Additionally, whilst not necessarily clinically relevant, 
inhibitors against all PDE families, with the exception of PDE11, have been developed (Maurice 
et al., 2014).  PDE3 inhibitors include milrinone (Primacor; Astellas Pharma/Sanofi), which can 
be used for acute treatment of adults with refractory heart failure and those awaiting heart 
transplants (Movsesian and Kukreja, 2011), and cilostazol (Pletal; Otsuka Pharmaceutical), 
extensively used to treat intermittent claudication (muscle ache due to peripheral arterial 
disease) (Kanlop et al., 2011).  PDE4 inhibitors, including roflumilast, are used clinically to 
reducing the risk of exacerbations in patients with chronic bronchitis and COPD, due to the 
cAMP-mediated anti-inflammatory responses (Fabbri et al., 2009).  PDE5 inhibitors, notably 
sildenafil (Viagra™, Pfizer), are used to treat male erectile dysfunction (Boolell et al., 1996), as 
well as pulmonary arterial hypertension (Ghofrani et al., 2006).  Broader spectrum PDE 
inhibitors, such as theophylline and caffeine (target all PDE families except PDE8 and PDE9), are 
used clinically as bronchodilators to treat various pulmonary diseases including COPD, 
emphysema and asthma (Schudt et al., 2011).   
As previously mentioned, certain signalling proteins can specifically interact with each other to 
form signalosomes.  The idea of signalling compartmentalisation was first proposed in the 80s, 
in a study looking at cAMP specific PKA activation in cardiomyocyte soluble and insoluble 
fractions (Buxton and Brunton, 1983).  This was later confirmed with the identification of AKAPs 
(Bregman et al., 1989).  Individual PDEs are interned within specific signalosomes, for example, 
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PDE3A, 4B and 4D are all cAMP specific PDEs that are sequestered into different AKAP-based, 
differentially localised signalosomes that regulate distinct functions all relating to myocardial 
contraction, allowing cross-talk between signalling networks (Dodge-Kafka et al., 2005; Maurice 
et al., 2014).   
1.11.1 Phosphodiesterases in Plasmodium falciparum 
The P. falciparum genome, and the genomes of all other species of Plasmodium sequenced so 
far, contains four single copy genes encoding for class 1 PDEs, named PDEα-δ.  The catalytic 
domains are closely related to the 11 human PDE families based on the signature HD(X2) H(X4)N 
binding pocket, and similarly to other known class I PDEs, the predicted catalytic domain is at 
the C-terminus.  Unlike most human PDEs, all plasmodial PDEs are integral membrane proteins, 
containing six transmembrane helices near the N-terminus.  Human PDE3 has a single TM 
domain (Maurice et al., 2014).   
In P. falciparum, the four PDEs have around 40% amino acid sequence conservation in their 
predicted catalytic domains, roughly akin to the homology between all the 11 human PDE 
families, suggesting that the Plasmodium proteins each represent a separate family (Conti and 
Beavo, 2007; Wentzinger et al., 2008).  The metal ion binding residues are conserved between, 
not only the Plasmodium PDEs, but all human PDEs as well (Manallack et al., 2005; Wentzinger 
et al., 2008).  Between all currently sequenced Plasmodium genomes, the amino acid identity 
between PDE sub-types is around 50-60% in the catalytic domains (Wentzinger et al., 2008).  
There are 16 amino acid residues that are conserved across all human PDEs, 13 of these are also 
conserved in PfPDEs (Howard et al., 2011). 
As mentioned above, the PfPDEs are predicted to contain 6 TM domains.  The membrane 
association has been confirmed experimentally.  Measurement of total endogenous PDE activity 
in asexual stage P. falciparum lysates has shown that membrane fractions contain more than 
95% of cyclic nucleotide hydrolysing activity (Taylor et al., 2008; Wentzinger et al., 2008).   
Several attempts have been made to express functional recombinant PfPDEs, both catalytic 
domains and full length proteins, in a number of different heterologous systems including E. coli, 
Saccharomyces cerevisiae and the baculovirus expression system ((Wentzinger et al., 2008) 
Pfizer, Personal Communication).  All attempts thus far have been unsuccessful for PDEβ, PDEγ 
and PDEδ.  The only successful approach was a codon optimised E. coli expression system for 
PDEα catalytic domain, although at very low levels (Wentzinger et al., 2008).   
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A recent investigation has performed active site similarity modelling between human and 
PfPDEs.  In the absence of crystal structures for the Plasmodium enzymes, homology models 
based on human PDEs were created.  The authors found that although the most suitable 
template for homology model construction was HsPDE9A, PDE1 active site architecture was 
most similar that that of the PfPDEs.  In addition, the authors were able to model the molecular 
docking of cGMP but not cAMP (Howard et al., 2011).    
1.11.2 PDEα 
PfPDEα (PF3D7_1209500) is located on chromosome 12 and encodes for a protein of 115 kDa.  
The polypeptide exists as two different alternative splicing variants.  The open reading frame of 
PfPDEαA is 62 amino acids longer than that of PfPDEαB, due to an additional intron excision 
(amino acids N360-D421) resulting in the loss of TM helices 4 and 5 (Wentzinger et al., 2008).  
Consequently PfPDEαA contains 6 TM helices and PfPDEαB contains 4.  At the N-terminus, 
before the start of the TM domains, the section of 260 amino acids has no putative functional 
domain, although it does contain a predicted phosphorylation motif.  This motif (K66KKSDMEY73) 
has the potential to be phosphorylated by PKA, casein kinase II and tyrosine kinase, and is 
conserved in other Plasmodium species.  After the last TM helix, there is an additional casein 
kinase II target sequence, which is again conserved between Plasmodium species.  The C-
terminal catalytic domain is a predicted 396 amino acids long and shares 22.8% homology with 
HsPDE4 including more than 93% of all the residues that are conserved between all human PDEs 
(15 0f 16) (Wentzinger et al., 2008).   
Illumina mRNA sequencing indicates that PfPDEα is expressed predominantly in late asexual 
stages, trophozoites and schizonts, and also potentially in stage V gametocytes (López-Barragán 
et al., 2011).   
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Figure 1.7 Illumina mRNA transcript data for PfPDEα  
mRNA was collected from seven different life cycle stages (x-axis) and sequenced using illumina 
methods.  The y-axis shows transcript levels of reads per kilobase of exon model per million 
mapped reads (RPKM).  PfPDEα mRNA is upregulated in late trophozoites and schizonts.  
Expression data for the splicing variant shows no difference in timing or level of expression 
(adapted from PlasmoDB). 
 
PDEα is the only Plasmodium PDE to have been successfully expressed as a biochemically active 
recombinant protein.  PDE assay data found that it is cGMP specific, no cAMP hydrolysis is 
observed even under a competitive environment (100 fold excess of cAMP).  The Km for cGMP 
as a substrate was 2 µM.  Wentzinger et al. tested a series of PDE inhibitors that are 
commercially available, only one, zaprinast, was found to be weakly potent (IC50 of 3-4 µM) 
(Wentzinger et al., 2008).  The others (e.g. IBMX, theophylline, sildenafil), had IC50s above 10 
µM.   
In a slightly earlier study by Yuasa et al., zaprinast was found to inhibit parasite growth with an 
IC50 of 35 µM (Yuasa et al., 2005).  Dipyridamole, E4021 and sildenafil also demonstrated a 
moderate inhibitory effect (IC50s 22±0.58, 46±1.8, and 56±11 µM, respectively), all of these 
compounds are human PDE5 inhibitors (Yuasa et al., 2005).   
The metal ion binding activity of the recombinant protein was also investigated.  Human PDEs 
are dependent on the presence of a divalent cation (magnesium, calcium, manganese etc.), and 
the metal ion binding sites in the PfPDEs are highly conserved.  PDE activity was measured in the 
presence of various cations and the most potent activator of PDEα was found to be Mn2+ (in 
comparison to Mg2+ and Ca2+), with maximum activity at 1 mM MnCl2 (Yuasa et al., 2005).   
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A complete knockout of PDEα resulted in no major discernible phenotype (Wentzinger et al., 
2008).  There was no visible difference in the morphology between the parental 3D7 and the 
PDEα-KO lines.  However, the authors noted a consistent cell cycle difference between the WT 
and PDEα-KO line, with the mutant line appearing to grow slightly faster than the WT.  
Wentzinger et al. found that after synchronisation, ring stages appeared earlier.  However, the 
number of cycles for this to be observed was not consistent, and the authors were unable to 
quantify the time difference.  While PDEα mRNA was ablated in the KO line, mRNA levels of the 
three other PDEs were not significantly altered compared to the WT, indicating that they are not 
being upregulated transcriptionally to compensate for the lack of PDEα (Wentzinger et al., 
2008).    
Overall, in the PDEα-KO line, cGMP hydrolysis decreased by approximately 20% with no effect 
on cAMP concentrations.  This indicates that at least one other PDE can hydrolyse cGMP in the 
asexual stages (Wentzinger et al., 2008).  Addition of greater than the IC50 of the PDE inhibitor 
zaprinast, decreased cGMP hydrolysis by about 50%, indicative of another PDE that is somewhat 
sensitive to zaprinast.   In addition, cGMP hydrolysis in membrane fractions was severely (>60%) 
inhibited by a 5-fold excess of cAMP, also indicative of another PDE with cGMP hydrolytic activity 
that can be inhibited by cAMP.  cAMP hydrolysis is significantly reduced in both WT and KO 
strains in an excess of cGMP (Wentzinger et al., 2008).  All these results taken together are highly 
suggestive that at least one other PDE remains functional in the PDEα-KO line and is a dual 
specific PDE.  Given the expression profile, this is most likely to be PDEβ as it is the only other 
PDE highly expressed in asexuals.   
1.11.3 PDEβ 
PfPDEβ (PF3D7_1321500) is located in chromosome 13, and encodes a protein with a deduced 
molecular mass of 133 kDa, with a predicted six TM domains.  There is also a recently 
characterised alternative splicing variant which leads to a single amino acid change from alanine 
to threonine (A630T) (PlasmoDB).  Little is known about PDEβ, including the cyclic nucleotide 
specificity, however the above PDEα-KO suggests it may be dual specific.  As with all the 
Plasmodium  PDEs, specificity for cAMP or cGMP cannot be predicted from the sequence.  It is 
also presumed to be an essential protein as all attempts to ablate the gene, in both P. falciparum 
and P. berghei, have been unsuccessful (David Baker, unpublished).  Hidden Markov topography 
predictions suggest that the catalytic domain faces towards the PV lumen, but this has not been 
verified experimentally (Gould and de Koning, 2011) and its location remains unknown.  
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Transcript sequencing data suggests PfPDEβ is expressed most highly in late trophozoites and 
schizonts (figure 1.8).    
 
Figure 1.8 Illumina mRNA transcript data for PfPDEβ  
mRNA was collected from seven different life cycle stages (x-axis) and sequenced using illumina 
methods.  The y-axis shows transcript levels of reads per kilobase of exon model per million 
mapped reads (RPKM).  PfPDEβ mRNA is upregulated in late trophozoites and schizonts.  
Expression data for the splicing variant shows no difference in timing or level of expression 
(adapted from PlasmoDB). 
  
 
1.11.4 PDEγ 
PDEγ (PF3D7_1321600) is also on chromosome 13, approximately 3000 bp downstream from 
PDEβ, transcribed from the opposite strand.  This arrangement may have been the result of a 
gene duplication event in a common Plasmodium ancestor.  This arrangement can be detected 
in all currently sequenced Plasmodium species but could not be identified in other Apicomplexa.  
It also has six predicted TM domains and encodes for a protein with a deduced molecular weight 
of 92 kDa, making it the smallest PfPDE protein.  mRNA sequencing data (from all the stages 
examined thus far) suggests that PDEγ is only expressed at very low levels in asexual blood 
stages, but is upregulated in stage V gametocytes.  A knockout of PDEγ showed no aberrant 
phenotype in asexual blood stages, gametocytes, rounding up or exflagellation (Taylor et al., 
2008).  However, PfPDEγ is important for sporozoite formation and infectivity (Cathy Taylor, 
Thesis).   
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Figure 1.9 Illumina mRNA transcript data for PfPDEγ  
mRNA was collected from seven different life cycle stages (x-axis) and sequenced using illumina 
methods.  The y-axis shows transcript levels of reads per kilobase of exon model per million 
mapped reads (RPKM).  PfPDEγ mRNA is upregulated in gametocytes, although the levels never 
get very high (adapted from PlasmoDB). 
 
1.11.5 PDEδ 
The PfPDEδ (PF3D7_1470500) gene is located on chromosome 14, it also has six predicted TM 
domains and encodes a protein with a deduced molecular weight of 97 kDa.  A PfPDEδ-KO was 
created by Taylor et al., which showed significantly reduced cGMP hydrolysis and corresponding 
increase in cellular cGMP levels (with no effect on cAMP hydrolysis or levels) compared to WT 
parasites, indicating that PDEδ is a cGMP specific PDE (Taylor et al., 2008).  Illumina mRNA 
transcript sequencing suggests that PDEδ is expressed in sexual stages only and is highly 
upregulated in stage V gametocytes and ookinetes (figure 1.10). 
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Figure 1.10 Illumina mRNA transcript data for PfPDEδ  
mRNA was collected from seven different life cycle stages (x-axis) and sequenced using illumina 
methods.  The y-axis shows transcript levels of reads per kilobase of exon model per million 
mapped reads (RPKM).  PfPDEδ mRNA is upregulated in gametocytes and ookinetes (adapted 
from PlasmoDB). 
 
The PfPDEδ-KO gametocytes, all the way up to stage V, are morphologically identical to wild-
type, however they show an extreme reduction in the number of parasites able to undergo 
gametogenesis (Taylor et al., 2008) due to an increase in the cGMP levels.  In the KO, cGMP-PDE 
activity was reduced by about 50%, but not completely abolished, suggesting that another PDE 
is active (and potentially upregulated) in gametocyte stages.  Additionally, the mutant gametes 
were not able to egress from the RBC at the same rate as WT parasites.  Addition of zaprinast to 
WT parasites reduced cGMP-PDE activity by about 75% compared to 100% in KO parasites.  It is 
therefore likely that PDEδ is less sensitive to zaprinast than the enzymes responsible for the 
residual PDE activity (Taylor et al., 2008).  The authors also note that a conserved glycine residue, 
implicated in interaction between zaprinast and human PDE5, is present in all PfPDEs except 
PDEδ, potentially explaining its relative insensitivity to the compound (Taylor et al., 2008; Turko 
et al., 1998).   
Interestingly the gametogenesis phenotype was absent in a P. berghei PDEδ-KO.  Moon et al., 
instead focused on P. berghei ookinete stages, which showed that PbPDEδ is important for 
transmission to the mosquito vector, ookinete formation and gliding motility.  As with PfPDEδ-
KO, PbPDEδ-KO cyclic nucleotide levels were measured and cGMP-PDE activity was lower in the 
PDEδ-KO at gametocyte stages.  During ookinete formation, the concentrations got closer 
together for WT and the mutant and by the time the ookinetes were fully mature, the cGMP-
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PDE activity was the same as WT.  The same study also created a GCβ-KO, which showed normal 
rounding up, exflagellation and fertilization in vitro, but were much less able to transmit to 
mosquitoes when measuring oocyst numbers compared to wildtype (Moon et al., 2009).  The 
PDEδ-KO and GCβ-KO total cGMP levels did not vary from WT in ookinetes, suggesting that PDEδ 
is not the predominant PDE in ookinetes nor is GCβ the predominat GC (Moon et al., 2009).  The 
biological relevance of these findings is discussed in more detail below.   
 
1.12 Roles of cyclic nucleotide signalling in Plasmodia 
1.12.1 cAMP signalling and sexual commitment 
The importance of cyclic nucleotide signalling in malaria was first investigated in the late 70s 
with the observation that cAMP production is increased in infected RBCs compared to 
uninfected (Hertelendy et al., 1979).  The following year, the remarkable observation that 
addition of 1 mM cAMP to asexual cultures of P. falciparum could trigger almost 100% switching 
to gametocytes was observed, however this has not been reproduced (Kaushal et al., 1980).  
Later that decade, it was shown that cAMP-PDE inhibitors could increase the numbers of asexual 
parasites switching to gametocytes (Trager and Gill, 1989).  Further evidence for the role of 
cAMP signalling in gametocytogenesis was provided by Read and Mikkelsen, when they 
compared the PKA activities of a gametocyte producing (LE5) and a gametocyte deficient strain 
(T9/96).  Despite basal levels of AC activity being equal, the levels of PKA activity were much 
higher in the gametocyte producing strain (Read and Mikkelsen, 1991b).   
As mentioned previously, the Plasmodium genome does not contain any obvious candidate 
genes for heterotrimeric G proteins based on sequence homology.  However, a study by Dyer 
and Day, utilising cholera and pertussis toxins which are used to study the involvement of 
stimulatory or inhibitory heterotrimeric G proteins respectively in other systems, suggested the 
involvement of a heterotrimeric Gsα subunit in P. falciparum gametocyte formation (Dyer and 
Day, 2000).  However, a more recent study looking at G protein signalling in sexual commitment, 
showed that although treatment with cholera toxin or MAS 7 (expected to down-regulate or 
have no effect of gametocytogenesis through indirect reduction in AC activity by inhibition of an 
α-subunit of the heterotrimeric G protein) increased the switching rate, only MAS 7 lead to 
increased cAMP levels.  This indicates that although the cholera toxin does increase 
gametocytogenesis, it is unlikely through the action of heterotrimeric G proteins.  The 
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unexpected MAS 7 result suggests that it acts, directly or indirectly, on the PfAC activity but the 
authors noted that these results were preliminary and further work was needed to ascertain 
exactly what role MAS 7 was playing in this study (Peatey et al., 2013).       
A study by Harrison et al. in 2003 reported that an erythrocyte G protein-coupled receptor 
signalling pathway via the β2-adrenergic receptor and heterotrimeric guanine nucleotide–
binding protein (Gαs), is involved in RBC entry by P. falciparum.  An inhibitory Gαs peptide, which 
blocks interaction with GPCRs and preventing downstream signalling, reduced formation of new 
rings when added to a P. falciparum culture.  Conversely, addition of β2-adrenergic receptor 
agonists increased infection by about two-fold.  Additionally, the use of Gαs antagonists in P. 
berghei infected mice was able to reduce parasitaemia in comparison to untreated mice 
(Harrison et al., 2003).  In follow up study, addition of the β2-adrenergic receptor antangonist 
propranolol also inhibited blood stage parasite growth (Murphy et al., 2006).  In mammalian 
cells, G protein signalling is important in cellular cytoskeleton reorganisation, a process that is 
also involved in merozoite invasion of RBCs (Vanhauwe et al., 2002).  It is possible that host G-
protein signalling is responsible for the rapid cytoskeletal reorganisation necessary for malaria 
RBC invasion.    
1.12.2 cAMP and melatonin  
Melatonin is a regulator of circadian rhythm in many organisms, in humans it is produced as a 
response to decreasing light levels in order to promote sleep (Trivedi and Kumar, 2014).  Data 
have been reported that suggest that the synchronicity seen in malaria parasite infection during 
asexual blood stages is dependent on signalling by host melatonin.  Addition of melatonin to 
Balb/C mice that had undergone removal of the pineal gland, restored the synchronicity of P. 
chabaudi, lost by the surgery, to the levels seen in un-pinealectomized mice.  Addition of 
melatonin resulted in a phospholipase C -dependent calcium release from Plasmodium 
intracellular stores (Hotta et al., 2000), and a 40% increase in cAMP levels leading to a 50% 
increase in PKA activity (Beraldo et al., 2005).  This is highly suggestive of a complex interplay 
between calcium and cAMP signalling in response to melatonin.  Further analysis of this pathway 
has shown that this is an IP3 dependent pathway.  The authors propose that melatonin activates 
phospholipase C, generating IP3, leading to opening of ER-localised IP3 sensitive Ca2+ channels 
(Alves et al., 2011).  A study by Lima et al., identified PfNF-YB as a potential transcription factor 
regulated by melatonin.  The authors also observed that cAMP regulates PfNF-YB expression 
(Lima et al., 2013).        
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1.12.3 cAMP in sporozoite stages 
In the 1970s, it was shown that sporozoite gliding motility could be induced by albumin in vitro 
(Vanderberg, 1974).  Sporozoite motility and hepatocyte invasion is dependent on secretion of 
adhesin proteins from apical organelles, including CSP and TRAP.  In a PbACα-KO strain, 
sporozoite infectivity is reduced by half due to an impairment in the ability to exocytose in 
response to cell migration, suggesting that microneme exocytosis is regulated by cAMP.  This 
phenotype could be restored by reintroduction of the PbACα gene (Ono et al., 2008).  This study 
also suggests a role for potassium ions, hypothesising that increased K+ permeability may induce 
ACα activity.  It is possible that Ca2+ signalling is linked to cAMP induced exocytosis in 
sporozoites, as incubation with calcium ionophores can also lead to microneme secretion (Mota 
et al., 2002).  Albumin may act as a signal to simulate calcium release and increase cAMP levels 
leading to gliding motility (Kebaier and Vanderberg, 2010).    
1.12.4 cAMP signalling and anion transport through iRBC membranes 
Parasites establish extensive anion transport systems through the host erythrocyte membrane 
to take up solutes, excrete metabolic waste products and maintain ion gradients (Kirk, 2001).  A 
study by Egee et al. indicated a role for cAMP signalling and endogenous PKA in the regulation 
of an anion exchange pathway in P. falciparum infected RBCs (Egee et al., 2002). However in 
patch clamp experiments by Merckx et al., it was observed that the addition of recombinant 
PfPKA regulatory subunit, PKI (mammalian PKA inhibitor) or overexpression of PfPKA-R resulted 
in a down regulation of anion conductance, suggesting that parasite PKA is also involved in anion 
transport.  The transgenic overexpression line also had a defect in asexual growth that could be 
repaired by increasing cAMP levels, demonstrating the importance of tightly regulated cAMP 
levels for parasite growth (Merckx et al., 2008).   
1.12.5 cAMP in merozoite stages 
As mentioned in chapter 1.7, invasion of merozoites involves formation of a tight junction and 
secretion of adhesion proteins from apical organelles.  One of the key proteins in tight junction 
formation is AMA1 (Alexander et al., 2006).  PfAMA1 is phosphorylated by PKA at serine 610, in 
the cytoplasmic tail of the protein.  When mutated to an alanine, thereby abolishing 
phosphorylation, invasion was roughly 4% efficient compared to WT, highlighting the 
importance of PKA in invasion (Leykauf et al., 2010).   
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A study by Saraiva et al. found that addition of angiotensin II, a peptide hormone involved in 
vasoconstriction, part of the rennin-angiotensin system (RAS), reduces RBC invasion by 
merozoites.  Angiotensin peptides can modulate PKA activity.  The inhibition of invasion could 
be reversed by addition of 1 µM dibutyryl-cAMP (a membrane permeable cAMP analogue).  The 
authors therefore postulated a role of RAS in P. falciparum blood stages (Saraiva et al., 2011). 
A recent phosphoproteome study has shown that PKA-dependent phosphorylation is extremely 
important in schizont stages, and is implicated in number of processes, including chromatin 
remodelling, cytoskeleton organisation, membrane lipid metabolic, phosphotase and kinase 
activity and merozoite motility.  The study also verified three novel PKA substrates, myosin A, 
GAP45 and CDPK1, using an in vitro kinase assay, which are involved in the merozoite 
glideosome motor (Lasonder et al., 2012).  The phosphorylation of CDPK1 is another example of 
overlap between the cyclic nucleotide signalling pathways and calcium signalling.   
1.12.6 cGMP in schizont stages 
The parasite PKG gene is essential in asexual blood stages and is therefore refractory to deletion.  
There are however, two highly selective compounds that specifically target PKG, named 
compound 1 (C1) and compound 2 (C2).  C1 is a tri-substituted pyrroles identified by Merck as 
an inhibitor of the coccidian Emieria PKG (Gurnett et al., 2002). C2 is an imidazopyridine which 
was developed later by Merck, using medicinal chemistry, to be more potent and specific than 
C1 (figure 1.11).  Both C1 and C2 are ATP competitive inhibitors that interact with a pocket 
adjacent to the ATP binding site (Donald et al., 2002).  C1 and C2 are low nanomolar inhibitors 
of recombinant PfPKG (Diaz et al., 2006; McRobert et al., 2008).   
 
Figure 1.11 Biochemical structure of compound 1 and compound 2 
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The entry of the fluorophenyl group of C1 and C2 into this small hydrophobic pocket, which 
connects with the ATP binding pocket, is mediated by a small gatekeeper residue (threonine 618 
in PfPKG), that when substituted to a more bulky glutamine side chain to create mutant 
PfPKGT618Q, the fluorophenyl group cannot access this pocket.  This reduces the sensitivity of the 
protein to the inhibitor more than 2000-fold.  A transgenic parasite line in which the endogenous 
PKG was replaced by PKG with the PfPKGT618Q mutation was also created (McRobert et al., 2008).      
Addition of C1 to asexual stage parasites prevents formation of new rings by blocking egress of 
schizont stages.  If added to rings, they are able to develop normally up to late schizonts which 
are then unable to rupture.  Merozoite protein localisation by IFA appeared normal and the 
parasites looked morphologically ready to egress, however the merozoites were unable to 
escape the RBC.  This effect was confirmed as PKG specific as the T618Q mutant was resistant 
to egress block by C1 and C2, rupturing and reinvading erythrocytes at levels comparable to the 
DMSO control (Taylor et al., 2010).  The sensitivity of T618Q parasites to C2 is about 10 fold less 
than WT due to some off target activity, however a recent medicinal chemistry effort between 
the David Baker’s laboratory and Medical Research Council Technology has lead to the 
development of a more potent and specific inhibitor (MRT00207065) with over a 1000 fold 
difference in IC50.   
Inhibition of PfPKG by C1 was found to prevent the functioning of PfSUB1, with the protease 
unable to process its target substrates, including MSP1 (Dvorin et al., 2010).  Conditional 
knockdown, using the destabilisation domain system, of PfCDPK5 also results in an egress block, 
yet the SUB1 activity is unaffected.  Additionally, manually ruptured CDPK5-DD arrested 
parasites were able to reinvade erythrocytes, whereas C1 blocked parasites were not.  This is 
suggestive of PKG activity upstream of CDPK5 activity (Dvorin et al., 2010).   
1.12.7 cGMP in liver stages 
In P. berghei, a conditional knockout system was used to remove a large portion of the PbPKG 
protein.  A parasite line containing flippase (FlpL, a temperature dependent site-specific 
recombinase) under the control of a sporozoite stage promoter, was transfected with a plasmid 
that inserted two FRT sites into the PKG locus, leading to disruption of the gene within the 
mosquito (Combe et al., 2009).  The resultant PbPKG-KO parasites were able to invade and 
develop inside the HepG2 human hepatocyte cell line, however release of merosomes and 
egress of the parasites was severely impaired (Falae et al., 2010).   
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Addition of C1 to sporozoites was found to reduce motility and block hepatocyte invasion 
entirely in the sub micromolar range.  However, addition of C1 to the PbPKG-KO parasites also 
prevented invasion, indicating that there is an additional non-PKG target mediating this effect 
(Panchal and Bhanot, 2010).   
1.12.8 cGMP in gametogenesis and exflagellation 
As mentioned previously, cGMP signalling has been implicated in gametogenesis, with several 
lines of evidence strongly indicative of this.  The addition of the PDE inhibitor zaprinast to stage 
V gametocytes can stimulate dose-dependent rounding up and exflagellation in the absence of 
XA, and without an appropriate pH shift (Taylor et al., 2008; Yuasa et al., 2005).  In a GCβ-KO 
line, reduction of GC activity has no effect on gametogenesis indicating that cGMP levels need 
to be maintained below a threshold for sexual development to continue (Taylor et al., 2008).  In 
PDEδ-KO parasites exflagellation levels were very low with stimulation both by XA and zaprinast 
(Taylor et al., 2008).  Antibody co-staining with band 3 (a RBC anion exchanger) as a marker for 
RBC presence showed that mutant gametocytes were unable to escape the erythrocyte (Taylor 
et al., 2008).  Furthermore, the addition of C1 to stage V gametocytes prevents the rounding up 
of WT parasites, with the PfPKGT618Q parasites able to proceed at normal levels (McRobert et al., 
2008).  Taken together, the data suggest that high levels of cGMP during the gametocyte stage 
are very detrimental to the parasites ability to perform gametogenesis, but that rounding up 
and exflagellation are mediated by PKG.  BAPTA-AM, a calcium chelator, did not block rounding 
up, indicating that cGMP dependent PKG activity is upstream of calcium signalling in 
gametogenesis (McRobert et al., 2008).   
1.12.9 cGMP in ookinetes 
In contrast to the findings for PfPDEδ-KO, PbPDEδ-KO parasites can proceed normally through 
gametogenesis, but have morphologically impaired ookinetes.  For the first 12 hours, the 
ookinetes develop normally, but then the usually banana-shaped cells round up or deteriorate 
into stumpy forms, resulting in poor oocyst formation.  The addition of C1 could reverse the 
stumpy/rounded up phenotype, as did a double PbPDEδ-KO/PbGCβ-KO mutant (Moon et al., 
2009).         
PbGCβ-KO parasites undergo normal rounding up, exflagellation and fertilization in vitro, 
however, ookinete motility was severely impaired.  The parasites have a very slow average speed 
and show only occasional slow gliding (Moon et al., 2009).  Addition of C1 to WT parasites 
strongly blocked gliding motility with an IC50 of less than 100 nM.   
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Interestingly, the round and stumpy forms produced in the PbPDEδ-KO were still viable and able 
to form oocysts when the ookinetes were injected directly into the mosquito haemcoel, 
bypassing the midgut epithelium.  Salivary gland infections were established at the same level 
as WT and the parasites were transmissible into mice.  GCβ-KO ookinetes were not able to 
establish oocysts or salivary gland infections (Moon et al., 2009).  There may therefore be an 
additional role of GCβ-KO in the oocyst/sporozoite stage.  In the PDEδ-KO, motor function was 
not abrogated, but the parasites rotated on the spot.  Ultrastructure data showing abnormalities 
in the IMC and subpellicular microtubules supports this finding (Moon et al., 2009). 
1.12.10 cGMP and phosphoinositide metabolism 
A recent study has revealed a cGMP-PKG link to phosphoinositide metabolism and calcium 
signalling in P. falciparum schizonts and P. berghei mosquito stages.  As mentioned previously, 
PKG activity was found to control the level of cytosolic Ca2+ necessary for gliding motility of the 
ookinete in P. berghei (Moon et al., 2009), as well as regulation of egress in P. falciparum (Taylor 
et al., 2010).  Disruption of these processes, using C2, has a major effect on phosphoinositide 
metabolism.  During ookinete gliding, PKG controls phosphoinositide biosynthesis.  
Furthermore, in schizonts, inhibition of PKG blocks hydrolysis of phosphatidylinostitol (4,5)-
bisphosphate, the precursor of IP3 (Brochet et al., 2014).    
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1.13 Phosphodiesterases as a target for anti-malarial drug discovery 
Novel antimalarial drug targets are desperately needed to counteract the growing threat of 
resistance by Plasmodium parasites.  In the past, drugs countering infectious diseases have been 
designed to act on targets not present in the human host, as this can result in highly specific 
drugs with low toxicity, the ‘silver bullet’ method.  Although this principle often works well for 
bacterial diseases (e.g. antibiotics against bacterial cell walls), eukaryotic pathogens share 
similar biological systems with the host.  More recently there has been a growing trend towards 
the ‘inverted silver bullet’, an established target in humans is used to develop a specific drug for 
its protozoan counterpart.  PfPDEs represent good candidates for this type of drug development.  
PDE inhibitors are well established for a variety of human ailments, including; chronic 
obstructive pulmonary disease, depression, asthma and erectile dysfunction (Bender and Beavo, 
2006; Maurice et al., 2014).  Current human PDE inhibitors are often extremely specific for their 
target, presenting the possibility that a specific, selective Plasmodium PDE inhibitor can be 
developed.  In the last few years there has been some advancement towards a PfPDE inhibitor.  
Two papers by Beghyn et al. have described the discovery of tadalafil based antimalarial 
compounds that have activity in the sub-low micromolar range.  After some optimisation, the 
authors were able to reduce the selectivity for HsPDE5.  The authors noted that potency against 
malarial PDEs would have to be increased and that no in vivo data was available (Beghyn et al., 
2011, 2012).  However, the therapeutic potential of Plasmodium PDEs as a drug target and the 
potential to reduce the activity against human PDEs was established.      
Cyclic nucleotide signalling is essential in many life cycle stages of Plasmodium parasites and 
disruption of many of the components results in aberrant parasite growth and often failure to 
transform to the next life cycle step.  Phosphodiesterases are key regulators of the cAMP and 
cGMP signalling pathways, and although PDEα, PDEγ and PDEδ are not essential in blood stages 
in vivo, the most easily druggable stage, PDEβ is predicted to be.  Therefore this project will focus 
on validation of PDEβ as a target for antimalarial drug discovery.    
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Chapter 2: Materials and methods 
2.1 Plasmodium falciparum culture 
2.1.1 General culture 
The clonal parasite line 3D7 was maintained in culture following standard culture practices 
(Trager and Jensen, 1977).  The parasites were cultured in A+ human erythrocytes (National 
Blood Transfusion Service), with RMPI 1640 (Sigma-Aldrich) supplemented with 50 mg/l 
hypoxanthine, 3.96 g/l glucose and 1.5 g/l L-glutamine (Sigma-Aldrich) and 0.5% complete 
Albumax II solution (Fisher-Scientific).  The cultures were incubated at 37oC in 5% CO2 in a static 
CO2 incubator (Binder).  To sustain a healthy culture the parasites were maintained at less than 
5% parasitaemia at 3-5% haematocrit.  To monitor the parasitaemia, 0.5 ml of the culture was 
removed and briefly centrifuged to pellet the RBCs.  The pellet was resuspended in an equal 
volume of culture medium to give 50% haematocrit and a thin blood smear was prepared on a 
glass slide (VWR).  The slide was fixed with methanol and stained with 10% Giemsa solution 
(Sigma-Aldrich) for 20 minutes.  The slide was examined under light microscopy.   
Parasite synchronisation to isolate ring stages was carried out according to standard practice 
with 5% sorbitol (Lambros and Vanderberg, 1979) to retain only the ring stages.  The parasites 
were pelleted by centrifugation, resuspended in five volumes of 5% sorbitol (in H2O, filter sterile) 
and incubated at room temperature for two minutes.  The culture was spun at 500 x g for two 
minutes, the sorbitol was removed and the cells were washed twice with warmed culture 
medium.  The pellet was resuspended in culture medium to give 5% haematocrit.   
Late stage parasites were purified using magnetic cell separation (MACS).  Briefly, mid-
trophozoite and schizont cultures were pelleted, resuspended in RPMI 1640 and captured in a 
magnetic column (Miltenyi Biotec).  Uninfected RBCs and early stages flow through and late 
stages are captured on the magnetic matrix by haemozoin binding.  Late stages are eluted with 
RPMI 1640 in the absence of the magnet.    
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2.1.2 Thawing and cryopreservation 
Parasites were quickly thawed from liquid nitrogen stocks in a 37oC waterbath.  The volume was 
measured and 1/5th of the volume of 12% NaCl (Sigma-Aldrich) was added dropwise, shaking 
after addition of each drop.  The culture was left to stand for two minutes.  Ten times the original 
volume of 1.6% NaCl was added dropwise with mixing, as before.  The cell suspension was 
centrifuged at 500 x g for 5 minutes and the supernatant removed.  To wash, the pellet was 
resuspended in culture medium and again centrifuged.  The washing step was repeated 2-3 
times.  After the final wash step, the pellet was resuspended in 10 ml culture medium and the 
cell suspension was transferred to a small cell culture flask (T25), and adjusted to 5% 
haematocrit with fresh erythrocytes.  All solutions were pre-warmed to 37oC and filter sterile.    
To freeze down parasite stocks, the cultures were pelleted and the medium removed.  An equal 
amount of cryosolution (28% glycerol, 3% sorbitol, 0.65% NaCl, filter sterile through a 0.22 µm 
membrane) was added to give a 1:1 mix.  0.5-1 ml was added to a cryotube (PAA) and stored in 
liquid nitrogen.  When freezing down, the cultures were at a minimum of 2% ring-stage 
parasitaemia.   
2.1.3 Transfection of P. falciparum  
Genetic manipulation of P. falciparum parasites was achieved using standard transfection 
methods (Wu et al., 1995).  80 µg of precipitated plasmid DNA was resuspended in 15 µl of 1 x 
TE buffer (10 mM Tris-HCl, pH8, 1 mM Na2EDTA).  Just before electroporation, 385 µl warmed 
cytomix (120 mM KCl, 0.15 mM CaCl2, 2 mM EGTA, 5 mM MgCl2, 10 mM K2HPO4/KH2PO4, 25 mM 
HEPES (pH7), filter sterile) was added.  A culture of synchronised ring-stage parasites at 5-10% 
parasitaemia was pelleted and all media removed.  The DNA-cytomix solution was added to 250 
µl of the packed cells, and transferred to a 0.2 cm cuvette (Bio-Rad).  The sample was 
electroporated at 950 microfarad (µF) at a voltage of 0.31 kilovolts (Kv) using a GenePulser 
Xcell™ (Bio-Rad).  The electroporated parasites were moved to a T25 culture flask (VWR) with 
10 ml culture medium and enough fresh blood (usually fresh from an LSHTM donor with 50 
U/ml) was added to give 5% haematocrit.  24 hours later, the positive selection marker WR99210 
was added at 5 nM concentration.  WR99210 is a selective inhibitor of the parasite dihydrofolate 
reductase (DHFR) (Fidock and Wellems, 1997; Fidock et al., 1998).  The transfection plasmids 
encode a mutant human dhfr gene which confers resistance to WR99210.  After starting positive 
selection with WR99210, 24 hours post transfection, parasites were visible by Giemsa smear at 
between 14-28 days.  To reduce the presence of episomes, and increase the proportion of 
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parasites with an integrated plasmid copy, the cultures were cycled off drug for three weeks 
then on drug until parasites reached 1% parasitaemia for one to four cycles.  Integration was 
monitored by PCR after each cycle, see chapter 2.2.2. 
2.1.4 Limiting dilution to generate clonal parasite lines 
Transgenic P. falciparum lines were cloned by limiting dilution.  Ring stage cultures were counted 
using a haemocytometer to get the number of parasitised cells in a microlitre of packed RBCs.  
The infected culture was diluted to give 0.25 parasites per well in a 96 well plate at 2% 
haematocrit.  Culture media was replaced every three days.  After 14-21 days, positive wells 
were identified by a lactate dehydrogenase assay.   
2.1.5 Lactate dehydrogenase assay 
The lactate dehydrogenase (LDH) assay can be used as a colorimetric measure of parasite 
positive wells.  LDH is an enzyme that catalyses conversion of lactate to pyruvate, simultaneously 
reducing NAD+ (Nicotinamide adenine dinucleotide) to NADH.  P. falciparum LDH can rapidly 
reduce 3-acetyl pyridine NAD (APAD), whilst erythrocytic LDH is only able to catalyse this 
reaction very slowly.  An NBT/PES (nitro blue tetrazolium/phenazine ethosulphate) solution is 
included that converts APADH into a coloured salt, which can be read at 650 nm on a 
spectrophotometer.  The LDH assay  was modified from previously described methods (Makler 
and Hinrichs, 1993; Makler et al., 1993).  20 µl of whole culture was removed from each well 
and transferred to a replica plate.  100 µl of Malstat reagent (0.1% Triton X-100, 130 mM L-
Lactate, 27 mM Tris-HCl, pH 9.0), supplemented with 33 µM APAD (Sigma-Aldrich) was added.  
25 µl of NBT/PES solution (2.2 mM nitro blue tetrazolium, 240 µM phenazine ethosulphate) was 
added to each well and the plate was incubated at 37oC for 30 minutes in the dark.  Positive 
wells can be identified by a colour change to dark blue/purple.  Positive wells were expanded 
for PCR and Southern blotting analysis of the clones.   
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2.2 Nucleic acid manipulation 
2.2.1 Oligonucleotide primer design  
All primers were designed by hand assessed for secondary structures and uniqueness using 
Oligocalc (http://www.basic.northwestern.edu/biotools/-oligocalc.html) and PlasmoDB, 
respectively, and supplied by Sigma-Aldrich.  Working stocks of 10 µM were used in all reactions.  
For a complete list of primers, see Appendix A1.   
2.2.2 Polymerase chain reaction (PCR) 
The Polymerase Chain Reaction (PCR) is used to amplify the number of copies of a specific DNA 
sequence for further analysis.  The reaction relies on thermal cycling of the DNA with a 
thermostable DNA polymerase.  The oligonucleotide primers are designed to bind to template 
DNA flanking the region of interest on the opposing DNA strands.  Firstly the double stranded 
DNA is denatured at 94-95oC.  The temperature is then lowered to the optimal primer-template 
annealing temperature which varies between primers and template, usually 40-60oC.  The 
primer anneals to the complementary template DNA.  The temperature is raised to 65oC 
(although normally 72oC, the AT-rich P. falciparum DNA requires a lower elongation 
temperature) to allow the polymerase to add nucleotides to the primer sequence, extending the 
complementary strand and creating double stranded DNA.  This is the elongation step.  The 
temperature is once again raised to 94oC to denature the DNA.  This cycle of denaturation, 
annealing and elongation is repeated around 30 times to exponentially increase the amount of 
DNA.   
For reactions that required high fidelity, PCR was carried out using PfuUltra II Fusion HS DNA 
Polymerase (Stratagene), unless otherwise stated.  PfuUltra is a proof-reading polymerase, used 
to reduce the chance of incorporating mutations in the PCR products.  Negative controls, 
without genomic DNA, were also carried out for each experiment.  PCR was performed according 
to the Stratagene protocol for PfuUltra II Fusion HS DNA Polymerase.  For reactions where high 
fidelity was not necessary, BioMix™ Red DNA polymerase (Bioline) was used according to the 
manufacturer’s instructions.   
To screen bacteria transformed with plasmids for colonies positive for an insert, Colony PCR was 
performed.  Colony PCR can be carried out on whole bacterial cells straight from an agar plate 
and is useful for screening plasmids with low efficiencies of ligation or transformation.  A master 
plate is used to refer back to the correct colony.  Firstly the appropriate number of PCR reactions 
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were set up using BioMix™ Red DNA polymerase (Bioline) and primers that are specific for the 
insert-plasmid junction, in a total volume of 10 µl.  A sterile pipette tip was used to touch a single 
colony from the transformed E. coli, streaked on to the master plate and then the tip was put 
into the PCR tube.  The PCR reaction was mixed with the tip and then the tip was discarded.  The 
reaction was cycled as follows; 94oC for 3 minutes, 60oC for 30 seconds, 65oC for 30 seconds, 
94oC for 30 seconds, 60oC for 30 seconds, 65oC for 30 seconds, steps 4-6 cycled for 25 times, 
then 65oC for 3 minutes.   
2.2.3 Agarose gel electrophoresis 
Agarose gel electrophoresis enables DNA fragments to be separated by size for further analysis 
or manipulation, and approximate concentrations to be calculated.  0.8-1.2% agarose (BioLine) 
gels were prepared in TAE Buffer (tris-acetate-ethylenediaminetetraacetic acid (EDTA), 40 mM 
Tris, 1 mM EDTA pH 8.0, 0.12% glacial acetic acid), with ethidium bromide solution (Sigma) at 
0.5 µg/ml.  DNA products were mixed with a 1/5 volume of 5x loading buffer (Fermentas) and 
were loaded and run alongside HyperLadder I (Bioline) to estimate to molecular weight of the 
bands.  The running buffer was TAE, and the gel was run at 100-120 volts (V).  The bands were 
visualised using UV light.  If necessary, bands were excised using a sterile scalpel blade to 
facilitate cloning.   
Two different methods were used for purifying DNA after PCR and restriction digests; PCR 
cleanup (QIAquick PCR Purification, Qiagen) and agarose gel extraction (Qiaquick Gel Extraction 
Kit, Qiagen).  The kits were used to remove proteins (e.g. polymerases and restriction 
endonucleases), primers, free nucleotides and other DNA fragments which could interfere with 
further experiments.  The kits were used as per the manufacturer’s handbook.  Agarose gel 
electrophoresis was used to assess the concentration and purity of the extracted DNA sample.   
2.2.4 Restriction digests and DNA ligation reactions 
All restriction endonucleases were supplied by Fermantas or New England Biolabs.  All digest 
reactions were incubated at 37oC for three hours, unless otherwise stated. 
Ligation reactions, with the digested insert and plasmid, were set up using T4 DNA ligase 
(Promega).  The total reaction volume was 10 µl and the ratio of insert:plasmid was calculated 
using the manufacturer’s formula.  The ligation was incubated for 4-18 hours at 15oC.  
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2.2.5 Transformation of competent E. coli cells 
Plasmid DNA was amplified using commercially chemically competent XL-1 Blue E. coli cells 
(Agilent).  Briefly, the cells were defrosted on ice and 50 µl was aliquoted into pre-chilled round 
bottom tubes (BD Falcon).  1.7 µl of β-mercaptoethanol was added and the tubes were gently 
shaken.  The cells were incubated on ice for ten minutes.  Plasmid DNA, 0.1-50 ng, was added to 
the tubes.  The reaction was then incubated on ice for 30 minutes.  The cells were heat-shocked 
at 42oC for 45 seconds and then incubated on ice for two minutes.  0.9 ml of SOC recovery 
medium (2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2 and 20 mM 
glucose), prewarmed to 37oC, was added and the cell suspension was incubated at 37oC for 1 
hour in a shaking incubator.  200 µl of the suspension was spread onto Luria-Bertani (LB) agar 
(1% tryptone, 0.5% yeast extract, 1% NaCl and 1.5% agar) supplemented with 100 µg per ml 
ampicillin (Sigma-Aldrich), and incubated at 37oC overnight.  Colonies were screened for 
presence of the insert by colony PCR, positives were grown up for DNA extraction.   
2.2.6 Extraction of plasmid DNA from transformed E. coli cells 
Single colonies of transformed E. coli were selected and incubated overnight in LB-broth (as LB-
agar without the 1.5% agar) supplemented with ampicillin.  The plasmid DNA was isolated from 
the transformed cells using the QIAprep Spin MiniPrep Kit (Qiagen) or QIAGEN Plasmid Mega 
Kit, following the supplier’s handbook.  Glycerol stocks were also created with a 1:1 ratio of cell 
culture solution to glycerol, and stored at -80oC.   
2.2.7 Sequencing of DNA 
DNA was sequenced using the BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems).  The reaction mix contains both deoxynucleotides (dNTPs), which can be 
incorporated into the amplifying strand, and fluorescently-labelled dideoxynucleotides 
(ddNTPs) which, when integrated into the DNA strand, result in termination of elongation.  This 
creates many strands of different lengths with a base specific fluorescently-labelled ddNTP 
which can be read on an ABI3730 capillary sequencer (Applied Biosystems).  Reactions were 
carried out in a 10 µl total volume (1.75 µl BigDye buffer, 0.5 µl BigDye 3.1, 1 µl of 10 µM primer, 
3 µl purified DNA and 3.75 µl dH2O).  The reaction was cycled as follows; 94oC for 1 minute, 55oC 
for 1 minute, 65oC for 1 minute, above steps repeated 25 times, and then 65oC for 5 minutes.   
The DNA from the sequencing reaction was precipitated, to remove dye, excess nucleotides and 
proteins, by the addition of 0.3 M sodium acetate, three times the volume of 100% ethanol and 
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put at -80oC for 30 minutes.  This was then spun at 4oC for 30 minutes at 13000 x g.  The 
supernatant was removed and 500 µl of 70% ethanol was added and the reaction was spun 
again.  The supernatant was carefully removed and the tubes were left to dry in the dark.  The 
samples were sequenced using an ABI3730 capillary sequencer using a faculty funded service.   
2.2.8 Isolation of P. falciparum genomic DNA 
P. falciparum genomic DNA (gDNA) was isolated from infected cultures using two different 
methods, depending on the amount of DNA required.  For smaller amounts of gDNA, less than 
10 µg, the QIAmp DNA Blood Mini Kit (Qiagen) was used, according to the manufacturer’s guide.  
This kit can extract DNA from up to 200 µl packed cell volume of infected RBCs.  For larger 
volumes, the following protocol was performed.  10 ml of late stage parasite culture was saponin 
lysed (see chapter 2.3.3), and the pellets resuspended in 400 µl of resuspention buffer A (500 
mM NaOAc pH 5.2, 100 mM NaCl, 1 mM EDTA).  Half the volume of 10% SDS (sodium dodecyl 
sulphate) was added, followed by one volume of buffered phenol:choloroform, pH 8, and the 
solution mixed.  The samples were centrifuged at full speed for five minutes at room 
temperature, by which time the aqueous and organic phases had separated.  The DNA remains 
dissolved in the aqueous phase, which is transferred into a fresh tube and the phenol:chloroform 
extraction repeated.  The aqueous phase is again transferred to a clean tube and the final 
extraction uses one volume of chloroform.  Finally, the DNA pellet is precipitated by adding two 
volumes of 100% ethanol, spinning at 4oC for 30 minutes at full speed.  The pellet is then washed 
once in 70% ethanol, and resuspended in 20-100 µl 1 x TE buffer.      
2.2.9 Southern hybridisation 
The purpose of a Southern blot is to detect a specific DNA sequence within a sample.  With 
respect to this project, Southern hybridisation was performed in order to detect integration 
events and episomal DNA within transgenic parasite lines.  5-10 µg of gDNA was digested for 
three hours with the appropriate restriction enzymes, at appropriate temperatures (see chapter 
3).  The digested DNA was precipitated in the same way as for preparing DNA for sequencing 
(chapter 2.2.7), and resuspended in 20 µl TE buffer.  The samples were then run on a 0.7% 
agarose gel with ethidium bromide (0.5 µg/ml) at 75V for three hours to achieve good separation 
of the fragments and photographed under UV light.  The gel was depurinated for 10 minutes in 
0.25 M HCl and denatured in alkaline transfer buffer (0.4 M NaOH) for 30 minutes, with one 
wash.  The gel was then transferred onto a positively charged nylon membrane (Brightstar, 
Ambion) overnight using capillary action.  Once transferred, the DNA was crosslinked onto the 
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membrane using 1200 joules of UV (UV Stratalinker™ 1800, Stratagene).  The membrane was 
washed twice in 2x saline-sodium citrate (SSC, 20x stock at 3 M NaCl, 0.3 M sodium citrate) 
buffer.  Hybridisation buffer (HYB, containing 10% dextran sulphate, 50 mM Tris, 10 mM EDTA, 
5x SSC buffer, 1x Denhardt’s solution and 0.2% SDS, pH 7) containing 100 µg/ml of sheared 
salmon sperm DNA (denatured at 95oC for 5 minutes) was used to pre-hybridise the membrane 
for 2 hours at 60oC.  The specific DNA probes were created using PCR (specific details in chapter 
3).  25 ng of probe DNA in TE buffer was denatured at 95oC for 5 minutes, then snap-cooled on 
ice for a further 5 minutes.  The probe was radiolabelled with [32P]dCTP (Perkin-Elmer) using 
Rediprime II random prime labelling kits (GE Healthcare) following the manufacturer’s protocol.  
Following the 30 minute 37oC incubation period, the probe was separated from the 
unincorporated nucleotides in an Illustra microspin G-25 column (GE Healthcare) and denatured 
at 95oC for 5 minutes before being added to the membrane-HYB.  Hybridisation with the labelled 
probe was carried out overnight at 60oC, after which the membrane was rinsed once and washed 
twice, for one hour, in 2x SSC buffer at 60oC.  The membrane was exposed to a phosphor screen 
for 24-48 hours and developed using a Typhoon PhosphorImager (GE Healthcare).    
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2.3 Parasite protein manipulation 
2.3.1 Immunofluorescence assay (IFA) on blood smears 
Thin blood smears were prepared on glass slides (VWR) and wells marked with a hydrophobic 
PAP pen (Sigma-Aldrich).  The slides were fixed in 4% formaldehyde (made up fresh from 
paraformaldehyde in PBS, pH 7.3, Sigma-Aldrich) for 20 minutes at RT, then washed twice with 
1x PBS.  The cells were then permeabilised with 0.1% Triton X-100 (Sigma-Aldrich) in 1x PBS for 
10 minutes at room temperature and again washed three times with 1x PBS.  The slides were 
incubated for 1 hour at RT or overnight at 4oC in blocking buffer (3% BSA in 1x PBS, Sigma-
Aldrich) to prevent unspecific binding, before incubation with the primary antibody, diluted to 
an appropriate concentration in blocking buffer, for 1 hour at RT.  The slides were washed thrice 
with 1x PBS and incubated with the secondary antibody, diluted 1:500 in blocking buffer, for 1 
hour at RT, before being washed for a final three times with 1x PBS.  The slides were mounted 
in Vectashield mounting media (Vector Laboratories) with DAPI, before analysis on the confocal 
microscope (Zeiss).   
Primary antibodies were diluted as follows: monoclonal rat anti-HA (clone 3F10, Roche) at 1:100 
and monoclonal mouse anti-HA (clone 16B12, Convance) at 1:500.  Rat anti-PfBiP and mouse 
anti-PfGAP45, obtained from Anthony Holder’s laboratory, NIMR, were used at 1:1000.  Rabbit 
antibodies against PfMSP-1 and PfEBA175, obtained from Mike Blackman’s laboratory, NIMR, 
were used at 1:5000, 1:200 and 1:200, respectively.  Rabbit anti-PfERD2, from the Malaria 
Research and Reference Reagent Resource Centre (MR4), was diluted 1:1000.  Rabbit anti-
PfAKAP, from Anaïs Merckx’s laboratory, Université Paris Descartes, was used at 1:500.   
Anti-peptide antibodies, provided by Pfizer, were generated by Cambridge Research 
Biochemicals using the Target™ Antibody service.  Short peptide sequences of PfPDEα and 
PfPDEβ, predicted to be immunogenic by a Pfizer immunogenicity program, were synthesised 
by Cambridge Research Biochemicals and conjugated to chicken gamma globulin (CGG).  The 
sequences and positions of the peptides are shown in appendix A2.  Two peptides were 
produced for PfPDEα and one for PfPDEβ.  The peptide conjugates were then used to immunise 
rabbits, two rabbits for each peptide.  Four booster immunisations were given, two weeks after 
the previous immunisation.  Serum samples were taken pre-immunisation, after each booster 
and the final bleed at the end of the course.  The final bleed was affinity purified using columns 
coated with the corresponding peptide to obtain specific antibodies.  Two elution buffers were 
used, glycine and triethanolamine (TEA).      
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The following secondary antibodies were all obtained from Invitrogen and used at 1:500: Alexa 
Fluor 488 goat anti-rat IgG (H+L), preabsorbed against mouse IgG (A11006), Alexa Fluor 594 goat 
anti-rat IgG (H+L), preabsorbed against mouse IgG (A11007), Alexa Fluor 594 F(ab’)2 goat anti-
rabbit IgG (H+L)(A11072), Alexa Fluor 594 goat anti-mouse IgG (H+L), highly cross absorbed 
(A11037) and Alexa Fluor 488 F(ab’)2 goat anti-mouse IgG (H+L), highly cross absorbed (A11017).  
2.3.2 Immunofluorescence assay (IFA) with ER-Tracker, in suspension  
50 µl of purified late stage parasites were resuspended in 50 µl RPMI 1640 and incubated with 
1 µM ER-Tracker™ Blue-White DPX (Molecular Probes, Life Technologies, kindly provided by 
Theresa Ward (LSHTM)) for 15 minutes at 37oC.  The cells were then washed three times with 
RPMI 1640 and once with 1x PBS at 500 x g.  The parasites were fixed with 1 ml fixation solution 
(4% formaldehyde, 0.01% glutaraldehyde in 1x PBS) for 30 minutes at RT, and then washed 5 
times with 1x PBS at 400 x g.  The cells were permeabilised with 0.1% Triton X-100 in 1x PBS for 
10 minutes at room temperature and washed three times with 1x PBS at 500 x g.  The cells were 
incubated for 1 hour at RT in blocking buffer (3% BSA in 1x PBS), then with an appropriate 
dilution of primary antibody (1:100 monoclonal rat anti-HA (clone 3F10, Roche)) in blocking 
solution.  The primary antibody was washed away 3 times with 1x PBS, and the cells incubated 
with 1:500 dilution of the secondary antibody (Alexa Fluor 488 goat anti-rat IgG, Invitrogen), and 
washed a final 3 times.  The cells were mounted in Vectashield mounting media (Vector 
Laboratories) without DAPI, before analysis on the confocal microscope (Zeiss).   
2.3.3 Saponin lysis of erythrocyte membranes 
To free parasites from the host cell, packed RBC pellets were resuspended in 5x the volume of 
0.15% saponin solution (Sigma-Aldrich) in PBS, containing EDTA-free protease inhibitor cocktail 
(Roche), and incubated for two minutes at RT.  The samples were pelleted for 1 minute at 10,000 
x g and washed three times in ice cold 1x PBS, also containing EDTA-free protease inhibitors for 
30 seconds at 10,000 x g.  The samples were then stored on ice for further work or frozen at -
20oC for future analysis.   
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2.3.4 Solubility assay 
Frozen saponin lysed parasite pellets were vigorously resuspended in 2-5 times the volume of 
ice cold 5 mM Tris-HCl, pH 8.0 containing EDTA-free protease inhibitor cocktail (Roche), and 
incubated for 10 minutes on ice.  The lysate was centrifuged at 16,000 x g for 10 minutes at 4oC, 
the supernatant removed, recentrifuged to remove residual insoluble material and saved as 
sample S1.  DNAse digestion was performed on the pellet, briefly, the pellet was resuspended 
in half the volume of DNAse digestion buffer (5 mM Tris-HCl and 2.5 mM MgCl2, plus EDTA-free 
protease inhibitor cocktail) and 1 µl DNAse I (stock concentration 5 mg/ml) per 100 µl sample 
was added.  The digestion was incubated at RT for 10 minutes and gently mixed every 2 minutes.  
The sample was centrifuged at 16,000 x g for 10 minutes at 4oC and the supernatant aspirated.  
The pellet was extracted for 30 minutes with 2-5 pellet volumes of 1% Triton X-100 on ice, then 
centrifuged at 16,000 x g for 10 minutes at 4oC to obtain the S2 fraction.  The final pellet was 
extracted using insoluble fraction extraction buffer (4% SDS (Sigma-Aldrich), 0.5% Triton X-114 
(Sigma-Aldrich), in 0.5x PBS), for 30 minutes at RT.  All extractions used the same extraction 
volume and equal amounts were analysed by immunoblotting.   
2.3.5 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Polyacrylamide gel electrophoresis is used to separate proteins based on their electrophoretic 
mobility, dependent on size, charge and conformation of the protein.  For all the work in this 
project, denaturing SDS-PAGE was used.  This linearises the protein and the SDS in the buffer 
gives the protein an overall negative charge, therefore the separation is mostly based on size.  
Estimations of the size of sample proteins can be made by comparison with proteins of a known 
molecular weight (Alberts et al., 2002).   
4x reducing sample buffer (200 mM Tris-HCl, pH 6.8, 8% SDS, 40% glycerol, 4% β-
mercaptoethanol, 50 mM EDTA, 0.08% bromophenol blue) was added to the samples (to give a 
1x final volume).  The samples were boiled for 5 minutes before running on a Tris-HCl 
polyacrylamide gel (8 or 10% gels were used, separating gel pH 8.8 (stacking gel pH 6.8, 4% 
polyacrylamide) Acrylogel 2.6 (40% solution, 37:1 acrylamide to N,N'-methylenebisacrylamide, 
VWR)).  The gel was run in Tris-glycine buffer (25 mM Tris-HCl pH8.3, 250 mM glycine, 0.1% SDS), 
for 1.5 hours at 120 V.  The molecular weight ladders used were Precision Plus Protein™ 
Standards, Unstained for Coomassie blue staining or All Blue for immunoblotting (both Bio-Rad).  
The gels where then analysed either by Coomassie blue staining or immunoblotting.  
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2.3.6 Coomassie blue gel staining 
To stain for total protein content, Coomassie blue gel staining was performed.  After SDS-PAGE, 
the gel was soaked in Coomassie blue staining solution (0.25% Coomassie Brilliant Blue R-250, 
45% methanol, 10% acetic acid) for 1 hour.  After which, the gel was incubated in destaining 
solution (45% methanol, 10% acetic acid) with gentle shaking for up to 16 hours.  The gels were 
stored in 5% acetic acid solution.   
2.3.7 Western blotting 
After SDS-PAGE, transfer to nitrocellulose membrane was performed using the Trans-Blot 
Turbo™ transfer system (Bio-Rad), according to the manufacturer’s instructions.  Membranes 
were blocked in 5% milk powder in 1x PBS with 0.1% Tween (Sigma-Aldrich) (PBS-T), at RT for 1 
hour or overnight at 4oC.  The membrane was probed with an appropriate primary antibody 
dilution (see below), at RT for 1 hour or overnight at 4oC, and washed twice for 15 minutes with 
PBS-T.  The blot was then incubated with a 1:3000 dilution of horse radish peroxidise (HRP)-
conjugated secondary antibody (see below) at RT for 1 hour.  Finally the blot was washed in PBS-
T three times for 10 minutes each.  The immunostaining was visualised using Pierce ECL 2 
western blotting substrate (Thermo Scientific) and ECL Hyperfilm (GE healthcare) according to 
the manufactures protocols.   
Primary antibodies were diluted as follows: monoclonal rat anti-HA (clone 3F10, Roche) at 
1:1000.  Polyclonal rabbit anti-human PKG (Enzo Life Sciences) used at 1:3000. Mouse anti-
PfGAP45, obtained from Anthony Holder’s laboratory, NIMR, was used at 1:3000.  Mouse anti-
PfGAPDH, obtained from Claudia Danbunberger (Swiss Tropical and Public Health Institute) was 
used at 1:30000.   
The following secondary antibodies were all obtained from Dako and used at 1:3000: polyclonal 
rabbit anti-rat immunoglobulin/HRP, Ig fraction (P0450); polyclonal goat anti-mouse 
immunoglobulin/HRP, affinity isolated (P0447); and polyclonal goat anti-rabbit 
immunoglobulin/HRP, affinity isolated (P0448).   
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2.4 [3H] Hypoxanthine incorporation growth inhibition assay  
Hypoxanthine is the major base used by Plasmodium to synthesise the adenylate and guanylate 
purine nucleotides during DNA synthesis (Webster and Whaun, 1981).  In iRBCs, hypoxanthine 
incorporation is linearly proportional to parasitaemia levels (Chulay et al., 1983) and can be used 
to assess relative parasite numbers.  Parasites are incubated with a drug of interest in a low 
hypoxanthine environment for a minimum of 24 hours before tritiated ([3H]) hypoxanthine is 
added, when the parasites are mostly trophozoites.  During DNA synthesis, the 3[H] 
hypoxanthine is incorporated into the genome.  Harvesting of the assay captures 
macromolecules, including gDNA, onto glass fibre filtermats, with the unincorporated radio 
labelled hypoxanthine washed away.  The counts per minute (CPM) are measured using a 
scintillation counter and used to determine relative parasite numbers.   
IC50s (50% maximal inhibitory concentrations) are used to determine the performance of drugs 
under particular assay conditions to assess whether the drug has desirable properties.  IC50 is 
the half maximal inhibitory concentration, the concentration of drug required in the assay to 
give 50% inhibition of parasite growth.  In a hypoxanthine assay, it is calculated using uninfected 
RBCs (uRBCs) as 100% inhibition and untreated parasites as 0% inhibition.    
Stock solutions of drugs were diluted in low hypoxanthine assay (IV) medium (with RMPI 1640 
supplemented with 0.5% complete Albumax II solution and 5 µM cold hypoxanthine) in a 96-
well flat bottom plate to give 2x final concentration in the first column, in triplicate.  The final 
DMSO concentration was always lower than 0.5%.  Serial dilutions were then performed across 
the plate to give a final volume of 100 µl.  A positive control row, iRBCs and no drug, and a 
negative control row, uRBCs and no drug, were included on each plate.  In addition, a control 
plate of at least one commercial antimalarial was included in each experiment, usually 
chloroquine and artemisinin.   
Synchronous ring-stage (>70% rings) P. falciparum cultures maintained in complete medium 
were washed twice in RPMI 1640 to remove all the hypoxanthine to ensure maximal uptake of 
[3H] hypoxanthine.  IV medium was used to adjust the culture to 0.5% parasitaemia at 5% 
haematocrit, resulting in a final 0.5% parasitaemia and 2.5% haematocrit.  100 µl of parasites or 
uRBCs (5% haematocrit) was added to each well.  The plates were incubated at 37oC, 5% CO2 for 
24 or 48 hours.    
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After 24 hours, 250 nanocurie (nCi) of 3[H] hypoxanthine (Perkin-Elmer) in 25 µl RPMI was added 
per well.  The plates were then incubated for a further 24 or 48 hours depending on the assay.  
After a total of 48 or 72 hours, the experiment was terminated by freezing in a -80oC incubator.  
Once frozen, the plates were then thawed and harvested onto glass fibre filtermats (Perkin-
Elmer), Meltilex solid scintillant (Perkin-Elmer) added and read using a Wallac BetaLux 
scintillation counter.   
Data analysis was performed using Microsoft Excel and GraphPad Prism.  Average positive (drug-
free wells) and negative (uRBC wells) controls were calculated for each plate and percentage 
inhibition was calculated using the following formula: 
 
 
 
Parasite growth was plotted against the logarithm of drug concentrations and IC50s were 
calculated by the non-linear regression analysis using Prism 6.0 software.  For the comparison 
assays, the difference between the best-fit logIC50 values was assessed using the compare 
function in Prism 6.0.  The level of significance was fixed at P<0.05.   
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2.5 Parasite growth assays 
Parasite growth assays, used to assess differences in growth rate between different parasite 
strains, or parasites under different conditions, were analysed by flow cytometery, adapted 
from previously published protocols (Wilson et al., 2010, 2013).  Synchronous ring stage 
parasites were diluted to 0.5% parasitaemia in 2% haematocrit in 6 well plates, 2 ml total 
volume.  The cultures were incubated for six days, according to culture practices in chapter 2.1.1.  
Culture media was changed daily and 50 µl samples (in duplicate for a technical repeat) were 
taken at 0 hours and once a day for the six days of incubation.  The samples were fixed in an 
equal volume of FACS fixation solution (4% formaldehyde, 0.01% glutaraldehyde) overnight at 
4oC.  The fixative was aspirated and the samples were kept in 1x PBS until the end of the assay.  
After all samples were collected, they were washed twice in 1x PBS.  The parasite DNA was 
stained with SYBR Green I (Life Technologies) nucleic acid stain (excitation 497 nm and emission 
520 nm) at a final concentration of 1:5000-1:10000 in 1x PBS, at 37oC for 30 minutes, in the dark.  
The samples were again washed in 1x PBS three times, and transferred to 1.2 ml microtubes 
(Starlab) in a total volume of 300 µl.  The samples were analysed using a BD™ LSR II flow 
cytometer system (BD Biosciences).  Typically, 50,000-100,000 events were counted for each 
sample.  The assay was analysed using FlowJo, v. 7.6.5 software (Tree Star Inc.).  Representative 
Giemsa smears were performed for a proportion of the samples to monitor the robustness of 
the flow cytometry based assay.  The following gating strategy was applied: 
84 
 
 
Figure 2.1 Standard gating strategy for growth assays 
Gates were used to identify singlets (top left panel), all RBCs based on size (top right panel) and 
to distinguish between uRBCs and iRBCs based on SYBR Green fluorescence (lower panel). 
 
The assays were performed in triplicate, with three biological repeats, unless otherwise stated.  
Growth curves were generated using GrapPad Prism (GraphPad Software).  Parasitaemias were 
adjusted to give 0.5% at day 0 to reduce variability in the differences in parasitaemia between 
experiments.   
 
 
 
 
 
85 
 
2.6 Phosphodiesterase activity assays 
To measure the PDE activity of a protein sample, a PDE assay was developed using a scintillation 
proximity assay (SPA).  SPA is dependent on the limited energy of a sub-atomic particle to travel 
through water.  When a tritium atom decays, a β-particle is released.  This particle is able to 
excite scintillant in an aqueous solution only if it is less than 1.5 µm away.  Scintillant is 
incorporated into beads coated with a specific molecule, in this case the beads allow direct 
binding of the primary phosphate groups of non-cyclic 5’AMP or GMP, and the assay relies on 
the fact that cAMP and cGMP are unable to bind (figure 2.2).  The PDE SPA beads (Perkin Elmer, 
RPNQ0150) are yttrium silicate based.  An ion chelation mechanism allows the linear nucleotide 
to bind to the bead in the presence of zinc sulphate.    
 
Figure 2.2 Phosphodiesterase assay diagrammatic representation 
Cyclic nucleotides are unable to bind to the SPA bead, but when hydrolysed by a PDE the AMP 
or GMP product will bind the SPA bead and excite the scintillant within the bead.   
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2.6.1 Parasite lysate preparation 
Packed parasite pellets were obtained by saponin lysis and centrifugation (see chapter 2.3.3).  
The pellet was resuspended in ice cold 5 mM Tris-HCl (with EDTA-free protease inhibitors), 
centrifuged at 16000 x g for 10 minutes at 4oC and the supernatant aspirated to remove residual 
RBC material.  This was repeated until the supernatant was clear.  Any colour in the final sample 
can affect the number of counts measured.  The pellet was then resuspended in 250 µl PDE lysis 
buffer (10 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% Nonidet P-40 and EDTA-free protease 
inhibitors) per 50 µl of sample, incubated on ice for 30 minutes with occasional mixing and 
centrifuged at 16000 x g for 20 minutes at 4oC.  The supernatant was saved for analysis by PDE 
assay.  When developing the assay, the Tris-HCl (1st wash) sample was saved as the cytosol 
fraction and the final pellet was further extracted with RIPA buffer (10 mM TrisH-Cl pH 7.5, 150 
mM NaCl, 0.1% SDS, 1% Triton X-100, 1% deoxycholate with EDTA-free protease inhibitors).  
EDTA was left out of all buffers because PfPDEs are magnesium dependent (Ross Cummings, 
Thesis).   
2.6.2 Immunoprecipitation of PDEβ-HA  
Pulldowns on the transgenic HA epitope tagged PDEβ-HA were performed using the Anti-HA 
Affinity Matrix (Roche, 11815016001) that incorporate immobilised rat monoclonal antibody 
(clone 3F10).  Packed parasite pellets of PDEβ-HA were obtained by saponin lysis (see chapter 
2.3.3).  The pellet was resuspended in 250 µl ice cold PDE lysis buffer (10 mM Tris-HCl pH 7.5, 
150 mM NaCl, 0.5% Nonidet P-40 and EDTA-free protease inhibitors) per 50 µl of sample, 
incubated on ice for 30 minutes with occasional mixing and centrifuged at 16000 x g for 20 
minutes at 4oC.  The supernatant was transferred to a pre-cooled tube, adjusted to 500 µl with 
PDE dilution buffer (10 mM Tris-HCl pH 7.5, 150 mM NaCl and EDTA-free protease inhibitors) to 
give a final detergent concentration of less than 0.2%, and the pellet discarded.  A sample of the 
supernatant was saved for analysis by immunoblotting, referred to as ‘input’.  20 µl of the matrix 
was washed twice with dilution buffer (centrifuged at 30 seconds 13000 x g to pellet the matrix), 
to equilibrate the anti-HA affinity matrix.  The lysate sample was then added to the equilibrated 
anti-HA affinity matrix, and incubated at RT for 2 hours with constant mixing.  After incubation, 
the matrix was pelleted at 13000 x g, the supernatant removed and a sample saved for analysis 
by immunoblotting, referred to as ‘unbound’.  The beads were washed twice with ice cold 
dilution buffer.  A small sample of the beads was saved for analysis by immunoblotting, referred 
to as ‘bound beads’.  The remaining beads were saved for analysis by PDE assay. 
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2.6.3 PDE assay 
PDE assays were conducted on parasite lysates, immunoprecipitated samples and putative 
recombinant proteins.  The general protocol is outlined below, with specific details on the 
relevant chapters.   
Assays were conducted in 100 µl volumes using a flexible-96 well plate (Perkin Elmer, 1450-401).  
Each well contained 90 µl of the enzyme mixture (lysates, immunoprecipitated samples, putative 
recombinant proteins or commercial bovine brain PDE) diluted in 1x PDE assay buffer (10x buffer 
contains 500 mM Tris-HCl, 83 mM MgCl2, 17 mM EGTA).  10 µl of a cNMP dilution (5 µl of [3H] 
cNMP tracer (Perkin Elmer cAMP-NET275250UC, cGMP-NET337250UC) in 995 µl 1x PDE assay 
buffer) was added to each well to start the reaction.  The plates were incubated at 37oC for 1 
hour.  The reaction was terminated by addition of 50 µl of resuspended PDE SPA beads 
(reconstituted to 20 mg/ml in distilled H2O).  The plates were sealed with Plateseal (Perkin 
Elmer) briefly shaken and then incubated for 20 minutes at RT to allow the beads to settle.  
Scintillation was measured using a Wallac 1450 Microbeta™ Scintillation Counter (Perkin Elmer), 
with each well counted for 30 seconds.   
To determine the dilution needed for the test sample, an initial dose-response assay was 
performed with doubling dilutions of the sample.  This was to ensure the substrate was not 
depleted during the course of the assay.  The initial sample was diluted to give roughly 30% 
hydrolysis of the cyclic nucleotide.   
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2.7 Baculovirus expression system 
A synthetic gene encoding the P. vixax PDEβ was purchased from GeneArt (Invitrogen) and 
codon optimised for Spodoptera frugiperda, the baculovirus insect host, to maximise the 
production of recombinant protein from the system.  Protein expression was performed in 
collaboration with Avnish Patel (LSHTM) and Meredith Stewart (LSHTM).  The donor plasmid, 
pRN16, the shuttle vector, Bacmid KO orf:1629 and the control plasmid pRN42-GFP were kindly 
provided by Meredith Stewart and Polly Roy (LSHTM) and pAcH10Mistic YMI by Avnish Patel. 
2.7.1 Bacmid shuttle vector preparation  
The baculovirus genome (KO:1629) was propagated inside E. coli as a bacmid, a bacterial 
artificial chromosome that replicates using a mini-F replicon sequence that mimics the host 
genome origin of replication thus utilising the genomic replication machinery of the bacterial 
host, (supplemented with chloramphenicol (50 µg/ml) and kanamycin (50 µg/ml)).  pRN42-GFP 
was used as a GFP control transfer vector to measure transfection efficiency and grown in E. coli 
(supplemented with ampicillin (100 µg/ml)).  Alkaline lysis, phenol:chloroform extraction and 
isopropanol precipitation was used to extract and purify the DNA.  Briefly, the bacterial pellet 
was lysed in an equal volume of Solution I (5 mM Tris-HCl, pH8, 2 mg/ml RNase), Solution II (1% 
SDS, 0.8% NaOH) and Solution III (29.5% glacial acetic acid, 3 M potassium acetate), until a white 
precipitate was formed.  The sample was centrifuged at 3,500xg for 10 minutes and the 
supernatant decanted into a fresh tube.  Half the volume of phenol:chloroform:isoamyl-alcohol 
(25:24:1) was added and the sample was centrifuged at 3000xg until the organic and aqueous 
phases separated.  The aqueous phase, containing the DNA, was decanted into a fresh tube and 
an equal volume of 100% chloroform was added.  The sample was again centrifuged and the 
aqueous phase removed to a new tube.  An equal volume of ice-cold isopropanol was added and 
left at 4oC for a minimum of five minutes.  The DNA was centrifuged at 3,500xg for 30 minutes, 
washed with 70% ethanol and the centrifugation repeated.  The ethanol was removed and the 
pellet dried.  The purified DNA was resuspended in nuclease-free water and stored at 4oC.    
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2.7.2 General Sf9 insect cell culture 
Sf9 insect cells were maintained at 28oC in Insect-Xpress medium (Lonza) supplemented with 
antibiotics and antimycotic solution (100 µg/ml penicillin streptomycin and 2.5 µg/ml 
amphotericin B).   
2.7.3 Transfection of Sf9 cells 
Transfection of Sf9 cells was performed using the X-tremeGENE HP DNA transfection system 
(Roche), according to the manufacturer’s protocol.  Briefly, 1x106 Sf9 cells were seeded into a 6 
well plate.  100 µl of sterile H20 was added to 100 ng linear bacmid DNA (digested with Bsu361 
restriction endonuclease for 2 hours at 37oC) and 500 ng of transfection vector (described in 
chapter 6).  Per reaction, 5 µl of transfection reagent (X-tremeGENE HP) was diluted in 100 µl 
sterile H2O and incubated for 5 minutes.  The transfection mix was then added to the DNA 
solution and incubated for 15 minutes at RT.  The Sf9 cell medium was aspirated and 800 µl of 
antibiotic and serum free medium was added.  The transfection mixture was added to the cells 
and incubated for four hours with rocking at RT.  The transfection mixture was aspirated and 
fresh culture medium was added to the cells.  The cells were then incubated for 3-5 days at 28oC.  
Transfection efficiency was monitored using light microscopy for cell morphology changes and 
UV microscopy (Eclipse TS100 inverted microscope, Nikon) with the pRN42-GFP control plasmid.   
2.7.4 Baculovirus plaque assay  
To quantify the viral titre, plaque assays were performed.  Plaque assays work by restricting the 
spread of new viruses to the neighbouring cells by application of a viscous medium over host 
cells.  When cell lyses due to infection with a virus, those viruses will be unable to diffuse far and 
will only infect cells in very close proximity to the original infected cell.  Over several cycles this 
will form a ‘plaque’, a region of cell death next to live, uninfected cells.  When the viral stock is 
sufficiently dilute only a few viral particles will infect per well, individual plaque formation will 
be visible and the number of plaques will equate to the initial concentration of virus added. 
10 fold dilutions of the virus stock in culture medium were created, which were then added to 
Sf9 cell monolayers in 6 or 12 well plates.  The plates were put on a rocker and the virus allowed 
to adhere for 2-3 hours.  The supernatant was then aspirated and an agar overlay (3% low gelling 
temperature agarose in PBS, sterilised by autoclaving), culture media mix at a 1:1 ratio and 
equilibrated to 42oC, was applied to the wells.  The agar overlay was allowed to set for 30 
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minutes before 0.5-1 ml of medium was added on top.  The plates were incubated at 28oC for 3-
5 days until plaque formation was visible.   
Plaques were visualised with neutral red solution (Sigma) at 1 mg/ml in PBS, filter sterilised, 
which stains healthy cells.  Liquid overlay was removed from the agarose gel and 1 ml of neutral 
red stain was added.  The plates were incubated at 28oC for 3 hours, the stain removed and the 
plates were then inverted for 1 hour.  After this time, the plaques will appear as a clear area and 
can be counted.  Viral titres are expressed as particle forming units (PFU) per ml of the neat 
solution.     
To clone individual viruses, plaques can be picked from the stained plaque assay.  Single plaques 
were removed with a sterile glass pipette and re-cultured on fresh cells.   
2.7.5 Viral amplification 
To amplify the virus, Sf9 cells were infected with low MOIs of virus (0.1-0.2).  MOI is multiplicity 
of infection and is the ratio of virus to cells.  Therefore an MOI of 1 is equivalent to 1 virus for 
every cell.  High MOIs (3-5) are used to ensure every cell is infected in the first round of 
replication, useful for protein expression where you want a high number of viruses and large 
amount of protein.  Low MOIs are used to amplify the viral stocks to give at least one round of 
cell replication before all cells are infected, thereby when the virus is harvested there will be a 
much higher concentration in the supernatant.  While amplifying the virus, the cells are 
monitored for signs of viral infection and decreasing viability.  After 4-7 days, the virus is 
harvested and the viral title measured by plaque assay.  To monitor protein expression during 
viral amplification, western blotting and IFAs were performed on the whole cells.  For 
immunoblotting, the cells were pelleted, the supernatant removed and the pellet resuspended 
in 1 pellet volume of 1x PBS before sample buffer was added.  Western blotting was performed 
as per chapter 2.3.7.  The Sf9 cell IFA method is shown below.    
 
 
 
 
 
91 
 
2.7.6 Immunofluorescence assay 
To visualise recombinant protein expression in the Sf9 cells, Immunofluorescence assays (IFAs) 
were performed.  Cells were seeded onto sterile glass coverslips in 6-well plates and incubated 
with virus for 48 hours.  The cells were then fixed in 4% formaldehyde for 1 hour at RT, before 
being washed twice in 1x PBS.  The cells were permeabilised with 0.5% Triton X-100 in PBS for 1 
hour at RT.  The coverslips were washed twice in 1x PBS and the blocking solution (1% BSA in 
PBS) was added.  The cells were blocked for 1 hour to prevent non-specific binding of the 
antibodies.  The primary antibody, mouse monoclonal anti-polyHistidine antibody (clone HIS-1, 
Sigma-Aldrich) was diluted to 1:300 in blocking solution, and added to the cells for 1 hour at RT, 
the cells were then washed 3 times with 1x PBS.  The secondary antibody, anti-mouse IgG (whole 
molecule)-FITC antibody produced in goat (Sigma-Aldrich) was diluted in blocking solution and 
added to the cells for 1 hour in the dark at RT, the cells were then washed 3 times with 1x PBS.  
The coverslips were then mounted on glass slides with Vectashield mounting media (Vector 
Laboratories) without DAPI, before analysis on the confocal microscope (Zeiss).   
2.7.8 Histidine tagged protein expression and purification 
The codon optimised PvPDEβ gene was cloned into the pAcH10Mistic YMI transfer vector using 
inframe BamHI restriction sites. This construct allows protein expression as an N-terminal 10 
times histidine mistic tagged fusion protein.  The Mistic tag has been demonstrated to improve 
the expression of complex membrane proteins (Xu et al., 2013). Recombinant baculovirus was 
produced by co-transfection using vector and purified KO orf:1629 bacmid genome, the virus 
was then grown to high titre for protein expression. A 100 ml culture of 2x106 Sf9 cells per ml 
was infected at an MOI of 10.  Expressed protein was purified using immobilised metal affinity 
chromatography (IMAC). 
Insect cells were lysed by dounce homogenisation in one tenth of the culture volume of lysis 
buffer (1% Triton X-100, 20 mM imidazole (Sigma-Aldrich) in 1x PBS, pH 7.4 with (EDTA-free 
protease inhibitor cocktail set V (Merck Millipore)).  The sample was centrifuged at 15000 x g for 
5 minutes, the pellet retained for analysis by SDS-PAGE and immunoblotting as the insoluble 
fraction.  To the supernatant, one hundredth of the volume of nickel fast flow sepharose bead 
slurry (GE Healthcare) was added and the sample was incubated under agitation for one hour at 
RT.  The beads were pelleted at 3000 x g for 5 minutes, the supernatant retained for analysis by 
SDS-PAGE and immunoblotting as the unbound fraction.  10 ml of lysis buffer was added to the 
beads and the sample was incubated under agitation for five minutes at RT.  The beads were 
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again pelleted at 3000 x g for five minutes and the supernatant removed.  This wash step was 
repeated two more times.  Protein was eluted off the beads by addition of 500 µl of elution 
buffer (1% Triton X-100, 400 mM imidazole in 1x PBS, pH 7.4 with (EDTA-free protease inhibitor 
cocktail), incubated under agitation for five minutes at RT.  The beads were pelleted at 5000 x g 
for five minutes and the supernatant was retained as the purified protein.   
Samples were analysed by SDS-PAGE, immunoblotting and PDE assay to determine the success 
of recombinant protein expression.   
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Chapter 3: Generation and characterisation of 
conditional knockdown constructs for PfPDEs 
3.1 Introduction 
3.1.1 Knockdown systems in Apicomplexa  
The ability to ablate the expression of a particular gene of interest a very important tool in 
assigning a function to the gene.  This technique is extremely challenging when it comes to 
essential genes, in particular for P. falciparum asexual stages, on which the drug selection is 
performed.   
Transfection for P. falciparum is very inefficient and must be performed during asexual stages 
while the parasite is within the red blood cell.  For a successful transfection, the DNA must 
therefore travel through four separate membranes to reach the inside of the nucleus.  It has 
been estimated that the integration efficiency for P. falciparum is around 10-6 (O’Donnell et al., 
2002).   
An additional complication in the generation of genetically manipulated P. falciparum parasite 
lines is the difficulty in creating large transfer plasmids.  The strong AT-richness results in larger 
plasmids being highly unstable in E. coli, impeding plasmid production (de Koning-Ward et al., 
2000).  There is also a limited repertoire of selectable markers suitable for use in Plasmodium.  
In P. falciparum, the human dihydrofolate reductase (DHFR), an enzyme involved in folate 
metabolism, is most commonly used which confers resistance to WR99210 (Fidock and Wellems, 
1997).  In addition, the fungal blasticidin S deaminase (BSD), bacterial neomycin 
phosphotransferase II (NEO) and Saccharomyces cerevisiae dihydroorotate dehydrogenase 
(DHOD) that confer resistance to blasticidin, neomycin and atovaquone, respectively, have been 
adapted for P. falciparum (Limenitakis and Soldati-Favre, 2011).   
In P. falciparum, integration occurs primarily by homologous recombination and the parasites 
are able to maintain circular plasmids as stable episomes.  To generate a stable integrated line, 
the episome must be lost by successive rounds of drug cycling before the concentration of 
integrated, episome-free parasites are high enough to clone.  With gene targeting strategies that 
are unfavourable to the parasite, the episomes can form stably replicating forms that are 
transferred to daughter merozoites even in the absence of selection pressure (O’Donnell, 2001).  
When performing double homologous crossover it is possible to use negative selection markers 
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such as the thymidine kinase (TK) from the herpes simplex virus, or the E. coli  cytosine 
deaminase, where the addition of ganciclovir or 5-fluorocytosine, respectively, poisons the 
parasites where single crossover has occurred, favouring parasites that have undergone double 
homologous recombination events (Duraisingh et al., 2002).  However, no such negative 
selection exists for single crossover recombination.  It can take months to generate a stable line 
and therefore removal of essential asexual stage genes is impossible.   
Traditional gene disruption at a specific locus involves double homologous recombination 
replacing the gene of interest (GOI) with the selectable marker cassette.  Single crossover 
recombination results in integration of the entire plasmid, including the selectable marker 
cassette, however, single crossovers are able to revert to WT as this process is reversible, 
therefore once established the mutant parasite line must be continually under drug pressure.  
Another problem with gene knockouts is with multifunctional proteins, only the earliest 
essential phenotype can be elucidated as any downstream function will be inaccessible 
(Carvalho and Ménard, 2005; Thathy et al., 2002).  Repeated failure to generate a double 
crossover knockout line is highly suggestive that the gene is essential (Slavic et al., 2010).  
However, alternative approaches, including conditional gene disruption, are needed to validate 
this conclusion.   
3.1.2 Conditional gene excision systems 
Experimental conditional gene expression control systems, adapted to Plasmodium species, fall 
into four categories which act either by, gene deletions or manipulation of transcription, 
translation or protein stability.    
Inducible gene deletion by site-specific recombinases is the most powerful way to disrupt gene 
function as it prevents protein expression by removal of the gene, reducing leakiness in 
expression of the GOI, and is irreversible.  However, achieving maximal recombination efficiency 
while ensuring the recombinase is not expressed inappropriately can be challenging (Pino, 
2013).    
In P. berghei, a flippase (FLP) recombinase technique has been developed.  The FLP is able to 
recognise FLP recombinase target (FRT) sites and excise the sequence in between. A 
temperature sensitive FLP which is much more active at lower temperatures, is used to achieve 
temporal control.  When the parasites are taken up into the mosquito, the drop in temperature 
activates the FLP.  By flanking the GOI, the sequence can be removed and gene expression 
prevented.  This technique best suited for genes that have functions in the mosquito and hepatic 
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stages (Combe et al., 2009; Lacroix et al., 2011).  FLP/FRT excision has been used in P. falciparum 
to recycle selectable markers, but not for inducible knockout of essential genes (van Schaijk et 
al., 2010).   
Cre-lox excision technology has been utilised in many other organisms since the 1980s.  A Cre 
recombinase recognises two loxP sites, resulting in excision of the intervening sequence (Sauer, 
1994).  Attempts to adapt this technology to Apicomplexa were unsuccessful.  In T. gondii, the 
use of a stage specific promoter, or even without a promoter, Cre recombinase expression was 
not tightly controlled enough to prevent inappropriate excision (Brecht et al., 1999).  In 2003, 
DiCre technology was developed.  The enzyme was split into two component parts, one fused 
to FKBP12 (FK506-binding protein) the other to FRB (binding domain of the FKBP12-rapamycin 
associated protein).  The moieties by themselves are inactive, however the addition of 
rapamycin leads to hetero-dimerisation and Cre activity (Jullien et al., 2003).  This was 
successfully applied to T. gondii in the inducible deletion of essential invasion genes 
(Andenmatten et al., 2013).  During the course of this project, the DiCre system was also being 
adapted to P. falciparum in Mike Blackman’s laboratory and various strategies exist to 
conditionally knockdown genes of interest.  For this project, the DiCre conditional knockdown 
system was used to attempt conditional knockout of PDEβ.  The results will be discussed later in 
this chapter.     
3.1.3 Gene transcription control strategies 
When conditionally controlling gene transcription, there are two strategies that have been 
applied to the study of malaria parasites, promoter swap and the Tet system.  For genes that are 
not expressed in the asexual stage, simply swapping the promoter for one that is not active in 
the stage of interest can be effective.  For example for PbMyoA, the endogenous promoter was 
changed to one that is inactive in ookinetes (Siden-Kiamos et al., 2011).  However, like the 
FLP/FRT system, this is limited to genes expressed in mosquito and liver stages.  The tetracycline-
controlled transcriptional activation (Tet) system, like the Cre-lox system, is widely utilised in 
other organisms, and a modified version had been adapted to Apicomplexa (Meissner et al., 
2002, 2005).  Briefly, a transactivator, composed of the tetracycline repressor (TetRep) fused to 
an activating domain, binds via the TetRep to tet operator sequences (TetO).  The TetO is placed 
before a minimal promoter and this activates transcription.  In the presence of tetracycline (or 
specific derivatives), binding affinity of the transactivator to TetO is highly diminished, 
preventing transcription (Pino, 2013).  More recently, the identification of transcriptional 
activation domains from the ApiAP2 family of transcription factors, allowed tetracycline-induced 
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repression of two essential P. berghei genes (Pino et al., 2012).  However this system is yet to be 
adapted to P. falciparum.     
3.1.4 Strategies to control mRNA translation 
In many other organisms, one of the most frequently used knockdown approaches is the use of 
RNA interference (RNAi).  However, Plasmodium species lack much of the necessary machinery 
and reports of limited success (Kolev et al., 2011; McRobert and McConkey, 2002) are therefore 
controversial.  There has been some success using other mRNA translation systems including; 
long double-stranded RNA (dsRNA) to interfere with mRNA expression (Gissot et al., 2005); 
targeting ribonuclease P activity to a specific mRNA to promote cleavage (Augagneur et al., 
2012) and using riboswitches (autocatalytic RNA), where the cis-acting hammerhead ribozyme 
N9 integrated near the start of translation was able to downregulate reporter genes in T. gondii 
and P. falciparum (Agop-Nersesian et al., 2008).  However further work to investigate the 
broader applications is necessary.   
3.1.5 Protein stability manipulation strategies  
Conditionally knocking down gene expression at the protein stability level has the potential to 
be fast responding and reversible, useful aspects for some phenotype analyses.  In 2006, 
Banaszynski et al., developed the destabilisation domain (DD) system by producing mutants of 
human FKBP12 that, when expressed, are immediately degraded in mammalian cells.  When this 
unstable FKBP12 was fused to a protein of interest (POI), the whole complex was targeted to the 
proteasome for degredation.  In addition, in the presence of a small synthetic ligand, shield-1, 
which binds to the FKBP, prevented this degradation (Banaszynski et al., 2006) (figure 3.1).  Soon 
after, the DD-system was adapted to P. falciparum (Armstrong and Goldberg, 2007) and there 
have been several publications that effectively utilise this system (including, but not limited to 
(Dvorin et al., 2010; Jain et al., 2013; Russo et al., 2009).    
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Figure 3.1 Diagrammatic overview of the DD-system 
Genetic fusion of a protein of interest (POI) to the destabilisation domain (DD, unstable FKBP12) 
leads to degradation of the whole fusion protein.  Addition of a stabilising ligand (shield-1) 
prevents degradation (Banaszynski et al., 2006).   
 
3.1.6 Control of gene expression in P. falciparum PDEs 
Traditional gene knockout has been applied to three of the four PfPDEs, PDEα, γ and δ (Taylor 
et al., 2008; Wentzinger et al., 2008).  As described in chapter 1, none of these knockout lines 
have an obvious phenotype in asexual blood stage culture.  Genetic knockouts of PDEβ have 
been attempted in both P. falciparum and P. berghei, but have never been successful (Ross 
Cummings, thesis; Oliver Bilker, personal communication).  It is therefore assumed that PDEβ is 
indispensable for asexual blood stage growth, however this remains a speculation as absence of 
parasite growth is insufficient proof.  Therefore this project has attempted to generate 
conditional knockdowns of PfPDEβ.  Initially the DD-system was pursued, secondly, in 
collaboration with Mike Blackman (NIMR), the DiCre system.   
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3.2 Results 
3.2.1 Construction of Plasmodium falciparum PDEα and PDEβ destabilisation domain plasmids 
for parasite transfection  
Constructs based on the pJDD41 vector (donated by Jeff Dvorin (Dvorin et al., 2010)) were 
generated in order to C-terminally tag the endogenous pdeα/β locus with both a haemagglutinin 
(HA) tag and a destabilisation domain (DD).  The constructs contained a 1.5 kb C-terminal 
fragment of the relevant pfpde gene, to enable single crossover recombination and without a 
stop codon, fused to the HA tag and DD tag.  Following this was the 3’UTR of pfhsp86.  The 
construct also contained a human DHFR gene which confers resistance to the antifolate 
WR99210.  The 3’ fragment of pdeα was amplified by PCR from genomic DNA (gDNA) using the 
primers 5’-AGCGCGGCCGC TAA CGATAGATAATACTATACCTACATCGCC-3’ (NotI restriction 
site underlined) and 5’-TAGCTCGAG TTCAAA TTTGATGAGCTCAAGTTTGCTTAG-3’ (XhoI 
restriction site underlined).  The 3’ fragment of pdeβ was amplified by PCR from genomic DNA 
(gDNA) using the primers 5’- AGCGCGGCCGC TAA 
GATTGTATAAGTACTGACAAAGTGGATTTAGA-3’ (NotI restriction site underlined) and 5’- 
TAGCTCGAG ATCGGAAACATTcTTTATgAAAAATAGAGTTAAATCAATATAAC-3’ (XhoI 
restriction site underlined).  The lower case letters c and g indicate where bases have been 
changed from T and A respectively (without altering the encoded amino acid), in the PDEβ 
reverse primer to prevent formation of secondary structures.  The PCR conditions were as 
described in chapter 2.2.2, however the annealing temperature was 42oC.  These fragments 
were cloned into pJDD41, which already contained the HA and DD tags, using the NotI and XhoI 
restriction endonucleases.  The plasmids were verified by restriction digest and sequencing 
(figure 3.2). 
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Figure 3.2 Restriction digests to verify the PDE-DD constructs are correct  
The expected sizes for both pPDEα-HA-DD and pPDEβ-HA-DD were as follows: NotI-XhoI double 
digest, 5.9 kb and 1.5 kb, XhoI single digest, 7.4 kb and BamHI-XhoI double digest, 2 kb and 5.4 
kb.  Although the gel is overloaded, the sizes are correct for both plasmids.  Sequencing of the 
inserts and junctions was also performed.   
 
Figures 3.3 and 3.4 show the allelic replacement strategy for pfpdeα and pfpdeβ, respectively.  
P. falciparum parasites were transfected with the plasmids as described above.  0.5 µM of shield-
1 was added at the time of transfection, and the parasites were then continually grown in the 
presence of this stabilising ligand.  WR99210 drug-resistant parasites were detected 3-4 weeks 
post-transfection.  Up to four rounds of drug cycling for PfPDEα-HA-DD and PfPDEβ-HA-DD were 
performed to reduce the presence of the episome and enrich the proportion of parasites 
containing integrated plasmid.  After each cycle, the parasites were screened by integration 
specific PCR, as described in chapter 2.2.2, to detect successful integration of the plasmid into 
the correct locus.  Integration PCR positive parasites for PfPDEα-HA-DD were detected after two 
cycles, however integration was never observed for PfPDEβ-HA-DD, even after four cycles (figure 
3.5).   
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Figure 3.3 Integration strategy for pfpdeα 
A schematic representation of the transfection plasmids and the pdeα locus before and after 
integration.  The 1.5 kb C-terminal fragment promotes recombination by single crossover 
resulting in a HA and DD tagged gene.  The integration PCR primer locations are depicted with 
dashed arrows and the expected fragments given, 1 kb for presence of the episome and 1.8 kb 
for an integration event.  The diagram also shows the locations of the restriction sites and the 
PDEα specific probe for Southern blotting.  The expected fragment sizes are 7.4 kb for the 
episome, 6.0 kb for the WT locus and 4.0 kb for the integration event.    
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Figure 3.4 Integration strategy for pfpdeβ 
A schematic representation of the transfection plasmids and the pdeβ locus before and after 
integration.  The 1.5 kb C-terminal fragment promotes recombination by single crossover 
resulting in a HA and DD tagged gene.  The integration PCR primer locations are depicted with 
dashed arrows and the expected fragments given, 1 kb for presence of the episome and 2.0 kb 
for an integration event.  The diagram also shows the locations of the restriction sites and the 
PDEβ specific probe for Southern blotting.  The expected fragment sizes are 7.4 kb for the 
episome, 8.2 kb for the WT locus and 5.3 kb for the integration event.     
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Figure 3.5 Integration specific PCR for PfPDEα-HA-DD and PfPDEβ-HA-DD 
Integration specific PCR was performed using the primers shown in figures 3.3 and 3.4  Genomic 
DNA was extracted from PfPDEα-HA-DD after two cycles and four for PfPDEβ-HA-DD.  WT 3D7 
gDNA was used as a negative control.  The arrows denote the expected product sizes.  For both 
constructs, an episomal band of 1 kb and the integration bands 1.9 kb and 2.0 kb for PDEα and 
PDEβ, respectively. PfPDEα-HA-DD is positive for integration, PfPDEβ-HA-DD is not.  
 
The PfPDEα-HA-DD transfected line was then cloned by limiting dilution and genotypic analysis 
was performed by repeating the integration specific PCR on the clones, including a WT control 
PCR which would only amplify in the absence of integration.  The forward primer was located in 
the genomic PDEα sequence, upstream of the cloned fragment.  The reverse primer was located 
in the endogenous 3’UTR.  The expected band size was 2.2 kb.  Two clones, positive for 
integration and negative for the endogenous WT locus, were selected and Southern blotting was 
performed.  The uncloned PfPDEβ-HA-DD transfected line was also genotypically analysed by 
Southern blotting to test if the lack of an integration band by PCR was due to a problem with the 
primers used.  The integration specific PCR for PfPDEα-HA-DD clones 6 and 7 showed the 
expected result, they were integration positive and WT negative.  The controls on the Southern 
blot showed the anticipated result, a 7.4 kb band for the plasmid, a 6.0 kb band for the WT and 
no band for the PDEα-KO.  The DNA of the clones was somewhat degraded, however, the two 
major bands, episomal (7.4 kb) and integration (4.0 kb) were visible.  The PDEα-KO line was a 
gift from (Selina Bopp and Hans-Peter Beck, Swiss Tropical and Public Health Institute).  The 
Southern blot of the PfPDEβ-HA-DD uncloned transfected lines showed very strong bands at the 
expected episomal size (7.4 kb).  The four lanes (1st-4th) contain samples from the individual 
separate transfection experiments performed with the plasmid. All the transfections show the 
same pattern.  The plasmid DNA was overloaded and it was difficult to infer size and the 3D7 
DNA was too dilute.  As the PfPDEβ-HA-DD was not positive for integration by PCR or Southern 
blotting, no further work was performed on this line.  
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Figure 3.6 Genotypic analysis of PfPDEα-HA-DD and PfPDEβ-HA-DD transfected lines 
Southern blotting (top left panel) and integration specific PCR (bottom panel) of PfPDEα-HA-DD 
cloned lines shows that the plasmid integrated in the correct locus and that there is no WT 
contamination.  The Southern blot shows the correct sized band for the plasmid (7.4 kb) and the 
3D7 WT line (6.0 kb), and no band for the PDEα-KO line.  The DNA for the clones appears 
degraded, resulting in smeary lanes, however the major bands are consistent with the expected 
sizes of 7.4 kb and 4.0 kb.  This finding is reinforced by the integration PCR.  The 3D7 line shows 
only the WT band (2.2 kb), whereas both clones shown have episome (1 kb) and integration (1.9 
kb) bands present and a negative PCR result for the unmodified locus.  The PfPDEβ-HA-DD 
Southern blot shows the episome band only.    
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3.2.2 Removal of the stabilising ligand shield-1 does not affect the growth of PDEα-HA-DD 
mutants 
Parasite growth assays, as described in chapter 2.5 were performed on the two PfPDEα-HA-DD 
clones, referred to as A6 and A7.  These assays were carried out initially to compare the growth 
rate of the mutants to the 3D7 parental line to verify normal growth (data not shown 
separately), and secondly to assess whether the growth rate changes in the absence of shield-1.  
Figure 3.7 shows that 3D7 (red lines), A6 (green lines) and A7 (blue lines) do not differ in growth 
rate.  The addition of 0.5 µM shield-1 to 3D7 parasites does not significantly impair their growth.  
The removal of shield-1 from the PDEα-DD mutants (dashed lines) does not result in a change in 
growth rate.   
 
 
Figure 3.7 The growth rate of 3D7 and PDEα-HA-DD mutants in the presence and absence of 
shield-1  
The growth rates of 3D7 (red), A6 (green) and A7 (blue) are not significantly different either 
between the strains or in the absence (dashed line) or presence (unbroken line) of the stabilising 
ligand.  The experiment was performed in duplicate and three biological repeats were 
conducted.  The error bars represent standard error of the mean (SEM). 
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3.2.3 PDEα-KO mutants have a higher replication rate than other parasite strains  
The creators of the PfPDEα-KO line, Wentzinger et al., reported a discrepancy in cell cycle timing 
between WT and knockout strains.  The authors noted that after synchronisation, ring stages 
were detected earlier in the KO than in the WT, although they were unable to quantify the 
precise timings (Wentzinger et al., 2008).  This phenotype was also observed during the course 
of the present study.  Additionally, the parasite line also appeared to grow to a higher 
parasitaemia than other strains.  A growth assay was performed to demonstrate this result.  
Figure 3.8 shows the growth rate of PfPDEα-KO (purple) compared to 3D7 (red), A6 (green), A7 
(blue) and the A4 line (pink).  A6 and A7 were kept off shield-1 with the expectation that this 
would knockdown the levels of PfPDEα.  PfPDEα-KO is a non-gametocyte producing line (as was 
the parent 3D7 line), therefore line A4 was also included to investigate whether this growth 
phenotype simply resulted from an inability to produce gametocytes.  The A4 line has a defect 
in the ApiAP2-g transcription factor, a master regulator for gametocytogenesis, and therefore is 
unable to produce gametocytes (Kafsack et al., 2014).  The reason for the lack of gametocytes 
in PfPDEα-KO is unknown.  Figure 3.8 demonstrated that PfPDEα-KO grows to a higher 
parasitaemia than all the other lines, when kept in the same culture conditions. 
 
Figure 3.8 The growth rate of PDEα-KO is higher than the other strains 
The parasitaemia of PDEα-KO is consistently higher than all other strains after day 2.  The A4 line 
is a non-gametocyte producing line.  All strains were grown in the absence of shield-1.  The 
experiment was performed in duplicate and three biological repeats were conducted.  The error 
bars represent standard error of the mean (SEM). 
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3.2.4 PfPDEα-HA-DD cannot be detected by western blotting or IFA 
Western blotting on late stage parasite extracts of PfPDEα-HA-DD A6 and A7, with 3D7 and 
PfPDEα-KO as negative controls, were performed.  The membrane was probed with a 
monoclonal rat antibody against HA, with an anti-GAPDH antibody as a loading control.  The 
expected size of PfPDEα-HA-DD is 145 kDa (115 kDa protein and a 30 kDa HA-DD tag).  No protein 
was detectable at a primary antibody concentration of 1:1000, although the amount of lysate 
loaded was lower than for the 3D7 control this assay was repeated several times and no band 
was ever seen (figure 3.9, left image).  To assess whether the concentration of shield-1 was 
insufficient to prevent protein degradation, increasing concentrations were tested.  Clone A6 
was cultured with four concentrations of shield-1, between 0 and 2 µM for two cycles.  Late 
stage parasite extracts were then analysed by western blotting.  No protein was detected in any 
of the four concentrations (figure 3.9, right image).    Immunofluorescence assays were also 
performed, with a primary antibody concentration of 1:100, in an effort to detect the protein.  
There was extremely weak staining with the antibody, but it could not be confidently identified 
as specific (figure 3.10).  The PfPDEα-HA-DD line was not analysed further. 
 
 
Figure 3.9 Transgenic PfPDEα-HA-DD clones are not detectable by western blotting 
Western blots of asexual late stage parasites showed that the HA tag in the PfPDEα-HA-DD lines 
could not be detected, even with increased amounts of shield-1 (left panel).  The predicted size 
was 145 kDa.  Anti-GAPDH (37 kDa) was used as a loading control.   
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Figure 3.10 Transgenic PfPDEα-HA-DD clones are not detectable by IFA 
IFAs using formaldehyde fixed smears of late stage asexual parasites were stained with rat anti-
HA antibodies.  Representative IFA images are shown alongside the bright field image.  DAPI was 
used to stain the parasite nuclei.  The staining for PfPDEα-HA-DD was extremely weak and it 
could not be confidently distinguished from background staining.  For antibody the negative 
controls, see appendix A3. 
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3.2.5 Construction of Plasmodium falciparum PDEβ 3’ replacement DiCre plasmids for parasite 
transfection 
Constructs based on the pHH1_SERA5del3DC vector (obtained through collaboration with Mike 
Blackman (Collins, et al. 2013)) were generated in order to C-terminally tag the endogenous 
pdeβ locus with both a haemagglutination (HA) tag and a loxP site prior to the 3’UTR.  The 
constructs contained a 0.9 kb C-terminal fragment of the pfpdeβ gene to enable single crossover 
recombination and without a stop codon, fused to the HA tag.  Following this was the loxP site 
and the 3’UTR of pbDT.  The construct also contained a second loxP site and a human DHFR gene 
which confers resistance to the antifolate WR99210.  The C-terminal fragments of pfpdeβ were 
excised from the pPDEβ-HA-DD plasmid using the endogenous restriction site AflII and XhoI, and 
cloned into pHH1_SERA5del3DC using the same enzymes, creating the pPDEβ-HA-DiCre.  The 
plasmids were verified by restriction digest and sequencing (figure 3.11). 
 
Figure 3.11 Restriction digests to verify the PDEβ-HA-DiCre constructs are correct  
The expected sizes for both pPDEβ-HA-DiCre were as follows: AflII-XhoI double digest, 5.9 kb 
and 0.9 kb and BamHI-XhoI double digest, 2 kb and 4.8 kb.  The sizes are correct for the plasmid.  
Correct sequence of the inserts and junctions was also confirmed.   
 
Figure 3.12 shows the allelic replacement strategy for pfpdeβ.  P. falciparum PreDiCre parasites 
were transfected with the pPDEβ-HA-DiCre plasmid as described above.  The PreDiCre line was 
generated by the Blackman lab and contains the DiCre cassette integrated by single crossover 
at the SERA5 locus, with no detrimental effect on the parasite (Collins et al. 2013).   
WR99210 drug-resistant parasites were detected 3-4 weeks post transfection.  Two rounds of 
drug cycling were performed to reduce the presence of the episome and enrich the proportion 
of parasites containing integrated plasmid.  After each cycle, the parasites were screened by 
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integration specific PCR, as described in chapter 2.2.2, to detect successful integration of the 
plasmid into the correct locus.  Integration PCR positive parasites were detected after two cycles 
(figure 3.13).   
 
Figure 3.12 Integration strategy for pfpdeβ 
A schematic representation of the transfection plasmids and the pdeβ locus before and after 
integration.  The 0.9 kb C-terminal fragment promotes recombination by single crossover 
resulting in a HA tagged gene, followed by a LoxP site, the pbDT 3’UTR and a second loxP site.  
The integration PCR primer locations are depicted with dashed arrows and the expected 
fragments given, 0.8 kb for presence of the episome and 1.4 kb for an integration event.  The 
diagram also shows the locations of the restriction sites (BclI and AvrII) and the PDEβ specific 
probe for Southern blotting.  The expected fragment sizes are 6.8 kb for the plasmid, 3.0 kb for 
the WT locus and 1.4 kb for the integration event.  There is also potential for a larger band to be 
present (~10 kb) depending on the location of the crossover as the downstream fragment may 
also contain the probe sequence.   
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The PfPDEβ-HA-DiCre transfected line was then cloned by limiting dilution and genotypic 
analysis was performed by repeating the integration specific PCR on the clones, including a WT 
control PCR which would only amplify in the absence of integration.  The forward primer was 
located in the genomic PDEα sequence, upstream of the cloned fragment.  The reverse primer 
was located in the endogenous 3’UTR.  The expected band size was 2.0 kb.  Two clones, positive 
for integration and negative for the endogenous WT locus, were selected and Southern blotting 
was performed.  The integration specific PCR for PfPDEβ-HA-DiCre clones 4 and 7 (named B4 
and B7) showed the expected result, they were integration positive and WT negative (figure 
3.13).  The controls on the Southern blot showed the anticipated result, a 6.7 kb band for the 
plasmid and a 3.0 kb band for the WT.  For both B4 and B7, the 1.4 kb integration band is present, 
as is a larger (~8 kb) band that probably indicates the downstream fragment.  The presence of a 
band the same size as the plasmid indicates that multiple copies have integrated.  As the plasmid 
contains only a 0.9 kb fragment of PfPDEβ, not preceded by a promoter and designed to start 
with a stop codon, it is extremely unlikely to be transcribed (data shown in chapter 3.2.6, figure 
3.17).   
 
Figure 3.13 Genotypic analysis of PfPDEβ-HA-DiCre transfected lines 
Integration specific PCR of PfPDEβ-HA-DiCre uncloned (left) and cloned lines (right) show that 
the plasmid integrated in the correct locus and that there is no WT contamination.   
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3.2.6 Addition of the excision inducing compound rapamycin effectively excises the 3’ UTR of 
pfpdeβ 
To induce excision of the 3’ UTR of pfpdeβ, the DiCre enzyme was heterodimerised by the 
addition of 100 nm rapamycin, or 1% DMSO as a negative control, to synchronised ring stage 
parasites (clones B4 and B7) for four hours.  The rapamycin or DMSO was then washed away 
and the parasites were allowed to develop for a further 24 hours in WR99210 free medium as 
the expected excision would remove the resistance cassette (figure 3.14).  After the parasites 
had developed to schizonts, gDNA was extracted.  The rapamycin treatment was repeated and 
gDNA was also extracted after 72 hours.  The gDNA samples were analysed by excision specific 
PCR which was designed to distinguish the intact modified locus from the expected DiCre 
excision genomic product.   
 
Figure 3.14 Excision strategy for the removal of the 3’ UTR of PfPDEβ-HA-DiCre  
Addition of rapamycin to PfPDEβ-HA-DiCre parasites is expected to remove the PbDT 3’UTR, the 
resistance cassette and much of the original plasmid backbone.  The upper scheme shows the 
modified locus pre-excision and the lower scheme shows the expected result of the excision 
event.  The dashed arrows and overhead numbers show the primer binding locations and 
designation.  In the absence of rapamycin, the primer pair 1 and 2 should produce a 1.5 kb band 
and the primer pair 3 and 4 should produce no product as it would be too large to amplify (>6.0 
kb).  After rapamycin induced excision, no band should be produced with primer pair 1 and 2 as 
site 2 will have been excised.  Primer pair 3 and 4 will be brought closer together, resulting in a 
1.0 kb band.  The locations of the restriction sites for Southern blotting are indicated under the 
loci.  The 1.4 kb integration band will still be present, however the larger band will be reduced 
in size (exact size depends on crossover location), and all extra plasmid copies (6.8 kb) should be 
absent.   
 
After 24 hours, in the absence of rapamycin, the expected 1.5 kb band was present for both 
clones, unfortunately this band was not lost with the addition of rapamycin.  For B7 with 
rapamycin, there appeared to be reduced band intensity, however this could be due to 
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differences in the PCR reaction as it is not quantitative.  With rapamycin treatment, primers pairs 
3 and 4 produced the expected 1.0 kb band, indicating that the excision event had taken place.  
There were also faint bands in the non-excised controls, suggesting that there is some leakiness 
in the control of rapamycin induced DiCre mediated excision.  After 72 hours and a second 
rapamycin treatment, the results were more or less the same (figure 3.15).  Monitoring by 
Giemsa staining showed no differences in growth and morphology between the excised and 
non-excised lines (data not shown).  The B7 line was then cloned by limiting dilution to obtain a 
pure excised population.  Four clones (E1-4) were analysed by excision PCR (figure 3.16).  All four 
clones were positive for integration and negative for any remaining non-excised locus.  Clones 
E1 and E2 were taken forward for further analysis.  Southern blotting was also performed on E1 
and E2.  The 1.4 kb integration band is still present, the larger downstream fragment band has 
reduced in size to about 3.0 kb, and all additional plasmid copies are absent (figure 3.17).   
 
Figure 3.15 Excision PCR on the uncloned rapamycin treated PDEβ-HA-DiCre lines  
Addition of a four hour treatment of rapamycin to PDEβ-HA-DiCre resulted in incomplete 
excision.  After 24 hours, the primer pair 3 and 4 showed an increase in excision (1.0 kb band) 
compared to untreated.  Primer pair 1 and 2 showed little difference between treated and 
untreated control (1.5 kb band), therefore the efficiency was not 100% as the bands for 
rapamycin treated would have disappeared.  After 72 hours and a second treatment, efficiency 
was not improved.  The gel of the left shows the WT controls which are negative, as expected.   
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Figure 3.16 Excision PCR on the cloned rapamycin treated PDEβ-HA-DiCre lines  
After cloning by limiting dilution, clones E1-4 were analysed by excision PCR.  Presence of a 1.0 
kb band for primer pair 3 and 4 and loss of the band from primer pair 1 and 2 indicated clonal 
populations of 3’ UTR excised PDEβ-HA-DiCre.  Clone E1 and E2 were continued.   
 
 
Figure 3.17 Southern blot of PDEβ-HA-DiCre excised and non-exciced lines  
gDNA was digested with BclI and AvrII.  The pfpdeβ fragments detected were as expected. The 
plasmid pPDEβ-HA-DiCre (major band was 6.8 kb, the smaller band is about the size of the 
excision event and may represent some minor recombination between the two loxP sites in the 
plasmid) and WT (3.0 kb) were present.  The B4 and B7 lines were positive for the 1.4 kb 
integration band as well as a larger (~8 kb) downstream fragment band.  Presence of a band the 
size of the plasmid indicates that multiple copies, possibly two as the band intensity is roughly 
double that of the other bands, have integrated.  When treated with rapamycin (clones E1 and 
E2), the integration band is still present, however the larger band has reduced in size to roughly 
3.0 kb and the plasmid copies have been excised.    
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3.2.7 Addition of the excision inducing compound rapamycin does not reduce the level of PDEβ 
protein  
As PDEβ is expected to be essential, the ability of the rapamycin treated parasites to survive, 
even to the point of forming a stable line, was a surprise.  To determine whether this was due 
to PDEβ not being essential, or the removal of the 3’ UTR no resulting in protein level reduction, 
phenotypic analysis was performed.  Firstly, growth assays were carried out according to the 
previously described method (chapter 2.5) on the PreDiCre line, non-excised B4 and B7 lines and 
the excised E1 and E2 lines.  No significant growth difference was found, confirming that there 
was no growth defect in the excised line (figure 3.18).  The parasites were also monitored by 
Giemsa smears which showed no obvious morphological differences between the lines (data not 
shown).      
 
Figure 3.18 The growth rate of PreDiCre and PDEβ-HA-DiCre excised and non-exciced lines  
The growth rates of PreDiCre (red), B4 (green), B7 (blue), E1 (purple) and E2 (pink) are not 
significantly different.  The experiment was performed in duplicate and three biological repeats 
were conducted.  The error bars represent standard error of the mean (SEM).   
 
The DiCre knockdown plasmid was also designed to include an HA-tag allowing analysis of 
protein presence by western blotting and IFA, and protein subcellular localisation by IFA.  
Western blots on late stage asexual blood stage culture of non-excised B7 and excised E1, 
probed with rat anti-HA monoclonal antibody, confirmed expression of HA-tagged PfPDEβ.  The 
136 kDa band is consistent with the expected size of PfPDEβ (133 kDa) plus the epitope tag (3.3 
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kb).  Parental PreDiCre does not react with the anti-HA antibody, as expected.  IFAs on mixed 
stage asexual blood stage culture of non-excised B7 and excised E1, probed with rat anti-HA 
monoclonal antibody, also confirmed expression of HA-tagged PfPDEβ.  The anti-HA staining did 
not colocalise with the DAPI stained nuclei.  Further co-staining experiments are needed to 
confirm subcellular localisation of PfPDEβ (discussed further in chapter 4).  Taken together, the 
data suggest that 3’UTR excision of PfPDEβ is not sufficient to reduce the level of protein, or 
have an effect on the growth or morphology of the parasites.  The excised lines E1 and E2 were 
not analysed further.  PDEβ-HA-DiCre was exploited further as an epitope tagged line and will 
be referred to as PDEβ-HA henceforth.   
 
 
Figure 3.19 Transgenic PDEβ-HA-DiCre excised and non-excised lines express tagged PfPDEβ 
Western blots of parental PreDiCre, non-excised B7 and excised E1 were probed with rat anti-
HA monoclonal antibody.  The predicted epitope tagged form of PfPDEβ (136 kDa) was present 
in both transgenic lines.  As expected, the PreDiCre line is negative.  Anti-GAPDH (37 kDa) was 
used as a loading control.   
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Figure 3.20 Transgenic PDEβ-HA-DiCre excised and non-excised lines express tagged PfPDEβ 
IFAs on formaldehyde fixed thin smears of mixed asexual stage non-excised B7 and excised E1 
were performed and representative images are shown for each strain.  The parasite nuclei were 
stained with DAPI, and the bright field image is shown on the right.  For negative control images, 
see appendix A3. 
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3.2.8 Construction of Plasmodium falciparum PDEβ internal-loxP DiCre plasmids to mediate 
conditional knockout 
PDEβ contains eight introns, mostly at the C-terminus.  After the failure of the transgenic PDEβ-
HA-DiCre line to knockdown the level of PDEβ in the cell following excision of the 3’ UTR, a 
construct was designed to insert a loxP site into one of the introns.  The predicted catalytic 
domain of PDEβ contains three introns and the furthest from the C-terminus was chosen as the 
location for the loxP site.  This would effectively cut the catalytic domain in two, hypothetically 
rendering the protein inactive.  A synthetic, partially recodonised (Spodoptera frugiperda codon 
usage) PDEβ, based on the predicted P. falciparum 3D7 sequence was synthesised by GenScript.  
The sequence contained a 5’ AflII and a 3’ XhoI site.  Upstream of the third from end intron was 
a 1.0 kb targeting sequence containing native PDEβ sequence, for recombination by single 
crossover.  The third intron was also native sequence, however a loxP site was inserted 58 bp 
from the 5’ end and 109 bp from the 3’ end.  34 bp after the intron also retained native sequence.  
Insertions into the middle of an intron rather than near the end are less likely to be detrimental 
to the parasite (Catherine Suarez, NIMR, personal communication).  cDNA was used for the final 
819 bp of PDEβ which was recodonised to prevent recombination downstream of the loxP site.  
An HA-tag was added to the end of the sequence, followed by a stop codon (see figure 3.22).   
The pPDEβ-HA-DiCre plasmid was digested with AflII and XhoI, resulting in the removal of the 
PDEβ sequence, the HA tag and the 3’ loxP site.  The synthetic PDEβ containing the internal loxP 
site and the recodonised sequence was then cloned into the plasmid with the same restriction 
enzymes.  This resulted in the plasmid pPDEβ-IntronLoxP.  The plasmids were verified by 
restriction digest and sequencing (figure 3.21).   
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Figure 3.21 Restriction digests to verify the PDEβ-IntronLoxP constructs are correct  
The expected sizes for both pPDEβ-IntronLoxP were as follows: AflII single digest, 8.0 kb, AflII-
XhoI double digest, 5.8 kb and 2.2 kb and BamHI single digest, 5.3 kb and 2.6 kb.  The sizes are 
correct for the plasmid.  Correct sequence of the inserts and junctions was also confirmed.   
 
Figure 3.22 shows the allelic replacement strategy for pfpdeβ.  P. falciparum PreDiCre parasites 
were transfected with the pPDEβ-IntronLoxP plasmid as described above.  The PreDiCre line was 
generated by the Blackman lab and contains the DiCre cassette integrated by single crossover 
at the SERA5 locus, with no detrimental effect on the parasite (Collins et al. 2013).  WR99210 
drug-resistant parasites were detected 3 weeks post transfection.  At the time of writing the 
parasites were undergoing drug cycling.  Figure 3.23 shows the expected product of rapamycin 
treatment, resulting in excision of the C-terminus of pfpdeβ, which is hypothesised to ablate the 
function of the enzyme.     
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Figure 3.22 Internal loxP integration strategy for pfpdeβ  
A schematic representation of the transfection plasmid and the pdeβ locus before and after 
integration.  The 1.0 kb gDNA fragment of endogenous sequence promotes recombination by 
single crossover resulting in insertion of a loxP site into an intron within the predicted catalytic 
domain, followed by 0.9 kb recodonised synthetic sequence (to prevent crossover after the loxP 
site), an HA-tag, the pbDT 3’UTR and a second loxP site.  The integration PCR primer locations 
are depicted with dashed arrows and the expected fragments given, 0.7 kb for presence of the 
episome and 2.5 kb for an integration event.     
 
 
Figure 3.23 Excision strategy for the removal of the C-terminus of pPDEβ-IntronLoxP 
Addition of rapamycin to pPDEβ-IntronLoxP parasites is expected to remove the C-terminus of 
the gene, as well as the resistance cassette and much of the original plasmid backbone.  The 
upper scheme shows the modified locus pre-excision and the lower scheme shows the expected 
result of the excision event.     
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3.3 Discussion  
3.3.1 The destabilisation domain system and asexual PDEs 
The DD system is used in many organisms, including P. falciparum, to knockdown the amount of 
a specific protein in an inducible manner.  DD-tagged PDEβ was unable to form a stable 
integrated parasite line.  In the Southern blot showing the four attempted transfections of PDEβ 
and it appeared that many episomes were present per genome copy, to the point where the 
genome band was barely visible and the plasmid band was very strong (figure 3.6).  This indicates 
that the plasmid formed highly stable episomes that were not lost with drug cycling, as 
previously reported (O’Donnell, 2001).  As this happened on four separate occasions, it is 
unlikely that a stable PDEβ-DD line could be produced, perhaps because the DD tag was too 
detrimental to parasite growth, even in the presence of shield-1.  PDEα-HA-DD was able to form 
a stably integrated line, confirmed by PCR and Southern blotting (figures 3.5 and 3.6).  However, 
the protein was undetectable by either western blotting or IFA, this may be because the protein 
level is naturally very low or that the HA-tag is inaccessible to the antibody by mis-folding or 
sequestration in the membrane.  As PDEα is not essential, it is also possible that there is no PDEα 
protein present in the parasites due to degradation.  RT-PCR could be used to detect a problem 
with transcription of the PDEα mRNA.  Unfortunately as there is no specific antibody to the PDEα 
protein, down regulation at the protein level cannot be investigated.  Late stage parasites were 
used for western blotting as this is when expression of PDEα is expected to be highest.  For the 
IFAs, mixed stage cultures were used.  As individual parasites can be identified, this would give 
the highest chance of visualising expression and indicate a rough time course of expression.  
However, little or no fluorescence above background was detected when the parasites were 
probed with monoclonal rat anti-HA antibody.  As ablation of PDEα is not detrimental to parasite 
growth, removal of shield-1 was not expected to negatively affect the growth rate of PDEα-HA-
DD.  0.5 µM of shield-1 in the culture was used as standard as this was the concentration used 
in previous studies (Dvorin et al., 2010; Russo et al., 2009), though this concentration does still 
delay parasite growth to some extent (de Azevedo et al., 2012).  Although 0.5 µM of shield-1 is 
sufficient to stabilise the DD tagged proteins in other published studies, increasing 
concentrations of shield on PDEα-HA-DD cultures were used and the protein level was assessed 
by western blotting.  Three concentrations of shield-1 (0.5, 1.0 and 2.0 µM), and a no shield 
control were used, however PDEα-HA-DD was not detected at any concentration.  Even if 2 µM 
or higher was able to stabilise PDEα, this concentration becomes, not only toxic to the parasite, 
but also prohibitively expensive to use routinely.  As there is currently no antibody able to 
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efficiently detect native PDEα, it is not known whether expression is totally ablated by addition 
of the tag, expression is below the detection level normally in WT parasites, or the tag is cleaved 
off within the parasite.   
The PfPDEs are transmembrane proteins, with six TM domains.  To my knowledge, there is only 
one study in which apicomplexan integral membrane proteins have been successfully targeted 
with the DD system.  TgAMA1 and TgROM4 levels were efficiently knocked down by DD tagging.  
TgAMA1 is an integral membrane protein with one TM domain and TgROM4 has six TM domains 
(Santos et al., 2011).  There are no reports of a successful knockdown of a TM protein in P. 
falciparum.    
A recent analysis of various aspects of the DD system in P. falciparum by de Azevendo et al., 
noted that proteins that reside in the organelles of P. falciparum may be targeted to the 
proteasome less efficiently that cytoplasmic proteins.  Additionally, the authors noted that C-
terminally tagged proteins that are co-translationally inserted in the endoplasmic reticulum may 
escape from proteasome degradation in the absence of shield-1 (de Azevedo et al., 2012).   
Reporting bias can be a significant problem in determining the efficiency of a particular system 
as frequently only the successes are published.  Many attempts to DD-tag proteins have failed, 
either due to rejection of the tag, as with PDEβ, or failure of the tag to regulate protein 
expression, as is probably the case with PDEα (de Azevedo et al., 2012).  Recent attempts to DD-
tag many kinases in P. falciparum resulted in only a few stable lines that generated efficient 
knockdown of the target protein.  It was estimated that the success rate was around 1 in 10 
(Manoj Duraisingh, Harvard School of Public Health, Personal Communication).    
3.3.2 The subtle growth phenotype of PDEα-KO  
Previous work by Wentzinger et al., reported that their PDEα-KO line had an unusual growth 
phenotype.  The authors noted that when synchronised using sorbitol, rings appeared faster in 
subsequent generations of PDEα-KO compared with their non-gametocyte forming 3D7 parental 
line.  This phenotype could not be quantified as the phenomenon was not consistent.  During 
the course of this study, it was also observed that the PDEα-KO parasites (used previously in the 
Wentzinger study) have a shorter lifecycle than the 3D7 line.  They also frequently reached a 
much greater parasitaemia than other strains.  When a growth assay was performed, the 
parasitaemia reached 10% by day four when all other strains were around 4%.  PDEα-KO does 
not produce gametocytes, however the parental 3D7 line was a non-gametocyte producer 
therefore the effect of PDEα knockout could not be investigated in gametocytes.  To investigate 
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whether the high growth rate of PDEα-KO was due to the lack of gametocyte production, the 
non-gametocyte producing ApiAP2-g mutant A4 line (Kafsack et al., 2014) was used as a control.  
The growth rate of A4 was no different from the other strains and significantly lower than that 
of the PDEα-KO.  The high growth rate being a product of the PDEα-KO line’s inability to form 
gametocytes would have been unlikely as the parental line, used for the comparison by 
Wentzinger et al., was also a non-gametocyte producer.   
It cannot be ruled out that the growth rate phenotype could be that when transfected and 
cloned, there was a mutation somewhere else in the genome that resulted in the observed 
growth phenotype.  Whole genome sequencing of PDEα-KO compared to 3D7 could be 
employed to determine the differences in the PDEα-KO line at the genome level.  The most 
appropriate 3D7 control would be the original parental line used by Wentzinger.  
Complementation of the PfPDEα gene could also be performed to see if a normal growth rate 
resumes when the gene is restored.     
The PDEα-HA-DD line, if it had been successful in mediating conditional knockdown, could have 
been used to assess the growth rate of parasites in the presence or absence of shield-1, however 
there are many conflicting factors to consider with this.  Firstly, shield-1 is known to have a 
slightly toxic effect on parasite growth, with one study finding that parasite reinvasion was 
reduced by 11% in a single cycle in the presence of 0.5 µM shield-1 (de Azevedo et al., 2012), 
which is not ideal when looking at slight differences in growth.  Secondly, it was not known if 
the HA tag was not being detected and that PDEα was active within the cells or if the DD tag 
resulted in inactive protein, even in the presence of shield-1.  PDEα-HA-DD was therefore not an 
appropriate control for a PDEα-KO growth phenotype.    
Although not the main focus of this project, the high growth phenotype of PDEα-KO is extremely 
interesting and warrants further investigation.  To fully examine whether removal of PDEα has 
a positive impact on in vitro growth, a second PDEα-KO line would need to be generated, using 
a gametocyte producing parental line.  This would not only confirm that the PDEα growth 
phenotype is not a non-gametocyte producer phenotype, but also to investigate the role of PDEα 
in gametocytes.  It may also prove beneficial to attempt to generate a P. berghei PDEα-KO to 
examine whether PDEα is truly indispensable in vivo at all stages of the life cycle.   
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3.3.3 The DiCre system and PDEβ 
During the course of this project, the DiCre system was adapted to P. falciparum.  In 
collaboration with Mike Blackman, attempts were made to generate a conditional knockdown 
of PDEβ using this system.  Results with the latest strategy are pending at the time of writing.  
Initially a construct was designed to excise the 3’ UTR of the PDEβ gene in an attempt to 
destabilise the mRNA, and preventing translation and therefore reducing the amount of protein.  
Both this study, and work by the Blackman group, has found that removal of the 3’ UTR, even 
with 100% efficiency, did not reduce the amount of protein for the genes targeted so far (Collins 
et al. 2013).  Whilst removal of the 3’ UTR is employed in studies on different organisms, it is not 
always successful.  As study by Ecker et al. in 2012, found that excision of the 3’UTR of P. berghei 
chloroquine resistance transporter gene (pbcrt) by the FLP/FRT system failed to reduce the 
protein level.  This was found to be the result of an alternative polyadenylation sites at the 3’ 
end of the excised locus, that was efficiently able to stabilise the pbcrt mRNA.  Further studies 
by Collins et al. showed that the hsp86 3’ UTR sequence used to regulate transcription of the 
FRB-Cre60 component of the DiCre cassette, possesses bidirectional transcription termination 
and polyadenylation functions, and was therefore able to stabilise the mRNA of SERA5.  
Strangely, the pPDEβ-HA-DiCre transfection plasmid did not contain a second 3’ UTR that would 
be present after rapamycin treatment and the reason for mRNA stability remains unknown, but 
is plausibly due to a cryptic polyadenylation site.  The PDEβ-HA-DiCre line was however 
detectable with an anti-HA antibody and has been used for further studies on PDEβ, which will 
henceforth be referred to as PDEβ-HA (see chapter 4).   
After the failure of 3’ UTR excision to reduce the amount of PDEβ, strategies were considered to 
remove either part of, or the whole of the coding sequence.  The first published study to 
successfully employ the DiCre knockdown system in P. falciparum was by Yap et al. (2014), 
where the authors ‘floxed’ the entire PfAMA1 sequence, which resulted in defective invasion.  
To achieve this, in the W2mef line, the endogenous PfAMA1 was entirely replaced with the 
antigenically distinct (to aid analysis) 3D7 gene, flanked by loxP sites at the N- and C-termini.  
This resulted in excision of the entire gene resulting in a protein knockdown of about 80% within 
a single intraerytrocytic growth cycle, and was sufficient to have an impact on invasion (Yap et 
al., 2014).  PfAMA-1 coding sequence is only 1.9 kb long, whereas PDEβ is 4.7 kb, with many 
introns and long stretches of repetitive sequence.  It would have been extremely challenging to 
clone by PCR and would have resulted in a very large transfection plasmid.  To have full length 
cDNA synthetically made would have been too expensive.  The Blackman group have employed 
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a similar approach to that of Yap et al. by tagging the upstream gene from SERA5 with a loxP 
site, and the 3’ end of SERA5.  With rapamycin treatment, this also resulted in excision of the 
entire SERA5 locus and lead to ablation of gene function (Mike Blackman, Personal 
Communication).  This approach for PDEβ would also have been extremely challenging as the 
upstream gene is in the opposite orientation to PDEβ.  C-terminally tagging this gene would have 
resulted in removal of both genes.  Instead, a transfection plasmid designed to insert a loxP site 
into an intron in the middle of the catalytic domain with the second loxP site within the plasmid.  
This would, hypothetically cut the catalytic domain in half, rendering it inactive (figure 3.24).  
The construct has been successfully created and transfected into the DiCre containing precursor 
line, PreDiCre, creating PDEβ-IntronLoxP.  Work with this line is currently ongoing.   
Although not employed in this study, the recent improvements in P. falciparum genome 
targeting should make transfections and generation of stable, genetically modified parasite lines 
significantly faster as linearised plasmid can be transfected, reducing the need for drug cycling.  
Both the use of zinc-finger nucleases (ZFNs) (Straimer et al., 2012) and the clustered regularly 
interspaced short palindromic repeat targeting of Cas9 (CRISPR/Cas9) (Ghorbal et al., 2014) can 
mediate specific double strand breakages, mediating editing from this site.  Host cell DNA repair 
machinery is employed and repairs the breakage using a homologous template.  As plasmid, 
with homologous targeting sequences, is added in excess of the genome, the repair machinery 
will use this as the template to fix the break, thereby inserting the plasmid into the genome.     
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Chapter 4: Characterisation of the asexual blood stage 
expression and localisation of P. falciparum PDEβ  
4.1 Introduction 
As mentioned in chapter 1, there are no published studies on PfPDEβ.  From the information on 
PlasmoDB (http://plasmodb.org/plasmo/) (genomic sequence data), pfpdeβ is predicted to 
encode a 133 kDa protein with six transmembrane domains.  Illumina-based sequencing of P. 
falciparum 3D7 mRNA on seven life cycle stages suggests that expression, of mRNA at least, 
peaks in late trophozoites and schizonts.  RT-PCR on mRNA transcripts produced in this group 
also corroborates this finding (Ross Cummings, Thesis).  Thus far, there has been very little 
biological evidence to indicate whether these results correlate with protein expression levels.  
PDE assays on cell fractions at all life cycle stages have shown highest cyclic nucleotide activity 
in the membrane fraction, supporting the finding that the PDEs are integral membrane proteins.  
The subcellular localisation of any of the PfPDEs, prior to this study, has been a mystery.  
Evidence from mammalian systems suggests that cyclic nucleotide phosphodiesterases are 
often strictly compartmentalised within the cell (Maurice et al., 2014).  In a review of cyclic 
nucleotide signalling in protozoa, Markov modelling of PDEβ predicted that the catalytic domain 
projects into the parasitophorous vacuole (Gould and de Koning, 2011).   
This chapter aimed to use the HA-tagged PDEβ, outlined in chapter 3, to investigate the 
expression and localisation of PDEβ in the asexual blood stages of P. falciparum.  In addition, the 
specificity of commercially produced antipeptide antibodies against both PDEα and PDEβ, 
provided by Pfizer, was explored.    
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4.2 Results 
4.2.1 PfPDEβ-HA is located in the membrane fraction of parasite extracts 
PDEβ has multiple predicted transmembrane domains, and previous work has indicated that the 
vast majority of Plasmodium PDE activity resides within the membrane fraction of parasite lysate 
preparations.  To further confirm this localisation, the PDEβ-HA epitope tagged parasite line was 
utilised for solubility assays which were performed as described in chapter 2.3.4.  Using 
sequential extraction buffers on mixed late blood stage parasites, different cell fractions were 
solubilised.  Cytosolic, membrane and insoluble fractions were obtained.  Western blotting of 
the resulting samples was performed and probed with rat anti-HA antibody to detect PfPDEβ-
HA.  To assess the success of fractionation, the same samples were probed with antibodies that 
react with PfPKG and PfGap45.  PfPKG is mostly cytosolic, but does have some membrane 
association as it can be detected at low levels with a carbonate extraction (about 50% in very 
late schizonts), which solubilises membrane-associated (peripheral membrane proteins) but not 
integral membrane proteins (Hopp et al., 2012).  PfGAP45 is N-myristoylated and palmitoylated 
and should therefore mostly be detected in the integral membrane fraction (Rees-Channer et 
al., 2006).  As expected, PfPKG was mostly found in the cytosolic (S1) fraction in mixed late stage 
parasites, with a minor band in the membrane fraction (S2).  PfGAP45 was detected in both the 
cytosol and membrane fractions.  However, PfPDEβ-HA was detected exclusively in the S2 
membrane fraction (extracted with 1% Triton X-100) supporting the sequence evidence that 
PfPDEβ is an integral membrane protein.   
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Figure 4.1 Solubility assay of PfPDEβ-HA indicates it is an integral membrane protein 
Western blots of sequential solubilisation of cytosolic (S1), membrane (S2) and insoluble (S3) 
parasite fractions of PfPDEβ-HA.  The blot was probed with anti-HA for PfPDEβ (1:1000, top 
panel), anti-human PKG for PfPKG (1:3000, middle panel) and anti-PfGAP45 (1:.3000, bottom 
panel).  Cytosolic S1 fraction was extracted with a high salt buffer, integral membrane S2 fraction 
was extracted with 1% Triton X-100 and insoluble S3 fraction was extracted with 4% SDS and 
0.5% Triton X-114.  Extractions were performed on mixed late stage parasites.  Equal volumes 
of each fraction were loaded and the same stock was used for all three blots.   
 
4.2.2 Expression of PfPDEβ-HA is highest in schizonts 
To determine the temporal expression of PfPDEβ-HA, western blotting was performed on 
synchronised parasites.  Samples were taken at three timepoints when the culture was highly 
enriched for rings (0-8 hours post invasion (h.p.i.)), trophozoites (16-24 h.p.i) and schizonts (32-
48 h.p.i).  PfPKG, probed with the anti-human PKG antibody, was used as a control.  PfPKG peaks 
in very late schizonts, but can be detected at low levels in trophozoites and very low levels in 
rings (Hopp et al., 2012).  This was reflected in the expression pattern obtained (figure 4.2).  
PfPDEβ-HA protein expression also peaked in schizonts with a low level of expression in 
trophozoites and no expression detected in ring stages.   
To further study the stage specific expression of PfPDEβ-HA, immunofluorescence assays were 
performed.  Tagged PfPDEβ showed low signal intensity in trophozoites which then peaked in 
mid to late schizonts, before reducing at very late schizonts.  No signal was detected in WT 
parasites probed with rat anti-HA monoclonal antibody (appendix A3).   
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Figure 4.2 Time course assay of PfPDEβ-HA expression indicates it peaks in schizont stages 
Western blots of whole parasite lysates taken at three timepoints, 0-8, 16-24 and 32-48 hours 
post invasion (h.p.i.).  Blots were probed with rat anti-HA (1:1000) to detect PfPDEβ-HA and 
anti human PKG (1:2500) to detect PfPKG.     
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Figure 4.3 Time course assay of PfPDEβ-HA expression indicates it peaks in mid to late schizont 
stages 
Representative images of formaldehyde fixed thin smears of ring, trophozoite and schizont 
stages of PfPDEβ-HA parasites, probed with rat anti-HA monoclonal antibody.  Parasite nuclei 
are stained with DAPI (second column).   
4.2.3 PfPDEβ-HA is located in the parasite endoplasmic reticulum  
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Subcellular localisation is an important step in fully characterising a protein.  From the time 
course assay, staining of PfPDEβ-HA appeared punctate, with dense focal points in the mid-
schizonts and more diffuse in the later schizonts.  Co-staining IFAs were performed with proteins 
of known subcellular location including, PfEBA175 which localises to the micronemes, PfERD2 
which localises to the Golgi body, PfGAP45 which localises to the inner membrane complex, 
PfMSP1 which localises to the merozoite plasma membrane and PfBiP which localises to the 
lumen of the endoplasmic reticulum.   
Dual-labelling of PfPDEβ-HA with anti-HA antibodies and PfBiP resulted in colocalisation, 
strongly suggesting that PfPDEβ is located in the endoplasmic reticulum (figure 4.4).  PfPDEβ-HA 
did not significantly colocalise with PfEBA175, PfERD2 or PfGAP45 (figure 4.5).  Interestingly, 
although little colocalisation was observed with segmented PfMSP1, significant overlap was 
seen in earlier, pre-segmentation schizonts (figure 4.6).       
In order to confirm the ER localisation of PfPDEβ-HA, IFAs with ER-Tracker™ Blue-White DPX 
(Molecular Probes, LifeTechnologies) were performed as described in chapter 2.3.2.  ER tracker 
is designed to be used on live parasites however due to that lack of a GFP-tagged PfPDEβ parasite 
line, staining was performed on fixed parasites.  The manufacturer’s protocol states that some 
staining is retained with fixation and permeabilisation, however the signal was very weak.  
Despite weak staining of both ER-tracker and PfPDEβ-HA, clear overlap can be observed 
supporting the PfBiP colocalisation data (figure 4.7).   
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Figure 4.4 PfPDEβ-HA co-localises with PfBiP 
Representative images of formaldehyde fixed thin smears of PfPDEβ-HA parasites, probed with 
mouse anti-HA monoclonal antibody (red) and rat anti-PfBiP (green).  Parasite nuclei are stained 
with DAPI (blue, first column) and bright field images are shown on the right.   
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Figure 4.5 PfPDEβ-HA does not co-localises with other cellular locations 
Representative images of formaldehyde fixed thin smears of PfPDEβ-HA parasites, probed with 
rat anti-HA monoclonal antibody (green) and (from top to bottom) PfEBA175, PfERD2 and 
PfGap45 (all red).  Parasite nuclei are stained with DAPI (blue, first column) and bright field 
images are shown on the right.   
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Figure 4.6 PfPDEβ-HA partially co-localises with MSP1 in pre- but not post-segmented 
schizonts 
Representative images of formaldehyde fixed thin smears of PfPDEβ-HA parasites, probed with 
rat anti-HA monoclonal antibody (green) and PfMSP1 (red).  Pre-segmented schizonts are shown 
in the top row and post-segmented schizonts are the bottom row.  Parasite nuclei are stained 
with DAPI (blue, first column) and bright field images are shown on the right.   
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Figure 4.7 PfPDEβ-HA co-localises ER-tracker 
Representative images of PfPDEβ-HA parasites, pre-loaded with ER-Tracker™ Blue-White DPX, 
fixed with formaldehyde, permeabilised and probed with rat anti-HA monoclonal antibody 
(green) in suspension.  Bright field images are shown on the right.   
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4.2.4 PfPDEβ-HA does not colocalise with an antibody raised to the putative PfAKAP protein 
In mammalian systems, signalling molecules are often complexed into signalosomes to 
compartmentalise and regulate the signalling response.  With regards to PKA, often a protein A 
kinase anchoring protein (AKAP) binds the regulatory domain of PKA to other signalling 
molecules at a specific subcellular localisation (Dodge-Kafka et al., 2005).  PKG interacting 
partners (GKIPs) have an analogous role to AKAPs in that they associate with PKG and other 
signalling molecules, thereby compartmentalising the pathway.  In P. falciparum, only one 
putative kinase anchoring protein, PfAKAP (PF3D7_0512900), has been identified (Anaïs Merckx, 
Personal Communication).  To determine whether PfAKAP and PfPDEβ-HA are spatially 
associated and could therefore be part of a signalosome, co-localisation IFAs were performed.  
The images obtained indicated that PfAKAP and PfPDEβ-HA do not co-localise.   
 
 
Figure 4.8 PfPDEβ-HA does not colocalise with PfAKAP 
Representative images of formaldehyde fixed thin smears of PfPDEβ-HA parasites, probed with 
rat anti-HA monoclonal antibody (green) and anti-PfAKAP (red).  Parasite nuclei are stained with 
DAPI (blue, first column) and brightfield images are shown on the right.   
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4.2.5 Screening of antipeptide antibodies against PDEα and PDEβ 
Antipeptide antibodies were generated by Cambridge Research Biosciences, commissioned by 
Pfizer, as described in chapter 2.3.1.  To determine the specificity of each purified antibody, the 
following schemes were applied.  For both PDEα and PDEβ, the antibodies were screened 
initially by IFA and then by western blotting.  IFAs were performed as the initial screen as they 
require much less antibody.  The immunogenicity of the pre-bleed, final bleed serum and final 
bleed affinity purified antibodies was assessed.  IFAs were used to test whether the antibodies 
were reactive and western blotting can determine if they are specific and react with band of the 
size predicted for each PDE.  Anti-PfPDEα was also tested on the PDEα-KO line to look for the 
loss of detection.  Anti-PfPDEβ was also tested on PfPDEβ-HA to determine co-localisation and 
similar western blotting pattern (with a slight size difference between WT and PfPDEβ-HA 
parasites relating to the epitope tag).  Figures 4.9 and 4.10 outline the screening scheme in more 
detail.   
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Figure 4.9 Anti-peptide antibody screening strategy for anti-PfPDEα 
Initially the final bleed antibodies (sera and affinity purified) were screened by IFA at four 
different dilutions (1:50, 1:100, 1:2500 and 1:10000).  The lowest reactive concentration was 
then used to screen the pre-bleed serum samples.  If the pre-bleed was negative, the samples 
were then screened on the PDEα-KO line.  The PDEα-KO parasites should not react with the 
antibodies.  The samples were then screened by western blotting, initially at 10x the lowest 
relative final bleed concentration, for example if 1:50 was the  lowest reactive concentration by 
IFA, a 1:500 dilution of the antibody was used for western blotting as it is a more sensitive 
technique.  This concentration was then adjusted as necessary.  If a band of the correct size was 
visualised, the antibody was also tested on the PDEα-KO line.  
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Figure 4.10 Anti-peptide antibody screening strategy for anti-PfPDEβ 
Initially the final bleed antibodies (sera and affinity purified) were screened by IFA at four 
different dilutions (1:50, 1:100, 1:2500 and 1:10000).  The lowest reactive concentration was 
then used to screen the pre-bleed serum samples.  If the pre-bleed was negative, the samples 
were then screened on the PDEβ-HA line.  The PDEβ-HA staining should co-localise with the 
antipeptide antibody.  The samples were then screened by western blotting, initially at 10x the 
lowest relative final bleed concentration, for example if 1:50 was the  lowest reactive 
concentration by IFA, a 1:500 dilution of the antibody was used for western blotting as it is a 
more sensitive technique.  This concentration was then adjusted as necessary.  If a band of the 
correct size was visualised, the antibody was also tested on the PDEβ-HA line, looking for a slight 
shift in size, corresponding to the epitope tag.    
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In total, 12 anti-peptide antibodies were screened using the above scheme, eight for PDEα (two 
peptides each in two rabbits, each with two elution techniques) and four for PDEβ (one peptide 
each in two rabbits, each with two elution techniques).  Table 4.1 summarises the screening 
results.  Generally there was no difference between the TEA (T) and glycine (G) affinity 
purification elution buffers or the response of the individual rabbits to the same peptide.  For 
PDEα, peptide α3 was not reactive by IFA for either of the two rabbits by both elution buffers, 
even at a concentration of 1:50 (figure 4.11, upper panel).  In some cases, proteins that are not 
detectable by IFA can still be identified by western blotting.  In IFAs the protein is in its native 
conformation, some epitopes will be hidden or in a conformation that is significantly distinct 
from the linear peptide used for immunisation.  The antibody may be unable to bind these 
epitopes, resulting in no signal in an IFA.  When the protein sample is run on a reducing SDS-
PAGE gel, the SDS and β-mercaptoethanol in the sample buffer will denature the protein and 
the linear polypeptide will be probed, resulting in a greater chance of detection.  This is 
particularly important in anti-peptide antibodies where a short linear peptide is used to elicit an 
immune response.  Therefore, samples 4608 and 4609 were also tested by western blotting, 
however the antibodies were also non-reactive.  Samples from peptide α3 were not tested 
further.  The second PDEα peptide, α4 was reactive at a dilution of 1:100, additionally the pre-
bleed sera was not reactive at this concentration suggesting a specific response to the 
immunisation.  The antibody reacted relatively strongly with what appears to be haemozoin 
crystals or the food vacuole in schizonts, but there was also a more diffuse staining pattern 
throughout the rest of the infected erythrocyte (figure 4.11, middle panel).  Unfortunately the 
antibody was also reactive to the PDEα-KO parasite line, with the same localisation, therefore 
samples from peptide α4 were not tested further.  The PDEβ peptide, β4 was reactive at a 
dilution of 1:100 by IFA.  The pre-bleed was not reactive at this concentration.  Co-localisation 
IFAs were performed with the PDEβ-HA parasite line.  PDEβ-HA did not colocalise with any of 
the antibody samples.  The staining pattern from all of the PDEβ anti-peptide antibodies was 
generally associated with the merozoite surface (figure4.11, lower panel).  This staining pattern 
could be a result of the antibodies cross reacting with proteins in the parasitophorous vacuole, 
merozoite surface, or inner membrane complex.  Pre-segmentation schizonts did not stain 
strongly.  To confirm that the β4 peptide staining was not due to PDEβ, and to rule out the 
unlikely possibility that the epitope tag on the PDEβ-HA resulted in a change in localisation, 
western blotting with one of the samples, 4606, was performed on WT parasites.  If the antibody 
was detecting PDEβ, a band of about 133 kDa should react with the antibody, if the antibody is 
cross-reacting with a different protein, the band is likely to be a different size.  Only an antibody 
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dilution of 1:500 resulted in a distinct band.  The pre-bleed was not reactive at this 
concentration.  PDEβ is predicted to be 133 kDa, unfortunately the band detected was about 
150 kDa, too large to be PDEβ (figure 4.12), however it would be beneficial to repeat with a 
PDEβ-HA control.  This was therefore assumed to be a cross reaction with another protein.  
Samples from peptide β4 were not tested further. 
 
 
Table 4.1 Summary of the results of the anti-peptide antibody screening 
The two PDEα peptide antibodies are shown in the first table.  Rabbits 4608 and 4609 were 
immunised with peptide α3 and rabbits 4668 and 4669 were immunised with peptide α4.  The 
PDEβ peptide antibody is shown in the lower table.  Rabbits 4606 and 4607 were immunised 
with peptide β4.  Two elution buffers were used for affinity purification for each rabbit final 
bleed, TEA (T) and glycine (G).   
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Figure 4.11 Example images of the anti-peptide antibody screening 
Representative images of formaldehyde fixed thin smears of 3D7 and PfPDEβ-HA parasites, 
probed with anti-peptide antibodies (red) and rat anti-HA monoclonal antibody (green).  
Parasite nuclei are stained with DAPI (blue, first column) and bright field images are shown on 
the right.  One image from each peptide, the final bleed with TEA as the elution buffer, is shown.  
The top panel shows peptide α3, sample 4608 (1:50), which was non-reactive. The middle panel 
shows peptide α4, sample 4668 (1:100), which also reacted to the PDEα-KO line.  The lower 
panel shows peptide β4, sample 4606 (1:100), which did not co-localise with PDEβ-HA.   
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Figure 4.12 Anti-peptide antibody sample 4606 is not specific for PDEβ 
An example western blot of 3D7 whole parasite lysates probed with anti-peptide antibodies.  
The first column was probed with the 4606 pre-bleed sample at a 1:500 dilution.  The second 
column was probed with the 4606 affinity purified, TEA elution buffer at a 1:500 dilution.  The 
third column was probed with the 4606 affinity purified, glycine elution buffer at a 1:500 
dilution. 
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4.3 Discussion 
4.3.1 Temporal expression of PfPDEβ-HA  
All four PfPDEs contain multiple predicted TM domains and there are several studies confirming 
the presence of cyclic nucleotide hydrolytic activity in the membrane fraction of whole parasite 
lysates (Taylor et al. 2008; Wentzinger et al. 2008; Ross Cummings, Thesis).  However, there is 
currently no published evidence to confirm the presence of PDEβ in parasite membranes.  Using 
PfPKG as a cytosol and peripheral membrane control, and PfGAP45 as an integral membrane 
fraction control, the solubility of PDEβ was investigated.  PKG is found primarily in the cytosol 
fraction of parasite lysates.  There is some PKG membrane association (50% in late schizonts) as 
a carbonate extraction, to solubilise peripheral membrane proteins, is required to completely 
extract the protein (Hopp et al., 2012).  As expected, PKG was mostly found in the cytosol (S1) 
fraction of the sequential extraction assay.  PfGAP45 resides in the parasite IMC and is associated 
with the parasite membrane via N-myristoylation and palmitoylation motifs (Rees-Channer et 
al., 2006).  PfGAP45 was extracted partially in the S1 fraction, but also in the membrane S2 
fraction.  Triton X-100, used in the S2 extraction, is a non-ionic surfactant detergent used to 
solubilise integral membrane proteins.  PDEβ-HA was extracted exclusively with the membrane 
extraction (S2) suggesting that it is an integral membrane protein.  The predicted TM domains, 
previous evidence for PDE activity in the membrane fraction of parasite lysates and the 
presented solubility data confirms that PDEβ is located in the parasite membrane.  To add weight 
to the solubility assay results, the fractions could also be probed with an antibody against a 
protein with transmembrane spanning domains.  The anti-plasmepsin V (PMV) antibody would 
be ideal as it is also a TM domain protein located in the parasite ER.   
Expression data for PDEβ has so far relied on mRNA transcript level data, which can differ from 
the stage specific expression of the actual protein.  In asexual blood stages, PDEβ mRNA peaks 
in late trophozoites and schizonts (López-Barragán et al., 2011).  Additionally, PDE activity, 
especially cAMP hydrolytic activity, peaks in schizonts stages (Ross Cummings, Thesis).  To 
determine for the first time when PDEβ is expressed at the protein level and to compare this 
with the stage specificity of cyclic nucleotide hydrolytic activity, time course western blotting 
and IFA experiments were performed on the PfPDEβ-HA parasite line.  Initially, samples for 
western blotting were taken at three timepoints over the 48 hour parasite lifecycle to get a 
broad picture of expression.  As predicted from the mRNA data, PfPDEβ-HA was not expressed 
in ring stages, with expression rising in trophozoites and peaking in schizont stages.  PKG 
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expression was used as a control.  PKG detection by western blotting is considerably easier than 
for PfPDEβ-HA.  A much higher antibody concentration and a significantly longer exposure time 
is needed for a signal to appear for PfPDEβ-HA, compared to both the PKG antibody and the 
PKG-HA tagged line (data not shown), this could reflect lower abundance of the protein, 
however, PfPDEβ-HA degrades very easily.  A high concentration of protease inhibitors present 
at all times in the sample is necessary to obtain a clear band.  For these reasons, it is difficult to 
compare PfPDEβ-HA and PKG levels by western blotting, however it is clear that PfPDEβ-HA 
peaks in schizont stages.  For a more focused view of expression, IFAs were performed on the 
various lifecycle blood stages, concentrating on late trophozoites and schizonts, and images 
were taken to cover the whole 48 hour cycle.  As expected, rings and early trophozoites had very 
little protein expression.  After the initiation of schizogony, the levels of PfPDEβ-HA increased, 
appearing as a diffuse mottling throughout the iRBC, with intense focal points of fluorescence.  
As the schizonts matured and segmentation of the merozoites occurred, the pattern changed to 
a more evenly distributed pattern of protein, distinct from the nuclei.  The patches of 
fluorescence then decreased, both in intensity and size until the merozoites ruptured and there 
was no visible PfPDEβ-HA.  The IFAs corresponded well to the western blot data and mRNA 
transcript data, however, it could be beneficial to perform a time course western blot on highly 
synchronised late stage parasites, with samples taken at closer intervals to confirm that the level 
of PfPDEβ-HA reduces in very late, segmented schizonts and merozoites.  Previous work in this 
group has shown that ring stage parasites have PDE activity (Ross Cummings, Thesis).  This 
activity is predominantly cGMP and the PfPDEβ-HA expression data adds weight to the 
hypothesis that this is PDEα activity.  An interesting point to note about figure 4.2 is that the 
band for PDEβ appears to be a double band.  This is most noticeable in the trophozoite stage 
band.  PDEβ is annotated as highly phosphorylated in PlasmoDB, it is possible that the two bands 
are different phosphorylation states.  For future work it would be interesting to treat the 
samples with a phosphatase to see if this is indeed the case.   
4.3.2 Spatial expression of PfPDEβ-HA 
As mentioned above, PfPDEβ-HA IFAs have an interesting pattern of fluorescence that changes 
over the course of schizogony.  Pre-segmentation schizonts have dense focal points of 
fluorescence, with punctate staining throughout the rest of the iRBC.  In segmented schizonts, 
the fluorescence pattern is more diffuse, and surrounds the merozoites.  It is not known whether 
this change in pattern was due to an active change in localisation of the protein or architectural 
rearrangements during segmentation.  Colocalisation IFAs have shown that PfPDEβ-HA and 
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PfBiP strongly overlap.  PfBiP is located in the lumen of the endoplasmic reticulum (ER) of the 
parasite.    
The endoplasmic reticulum is essential for protein transport in all eukaryotic cells, as well as 
being the main intracellular calcium store.  Protein transport involves precursor polypeptides 
that contain an amino-terminal signal peptide, as well as cytosolic and ER transport components.  
Transport into the ER can occur either cotranslationally or posttranslationally.  BiP is a heat-
shock protein 70 (Hsp70) –type molecular chaperone, located at the luminal face of the ER 
(Dudek et al., 2014).  BiP pulls proteins, posttranslationally into the ER via the ER translocator 
and distinguishing incorrectly folded proteins, preventing aggregation and further transport 
through the Golgi (Alberts et al., 2002).  Plasmodia also contain BiP which is located in the ER 
lumen (Kumar et al., 1991).   
PfPDEβ-HA and PfBiP co-localisation was consistent throughout the schizont stages.  It is 
therefore likely that the apparent change in staining pattern is rearrangement of the ER rather 
than relocation of PfPDEβ-HA in very late schizonts.  In the mid-schizont stage, the ER comprises 
an extensive network of reticulated branches extending through the cytosol.  In late schizonts, 
the ER fragments, forming crescent shaped organelles in each merozoite (van Dooren et al., 
2005).  This is consistent with the morphology seen with PfPDEβ-HA IFAs.  PfPDEβ-HA staining 
was distinct from all other cellular organelles tested by protein co-staining, including the Golgi 
marker ERD2, suggesting that PfPDEβ-HA does not get transported via the ER, but is a 
fundamental component.  A notable point for the PfPDEβ-HA and PfBiP co-staining is that, unlike 
all other IFAs, a mouse anti-HA monoclonal antibody was used instead of the usual rat anti-HA 
antibody.  This was due to the fact that the PfBiP antibody was raised in rat and an anti-rat 
secondary antibody was necessary to stain for BiP, precluding its use for PfPDEβ-HA.  The mouse 
anti-HA antibody was tested on WT parasites by IFA and both WT and PfPDEβ-HA parasites by 
western blotting and although highly sensitive for the HA tag, it is less specific than the rat anti-
HA antibody (data not shown).  Therefore, other lines of evidence were pursued to further 
explore the potential ER localisation of PfPDEβ-HA.  Firstly, there is the evidence that prior to 
segmentation and formation of the merozoite IMC and surface membranes, PfPDEβ-HA and 
MSP-1 co-localise.  Post-segmentation, MSP-1 is located on the outer surface of the merozoites, 
leading to staining defining the membranes surrounding the daughter cells, the ‘bunch of 
grapes’ phenotype (Child et al., 2010).  Before reaching their final locations, MSP-1 is presumably 
trafficked through the ER, during which co-localisation with PfPDEβ-HA occurs (figure 4.6).  
Secondly, an experiment using ER-tracker was performed.  ER-Tracker™ Blue-White DPX (Life 
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Technologies), a low toxicity, highly specific ER stain.  ER tracker is primarily used as a live cell 
stain, however due to the lack of a PfPDEβ-GFP tagged line, ER tracker loaded parasites were 
fixed with formaldehyde and stained with rat anti-HA antibodies.  As a result, the signal was very 
weak, both with the ER stain and with the anti-HA staining, however, there was clear overlap 
between the staining patterns.  These three line of evidence, PfBiP co-localisation, MSP1 co-
localisation during ER trafficking and ER tracker co-localisation, are strong evidence for PfPDEβ-
HA residing within the ER.  To provide more evidence for this result, it might be beneficial to 
perform a full timecourse with PfPDEβ-HA and PfBiP co-staining IFAs to confirm co-localisation 
throughout the time that PfPDEβ-HA is expressed.  It would also be worthwhile to produce a 
PfPDEβ-GFP tagged line to allow more accurate ER-tracker, live staining experiments.  Co-
staining with a second ER marker, such as plasmepsin V, ideally not raised in a rat, would also 
be an important future experiment.  It would also be highly beneficial to produce an antibody 
against the native PDEβ to allow staining of WT parasites and other parasite lines, such as the 
PDEα-KO line.  This would be important to determine conclusively that the epitope tag of 
PfPDEβ-HA is not resulting in mis-localisation of the parasite.  As the parasite line is viable, with 
no growth defect, it is unlikely that this would be the case.  The functional significance of PfPDEβ-
HA residing in the ER is unknown.   
In many other organisms, signalling molecules form complexes, termed signalosomes, to allow 
efficient responses to cellular stimuli.  By homology detection, a putative AKAP has been 
identified in P. falciparum.  However, PfAKAP and PfPDEβ-HA do not colocalise, suggesting that 
they do not form a complex.  As PKG does not reside in the ER, PfPDEβ-HA is unlikely to form a 
complex with PfPKG either (Hopp et al., 2012).  For future work it would be beneficial to 
investigate interaction between PfPDEβ-HA and PfPKA using a PKA specific antibody.  To further 
investigate PfPDEβ-HA binding partners, immunoprecipitations could be performed, using mass 
spectrometry to identify the proteins that are co-precipitated.  An initial screening 
immunoprecipitation and subsequent western blotting has shown that PKG is not pulled down 
with PfPDEβ-HA immunoprecipitation (Oriana Kreutzfeld, LSHTM, MSc Project).       
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4.3.3 Antipeptide antibodies against PfPDEα and PfPDEβ 
Twelve anti-peptide antibodies against two PDEα and one PDEβ peptides, raised in rabbits using 
a commercial system, were screened by IFA and western blotting.  Anti-peptide antibodies were 
used due to the difficulties encountered by several groups to express recombinant PDE proteins.  
The peptides were derived from the predicted catalytic domains of the proteins, in regions 
predicted to be immunogenic.  One immunisation and four booster injections were performed 
as part of the commercial package.  The pre-bleed, final bleed and affinity purified antibodies 
were analysed.  The elution of a protein from an immobile ligand (in this case the initial peptide), 
involves dissociation and recovery of the target molecule using a specific buffer.  For elution of 
the anti-peptide antibodies, buffers of extreme pH were used, TEA at pH 11.5 and glycine at pH 
2.5-3.0.  However, there was no difference between the sensitivity or specificity of the buffers 
by IFA or western blotting.  The antibody based on the PDEα peptide α3 was non-reactive by IFA 
and western blotting, even at a dilution of 1:50.  The antibody based on the PDEα peptide α4 
was also reactive with the PDEα-KO line, implying the antibody was not specific to PDEα.  The 
antibody based on the PDEβ peptide β4 was highly reactive with schizont stages and the pre-
bleed sera was non-reactive, however when co-staining was performed with PDEβ-HA, there 
was no colocalisation, implying that the antibody was not specific to PDEβ.  To confirm this 
result, western blotting was performed which gave a band of approximately 150 kDa, which is 
too large to be PDEβ (133 kDa), although this would need to be confirmed using the PDEβ-HA 
line as a positive control.   
There has been a previous attempt to generate an anti-peptide antibody against PDEβ using N-
terminal peptide sequences by Ross Cummings.  Unfortunately the pre-bleeds were quite 
reactive and there was therefore high background in the final images.  Additionally, western 
blots with the antibody gave a band of around 50 kDa, too small to be PDEβ.  It was hypothesised 
that the final IFA images could show an ER localisation, however in the absence of co-
localisations, an incorrectly sized western blot band and a high IFA background, it is unlikely that 
the antibody was specific to PDEβ (Ross Cummings, Thesis).   
Thus far, there has been no antibody produced that is specific to any of the native PfPDEs and 
all attempts to generate useful anti-peptide antibodies have failed.  To improve the likelihood 
of generating specific antibodies, immunisation with recombinant protein would be ideal.  
Generation of recombinant proteins will be discussed in more detail in chapter six.   
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Chapter 5: Investigation of the effects of human 
phosphodiesterase inhibitors on P. falciparum 
5.1 Introduction 
Phosphodiesterase inhibitors have long been utilised in various studies on Plasmodium 
parasites.  In 1978, Martin et al. found that addition of the human PDE4 inhibitor etazolate (SQ-
20,009, cGMP specific) and the broad spectrum human PDE inhibitor caffeine, as well as a 
membrane permeable cAMP derivative (8-bromo-cAMP), could stimulate gametogenesis in the 
chicken Plasmodium, P. gallinaceum (Martin et al., 1978).  This observation was duplicated in 
1982 where caffeine was also shown to enhance gametocytogenesis at 2 mM in P. falciparum 
(Brockelman, 1982). Additionally, the gametogenic property of 8-bromo-cAMP (1 mM) was also 
duplicated in a 1989 study (Trager and Gill, 1989).  Another broad spectrum PDE inhibitor, IBMX 
(0.5 mM), was found to enhance exflagellation of male gametes in both P. falciparum and P. 
berghei (Kawamoto et al., 1990).  However, these studies were concentrated on improving the 
numbers of parasites switching to gametocytes in culture rather than investigating the role of 
the PDE enzymes themselves in the life cycle of the parasites.  
Ross Cummings, a previous PhD student in the Baker group at LSHTM in 2005, focused on the 
PfPDEs.  Several commercial human PDE inhibitors were tested in PDE assays performed on 
parasite lysate, including IBMX, caffeine and etazolate.  However, IBMX and caffeine had little 
or no effect on PDE activity on any parasite stage, with IC50 values over 200 µM.  This calls into 
question the interpretations made in earlier studies and suggests that specific inhibition of PDE 
activity may not be responsible for gametogenesis and that other targets may be involved.  
However some of the earlier work was on P. gallinaceum and may represent different inhibitor 
sensitivities between Plasmodium species.  The study by Ross Cummings found that 
dipyridamole (human PDE 5 and 6 specific, cGMP) and etazolate hydrochloride (human PDE4 
specific, cAMP) were found to be the most potent compounds and able to inhibit both cAMP 
and cGMP PDE activity with IC50 values of around 6 and 20 µM, respectively, using asexual blood 
stage lysates.  However, in sexual stages, the compounds were relatively ineffective (>200 µM).  
The most effective inhibitor tested, and that had activity on both asexual blood stage and 
gametocytes, was zaprinast.  Zaprinast had IC50s of about 12 µM on schizont cAMP hydrolytic 
activity, 3 µM on schizont cGMP hydrolytic activity and 33 µM stage V gametocyte cGMP 
hydrolytic activity in the membrane fraction of the parasite lysates.  Zaprinast also inhibited ring 
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stage cGMP hydrolytic activity at an IC50 of about 3.5µM.  Zaprinast was therefore the most 
potent, PfPDE inhibitor tested (Ross Cummings, Thesis).   
Zaprinast (previously known as M&B 22948) is a competitive inhibitor of mammalian PDE5 and 
was originally synthesised as an anti-allergy compound for allergic asthma (Broughton et al., 
1974).  It was subsequently found to cause vasodilatation and smooth muscle relaxation via 
nitric oxide induced cGMP production (Gibson, 2001; Merkel et al., 1992).  It was also noted that 
zaprinast treatment facilitated penile erection, which subsequently lead to the development 
and introduction of a second PDE5 inhibitor, sidenafil citrate, also known as Viagra™(Boolell et 
al., 1996). 
In the two PDEα papers by Yuasa et al. 2005, and Wentzinger et al. 2008, a series of inhibitors 
were tested on parasite growth, parasite lysates and on recombinant protein.  In keeping with 
data from Ross Cummings, zaprinast was found to be the most potent inhibitor of all three.  The 
EC50 in a P. falciparum blood stage growth inhibition assay was 35 µM, the IC50 of zaprinast on 
PDE activity in parasite lysates was 4.1 µM (Yuasa et al., 2005) and about 3.4 µM on recombinant 
protein (Wentzinger et al., 2008), which compares quite well with the values obtained by Ross 
Cummings (thesis).  This is about 10 times higher than the expected IC50 on the target hPDE5 
(Gibson, 2001).  Zaprinast is also able to stimulate rounding up of stage V gametocytes in the 
absence of XA and in a non-permissive pH, and male gamete exflagellation (McRobert et al., 
2008).  Recent work has also shown that zaprinast is able to induce egress of blood stage 
schizonts in a PKG-dependent manner.  Addition of 75 µM of zaprinast was able to promote 
microneme and exoneme discharge, even in unsegmented schizonts, and lead to the premature 
release of non-invasive merozoites (Collins et al., 2013a).   
As part of this project, a small panel of phosphodiesterase inhibitors was provided by Pfizer as a 
collaborative venture to help address the suitability of malaria PDEs as novel targets for 
antimalarial drug discovery.  Fourteen novel compounds from various development series, as 
well as eight commercially available compounds including zaprinast were provided.  The 
structures and original human PDE target of the Pfizer compounds were unknown.  The names 
and structures of the commercially available compounds are shown in table 5.1 
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Zaprinast: 
5-(2-Propoxyphenyl)-1H-[1,2,3]triazolo[4,5-
d]pyrimidin-7(4H)-one 
Selective inhibitor of PDE-5 (cGMP) 
 
CP 80633: 
5-[3-[(1S,2S,4R)-Bicyclo[2.2.1]hept-2-yloxy]-4-
methoxyphenyl]tetrahydro-2(1H)-pyrimidinone 
Selective inhibitor of PDE- 4 (cAMP) 
 
Dipyridamole: 
2,2',2'',2'''-(4,8-di(piperidin-1-yl)pyrimido[5,4-
d]pyrimidine-2,6-diyl)bis(azanetriyl)tetraethanol 
Inhibitor of PDE-5 (cGMP)  
 
IBMX: 
1-methyl-3-(2-methylpropyl)-7H-purine-2,6-dione
  
Non-selective human PDE inhibitor 
 
EHNA Hydrochloride: 
erythro-9-(2-Hydroxy-3-nonyl)adenine hydrochloride 
Adenosine deaminase inhibitor, also inhibits PDE-2 
(cGMP) 
 
BRL 50481: 
N,N,2-Trimethyl-5-nitro-benzenesulphonamide 
Inhibitor of PDE-7 (cAMP) 
 
T 0156 Hydrochloride: 
1,2-Dihydro-2-[(2-methyl-4-pyridinyl)methyl]-1-oxo-
8-(2-pyrimidinylmethoxy)-4-(3,4,5--
trimethoxyphenyl)-2,7-naphthyridine-3-carboxylic 
acid methyl ester hydrochloride 
Selective inhibitor of PDE- 5 (cGMP) 
 
Vinpocetine: 
(3α,16α)-Eburnamenine-14-carboxylic acid ethyl ester 
Selective for PDE-1 (cGMP), also blocks voltage-gated 
Na+ channels. 
 
Table 5.1 Commercial phosphodiesterase inhibitors 
A table containing the name, structure and primary human PDE target for the eight tested 
commercial compounds.   
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5.2 Results 
5.2.1 Comparison of 48 hour and 72 hour hypoxanthine growth inhibition assays for PDE 
inhibitors 
Radiolabelled hypoxanthine uptake assays are used to rapidly evaluate the effect of inhibitors 
on the in vitro growth of P. falciparum.  Hypoxanthine uptake is proportional to the number of 
parasitised RBCs present (see chapter 2.4).  A standard hypoxanthine assay has a 48 hour 
duration, [3H]hypoxanthine is added to the parasites after 24 hours and the assay is stopped 
after a further 24 hours.  This is extremely effective for fast acting compounds that kill in ring 
and trophozoites stages.  For slower acting compounds or compounds that act very late in the 
cell cycle, often a 72 hour assay is preferred.  This is because the parasites incorporate the 
radiolabel during DNA synthesis and some drugs will inhibit the parasites growth only in late 
schizont stages or during invasion, post DNA replication.  For example compounds that target 
PfPKG, delay rupture of the parasite causing a static phenotype.  This only becomes cidal 
(resulting in parasite death) if the egress block is continued for over 6 hours (Taylor et al., 2010).  
A difference in growth may therefore be missed if the life cycle is extended due to the action of 
the compounds.   
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Figure 5.1 The life cycle of P. falciparum growth in vitro 
The life cycle of P. falciparum is 48 hours long.  Post invasion, the parasites are ring stages for 
about 18 hours.  They then develop to trophozoites and as DNA synthesis begins, the parasites 
are classed as schizonts.  A hypoxanthine assay is initiated when the parasites are ring stages, 
usually between 6 and 12 h.p.i (hours post invasion).  Tritiated hypoxanthine is added at about 
36 h.p.i., as the parasites start to undergo schizogony.  The radiolabel will be incorporated into 
the parasite DNA during DNA replication.  If an inhibitory compound is present that kills parasites 
prior to schizogony, the parasites will not be viable and will not undergo DNA replication.  When 
the assay is stopped 24 hours later, the radiation counts will be lower, reflecting the efficiency 
of killing.  For compounds that are active in the parasite later than schizogony, the counts are 
likely to be similar at 48 h.p.i.  Therefore the assay is continued for a further 24 hours, allowing 
time for reinvasion of the parasites and the level of reinvasion will be proportional to radiation 
counts.   
 
As the stage specificity of PDE inhibitors for P. falciparum was unknown, although hypothesised 
to act in schizogony based on PDE protein expression data (see chapter 4), both 48 and 72 hour 
assays were performed and compared.  72 hour assays were found to be significantly more 
reliable than 48 hour experiments, in terms of reproducibility.  The IC50s of the control drugs 
artemisinin and chloroquine were not drastically different between the assays (figure 5.2).  This 
is as expected as both compounds can kill the parasites pre schizogony.  For the test compounds, 
results obtained from 48 hour assays resulted in large standard errors and confidence intervals, 
as well as producing higher IC50s (data shown in appendix A4).  72 hour assays gave much more 
reproducible results and lower IC50s (full data shown in chapter 5.2.3).  Figure 5.3 
(representative graph, full IC50 results shown below) shows the six Pfizer compounds with the 
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lowest IC50s (in both the 48 and 72 hour assays), and the difference between the 48 and 72 hour 
assays.  The standard error of the mean (as shown by the error bars), is much higher in the 48 
hour assays.  Therefore, the 72 hour assay was used to determine the IC50s of all the compounds 
tested.   
 
Figure 5.2 Comparison of the IC50s of the control drugs in 48 and 72 hour hypoxanthine uptake 
assays 
The IC50s of artemisinin (red) and chloroquine (blue) are within the expected range for a 
hypoxanthine uptake assay.  Each of the assays was performed in triplicate and the assays were 
repeated three times.  The error bars represent the SEM.   
 
 
 
Figure 5.3 Comparison of the IC50s of six of the Pfizer compounds in 48 and 72 hour 
hypoxanthine uptake assays 
The IC50s of six of the Pfizer test compounds for the 48 hour and 72 hour assays are shown.  The 
IC50s are vastly lower for the 72 hour assay, with a much narrower standard error.  Each of the 
assays was performed in triplicate and the assays were repeated three times.  The error bars 
represent the SEM.  The graph was capped at 1 µM average IC50.   
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5.2.3 Results of the 72 hour hypoxanthine growth inhibition assays 
72 hour hypoxanthine uptake assays were performed on P. falciparum parasites, starting at ring 
stages, using the eight commercial compounds, fourteen test Pfizer compounds and the control 
drugs artemisinin and chloroquine.  Table 5.2 and figures 5.4 to 5.7 show the average IC50s of 
three assays.  The IC50s of the control drugs artemisinin and chloroquine fall within the expected 
low nanomolar range, 31 and 6 nM, respectively.  The IC50 of zaprinast (26 µM) is similar to 
what has been reported previously.  For the commercially available compounds, IMBX had an 
IC50 over 100 µM.  CP 80633 and BRL50481 also had IC50s greater than 100 µM.  EHNA 
hydrocholate and dipyridamole were the most potent commercial compounds (2.8 and 4.7 µM, 
respectively).  T0156 hydrochloride and vinpocetine had IC50s of 22 and 60 µM, respectively.  
The IBMX and dipyridamole results are in keeping with results reported by Ross Cummings on 
inhibition of PDE activity on parasite lysates.   
Only one of the Pfizer compounds had an IC50 over 100 µM (PF-03120399), all of the rest were 
below 20 µM.  Seven of the compounds had IC50s in the sub-micromolar range, below 200 nM.  
The lowest IC50s were for compounds PF-05225388 and PF-05257670 at 5.3 and 7.5 nM, 
respectively, which compares well with several antimalarials currently in clinical use.   
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Table 5.2 Results of the 72 hour hypoxanthine uptake assay 
The average IC50s of three separate assays, each performed in triplicate, are shown in µM and 
nM.  The IC50 is the concentration of inhibitor that gave 50% growth in vitro in comparison to a 
no drug control.  The IC50 values, the standard error of the mean and 95% confidence intervals 
were calculated using Prism software.  >100 denotes sufficient inhibition was not observed and 
no IC50 could be calculated.  The rows in grey are the compounds that have IC50s lower than 
160 nM.    
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Figure 5.4 Dose-response curves of the control compounds including zaprinast in a 
hypoxanthine uptake assay 
Inhibition profiles are displayed as percentage inhibition relative to absence of inhibitor.  The 
data shown represents three separate assays, each performed in triplicate.  Error bars represent 
standard error of the mean.   
 
 
 
 
 
Figure 5.5 Dose-response curves of the commercial compounds in a hypoxanthine uptake 
assay 
Inhibition profiles are displayed as percentage inhibition relative to absence of inhibitor.  The 
data shown represents three separate assays, each performed in triplicate.  Error bars represent 
standard error of the mean.   
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Figure 5.6 Dose-response curves of the first seven Pfizer compounds in a hypoxanthine uptake 
assay 
Inhibition profiles are displayed as percentage inhibition relative to absence of inhibitor.  The 
data shown represents three separate assays, each performed in triplicate.  Error bars represent 
standard error of the mean.   
 
 
 
Figure 5.7 Dose-response curves of the final seven Pfizer compounds in a hypoxanthine uptake 
assay 
Inhibition profiles are displayed as percentage inhibition relative to absence of inhibitor.  The 
data shown represents three separate assays, each performed in triplicate.  Error bars represent 
standard error of the mean.   
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5.2.4 Comparison of wild-type and PfPDEα-KO IC50s in 72 hour growth inhibition assays 
mRNA expression data (PlasmoDB) indicate that PDEα and PDEβ are likely to be the two PDEs 
expressed during P. falciparum blood stage development. PDEβ has proved refractory to 
deletion, but PDEα has been knocked out successfully with only a subtle growth phenotype. It 
was of great interest to determine whether any of the Pfizer inhibitors was selective for PDEβ as 
it is presumed that this isoform is essential in the blood stages.  To determine whether any of 
the compounds gave a different inhibition profile in the absence of PDEα, 72 hour hypoxanthine 
assays were performed on the PDEα-KO parasite line and the parental 3D7 wild type line.  Using 
Prism software, the IC50s were calculated and a comparison between the two was performed, 
using the extra sum-of-squares F-test.  Initially all of the compounds were tested on the PDEα-
KO line and compared to the previously determined 3D7 IC50s, however it was difficult to 
conclude whether there was any difference between the IC50 values as the concentration range 
was extremely large (~100 µM to 0.1 nM, data not shown).  It was there therefore decided to 
concentrate on the five most potent compounds and zaprinast, using a narrower concentration 
range in order to plot more points around the IC50.  Artemisinin and chloroquine were again 
used as controls.  Unexpectedly, artemisinin and chloroquine gave significant P values for a 
difference in IC50s between the two strains (p<0.001 and p=0.002).  The IC50 for zaprinast was 
also significantly different between the parasite lines, p=0.001.  None of the five tested Pfizer 
compounds had a significant difference in IC50 between the strains (table 5.3 and figure 5.8), 
potentially suggesting that PDEα is not a primary target of the compounds.  Artemisinin and 
chloroquine were not expected to have different IC50s as there should be no difference between 
the two strains, apart from the lack of PDEα and this is not a target of either of the two drugs.  
However, as there is a significant growth rate difference between the two strains, this could be 
affecting the results.    
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Table 5.3 Results of the 72 hour hypoxanthine assays for 3D7 and PDEα-KO parasite lines 
The average IC50s of three separate assays, each performed in triplicate, are shown in µM and 
nM.  The IC50 is the concentration of inhibitor that gave 50% growth in vitro in comparison to a 
no drug control.  The IC50, R2 and P values (using the extra sum-of-squares F-test) were 
calculated by Prism software.  Significance was set at p<0.05.  R2 is the coefficient of 
determination, indicating how well the curve fits the data.   
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Figure 5.8 Dose-response curves of the comparative hypoxanthine uptake assays for wild type 
and PDEα-KO parasite lines 
Inhibition profiles are displayed as percentage inhibition.  Error bars represent standard error of 
the mean.  The wild type IC50 is shown in red and the PDEα-KO is shown in blue.   
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5.2.5 Development of a native P. falciparum phosphodiesterase assay 
For this project, a new PDE assay was developed, based on scintillation proximity assay (SPA) 
beads (Perkin Elmer).  The basic protocol was adapted for P. falciparum from the PDE assay kit, 
also produced by Perkin Elmer (Catalogue nos. TRKQ 7090 and TRKQ 7100).  The final protocols 
for the assay and parasite material preparation are described in chapter 2.5.  PDE activity was 
monitored using a discontinuous tritium [3H] based cyclic nucleotide hydrolysis assay.  Native 
enzyme (either from parasite lysate or HA-immunoprecipitation), was incubated with 
radiolabelled cAMP or cGMP for one hour at 37oC.  Any PDE enzyme in the sample will hydrolyse 
the phosphodiester bond within the cyclic nucleotide.  The assay is stopped by addition of the 
SPA beads.  The hydrolysed nucleotide is able to bind to the beads, leading to scintillation which 
can be measured in a scintillation counter, whereas the intact cyclic nucleotide does not bind.  
The PDE assay used previously in the group, based on phosphatase enzymatic cleavage of the 
phosphate group of the hydrolysed cyclic nucleotide and Dowex exchange resin separation, was 
not used due to unavailability of some of the reagents and the potentially simplified protocol of 
the SPA based method.   
The first steps to optimise the assay used whole parasite lysates.  Whole lysate was incubated 
in the presence or absence of 100 µM of zaprinast (zap).  In the absence of the PDE inhibitor, 
the lysate produced high counts, indicating cNMP hydrolytic activity within the samples.  In the 
presence of zaprinast, this activity was severely reduced, indicating that the hydrolytic activity 
was the result of phosphodiesterase activity.  Commercial PDE enzyme extracted from bovine 
brain (Enzo Life Sciences) was used as the positive control, which hydrolyses both cAMP and 
cGMP, with a greater preference for cGMP and could be effectively knocked down with zaprinast 
(figure 5.9).  Additionally, saponin lysed erythrocytes, treated in the same way as the parasite 
lysate samples, were tested and shown to contain no PDE enzyme activity (data not shown).   
When designing the assay buffer for optimal PDE activity, it was necessary to include a divalent 
cation.  All PDEs are predicted to contain two divalent metal ions, zinc and another, usually 
magnesium (Ke and Wang, 2007).  Zn2+ is held in the catalytic domain by invariant residues that 
lead to very strong coordination of the ion.   Ross Cummings investigated the effect of different 
divalent cations (Zn2+, Mg2+, Mn2+ and Ca2+) on the PDE activity of parasite lysates.  He found that 
it was not necessary to add zinc to the reaction, presumably due to the strong coordination of 
Zn2+ seen in crystallised PDEs, the ion remains bound to the enzyme in parasite preparations.  
However, recombinant PDEα requires 20 µM ZnSO4 for full activity (Wentzinger et al., 2008).  In 
an earlier study utilising recombinant PDEα, it was determined that manganese (1 mM MnCl2) 
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was the most potent activator (Yuasa et al., 2005).  Ross Cummings found that for whole parasite 
lysate, highest activity was with Mg2+, followed by Mn2+.  Ca2+ was not able to support enzyme 
activity (Ross Cummings, Thesis).  Therefore, the PDE assay buffer was supplemented with 
MgCl2.   
To further test the PDE activity assay, negative controls with no enzyme, no substrate and a 
blank (no enzyme or substrate) were performed.  As expected these gave very low readings.  The 
sample that contained the cyclic nucleotide, but no enzyme gave the highest background 
reading, possibly due to a background scintillation from the cyclic nucleotide or the low level 
presence of some hydrolysed cyclic nucleotide in the original sample.  This background was still 
very low and was used as the negative control in subsequent experiments.  A sample of lysate 
that had been boiled for 5 minutes at 95oC was also tested.  The boiled sample gave a reading 
comparable to the negative controls, indicating that the hydrolytic activity was a result of a heat 
labile factor, i.e. a protein (figure 5.10).   
 
 
Figure 5.9 Initial assays to characterise native parasite PDE activity 
Hydrolysis of cAMP (left) and cGMP (right) by whole parasite lysate displayed in combined 
counts per minute (CCPM), a relative measure of scintillation.  Parasite lysate had PDE activity 
comparable to the positive control commercial PDE extracted from bovine brain tissue.  This 
activity could be substantially reduced by addition of the PDE inhibitor zaprinast (zap, 100 µM).  
The blank represents no enzyme and no substrate.  The figure contains data from a single 
representative experiment that was repeated several times.   
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Figure 5.10 Initial assays to characterise parasite PDE activity 
Hydrolysis of cAMP (left) and cGMP (right) by whole parasite lysate displayed in combined 
counts per minute (CCPM), a relative measure of scintillation.  Parasite lysate had PDE activity 
that could be severely reduced by addition of the PDE inhibitor zaprinast (100 µM).  The blank 
represents no enzyme and no substrate.  Controls of no enzyme, plus substrate and no substrate 
plus enzyme were included.  Lysate that was boiled for 5 minutes at 95oC ablated PDE activity.  
The assay was performed in triplicate and the error bars represent standard error of the mean.     
 
Previous studies have identified that PfPDE activity is in the membrane fraction (Wentzinger et 
al. 2008; Yuasa et al. 2005; Ross Cummings, Thesis).  This is consistent with the multiple 
predicted TM domains within the protein sequences, and with findings in this study, that 
PfPDEβ-HA is located in the membrane fraction of parasite lysates (see chapter 4.2.1).  To 
confirm the presence of PDE activity in the membrane fraction of parasite lysates, fractionation 
was performed as described in chapter 2.6.1.  The fractionations were performed on the both 
3D7 and PfPDEβ-HA parasite lines.  Two times the volume of the saponin pellet of extraction 
buffer was used for the extractions.  Western blotting with the rat anti-HA monoclonal antibody 
was also performed to confirm the presence of PDEβ.  PDEα is assumed to be solubilised in the 
same fraction as PDEβ as it also contains multiple TM domains.  Anti-GAPDH antibody was used 
as a control.  As predicted, the majority of PfPDEβ-HA is located in the membrane fraction (S2 – 
nonidet P-40 extraction), with some residual activity in the S3 fraction (RIPA extraction, a 
harsher membrane extraction buffer than nonidet P-40).  There was no activity in the S1 
cytosolic fraction.  For future experiments the volume of extraction buffer was increased to five 
times the volume of the saponin pellet in an attempt to solubilise more of the protein.  GAPDH 
is a cytosolic protein and as expected, was mostly found in the S1 fraction.  A lesser amount was 
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also in the integral membrane S2 fraction which was probably due to the sheer volume of 
protein present (figure 5.11).   
 
Figure 5.11 PDE activity is in the membrane fraction of the parasite lysate 
Upper panel: Hydrolysis of cAMP (left) and cGMP (right) by parasite lysate fractions, displayed 
as combined counts per minute (CCPM), a relative measure of scintillation.  The majority of the 
PDE activity was in the membrane fraction of the parasite lysate (S2).  The cytosol fraction (S1) 
contained no hydrolytic activity.  The S3 fraction contained some PDE activity, but significantly 
less than the S2 fraction.  The results shown are for PfPDEβ-HA, very similar results were 
obtained for 3D7 (not shown).  The assay was performed in triplicate and the error bars 
represent standard error of the mean.  Lower panel: western blot showing the equivalent 
fractions to the upper PDE assay.  The majority of PfPDEβ-HA is found in the S2 extraction, with 
some activity also in the S3 extraction.  This correlates well with the PDE activity assay.  Blots 
were probed with rat anti-HA (1:1000) to detect PfPDEβ-HA and anti-GAPDH (1:30,000) to detect 
PfGAPDH. 
 
Finally, dose-response curves were performed using the membrane fraction of the parasite 
lysates.  Ten-fold serial dilutions, starting using 10 µl of the extraction sample, were performed 
and assayed.  Both the 10 µl/well and the 1 µl/well saturated the experiment, presumably the 
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activity of the enzyme exceeded the available cyclic nucleotide concentration.  Dose dependent 
activity is observed at concentrations lower than 1 µl/well.  Figure 5.12 shows an example assay.  
Serial dilutions were performed and assayed prior to each following experiment and the lysate 
was diluted to give 30% hydrolysis of the substrate.   
Figure 5.12 PDE activity is dose-dependent  
Hydrolysis of cAMP (left) and cGMP (right) by membrane fraction parasite lysate displayed in 
combined counts per minute (CCPM), a relative measure of scintillation.  A dose-response was 
performed from 10 µl per well at 10-fold serial dilutions.  The blank represents no enzyme, plus 
substrate.  This is a representative graph from one assay.       
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5.2.6 Analysis of the effects of PDE inhibitors on native PDE activity in wild-type parasite 
lysates 
PDE inhibitor assays were performed in order to confirm whether the Pfizer compounds were 
targeting the PfPDEs.  Some of the compounds had very high potency (IC50 values in the low 
nanomolar range) in the hypoxanthine incorporation assays on parasite growth, however it was 
not known if the killing was due to on- or off-target effects.  All the Pfizer compounds were 
initially screened at two concentrations, 5 µM and 200 nM in cAMP and cGMP PDE assays.  
Zaprinast was used as a positive control at 100 µM and 1 µM.  Artemisinin and the PKG inhibitor 
compound 2 were used as negative controls, also at 5 µM and 200 nM.  Values were expressed 
as percent of uninhibited control.  Compounds that had IC50s of lower than 250 nM in 
hypoxanthine incorporation assays are denoted by a star (), compounds with IC50s below 100 
nM are denoted by two stars ().  As expected, the higher concentration of zaprinast (100 
µM) significantly inhibits PDE activity, the lower concentration (1 µM) does not.  As previously 
found by Ross Cummings, Zaprinast inhibits both cAMP- and cGMP-PDE activity, whereas in 
humans it is selective for PDE5, a cGMP specific PDE.  Artemisinin and compound 2 do not reduce 
PDE activity at either concentration.  Of the seven Pfizer compounds that have IC50s of greater 
than 250 nM in hypoxanthine incorporation assays, none show significant loss in activity in this 
assay, indicating that they are either off target or not potent enough to inhibit the native 
Plasmodium PDE in this assay.  Of the seven compounds that do have IC50s of less than 250nM 
in parasite growth inhibition assays, five of them, PF-01273175, PF-05184913, PF-05225388, PF-
00394183 and PF-00388991, reduce cyclic nucleotide hydrolysis at both 5 µM and 200 nM.  This 
effect is much more pronounced for cAMP hydrolysis.  Two of the highly potent inhibitors in 
hypoxanthine uptake assays, PF-05257670 (IC50 of 7.5 nM) and PF-05197824 (IC50 of 140.5 nM) 
have no effect on cyclic nucleotide hydrolysis for either cAMP or cGMP.  Presumably, they are 
therefore not primarily hitting a PfPDE in the whole parasite.   
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Figure 5.13 Screening of Pfizer inhibitors in a native PDE assay on WT parasites 
Hydrolysis of cAMP (upper) and cGMP (lower) by membrane fraction parasite lysate with either 
5 µM (red) or 200 nM (blue) of compound.  Zaprinast concentrations are 100 µM (red) and 1 µM 
(blue) due to the lower potency of the inhibitor.  Values are expressed as percent of uninhibited 
control.  Compounds that had IC50s lower than 250 nM in hypoxanthine incorporation assays 
are denoted by a star () and compounds with IC50s below 100 nM are denoted by two stars 
().  Due to time and financial constraints, the results presented represent single data points.  
The graph was capped at 100%.   
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5.2.7 Comparison of the effects of the Pfizer compounds on native PDE activity on wild-type 
and PfPDEα-KO parasite lysates 
The differential results above of the phosphodiesterase screen on 3D7 parasites for cGMP and 
cAMP were quite unexpected.  Although the cAMP hydrolysis levels were highly inhibited in the 
presence of some of the compounds, the effect was much less pronounced for cGMP hydrolysis.  
Apart from compound PF-01273175, the pattern was quite different between the cyclic 
nucleotides.  Zaprinast also gave the same pattern between cyclic nucleotides which was 
expected as it is presumed to be a broad Plasmodium PDE inhibitor.  PDEα is a cGMP specific 
phosphodiesterase.  Therefore it was hypothesised that some of the inhibitors might be 
specifically targeting PDEβ and not PDEα, resulting in residual cGMP hydrolytic activity.  To test 
this hypothesis, the assay was repeated on the PDEα-KO line.  In the absence of PDEα, the effect 
of the inhibitors on PDEβ could be dissected.  Figure 5.14 shows the screening of inhibitors on 
the PfPDEα-KO parasite lysates.  As with the previous figure, the Pfizer compounds, artemisinin 
and the PKG inhibitor compound 2 were screened at two concentrations, 5 µM and 200 nM.  
Zaprinast was used as a positive control at 100 µM and 1 µM.  Values are expressed as percent 
of uninhibited control.  Compounds that had IC50s lower than 250 nM in hypoxanthine 
incorporation assays are again denoted by a star (), compounds with IC50s below 100 nM are 
denoted by two stars ().  As with the 3D7 results, the higher concentration of zaprinast (100 
µM) significantly inhibited PDE activity, the lower concentration (1 µM) does not.  Artemisinin 
and compound 2 did not reduce PDE activity at either concentration.  The seven Pfizer 
compounds that have IC50s of greater than 250 nM, and show no cNMP hydrolysis in the WT 
assay, none showed significant loss in activity in this assay. In both assays, compounds PF-
05257670 and PF-05197824 (highly potent in the growth inhibition assay) had no effect on cyclic 
nucleotide hydrolysis for either cAMP or cGMP, indicating that they have off target effects on 
the parasite.  In the PDEα-KO assay, the inhibition patterns for the five potent, on target 
inhibitors (PF-01273175, PF-05184913, PF-05225388, PF-00394183 and PF-00388991) is the 
same for both cAMP and cGMP hydrolysis.   
To present this more clearly, figure 5.15 shows a comparison between 3D7 and PDEα-KO 
phosphodiesterase activity inhibition at the highest (5 µM for the Pfizer inhibitors and 100 µM 
for zaprinast) concentration.  For cAMP hydrolysis inhibition, WT and PDEα-KO parasite lysate 
shows the same pattern of inhibition.  For cGMP hydrolysis inhibition, WT and PDEα-KO parasite 
lysate show different patterns of inhibition.  Zaprinast and PF-01273175 inhibited cGMP 
hydrolysis equally in WT and PDEα-KO lines.  However for PF-05184913, PF-05225388, PF-
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00394183 and PF-00388991, cGMP hydrolysis was only partially reduced (about 50% inhibition) 
in WT lysate, however in PDEα-KO lysate, cGMP hydrolysis was reduced to almost baseline 
levels.  This strongly suggests that zaprinast and PF-01273175 inhibit both PDEα and PDEβ.  PF-
05184913, PF-05225388, PF-00394183 and PF-00388991 primarily target PDEβ.  Since PDEα and 
PDEβ are the only PDEs expressed in blood stages and the PDEα-KO line retains cAMP and cGMP 
hydrolytic activity, which can be specifically inhibited with PDE inhibitors, this is also strong 
evidence that PDEβ is a dual specific PDE.   
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Figure 5.14 Screening of Pfizer inhibitors in a native PDE assay on PDEα-KO parasites 
Hydrolysis of cAMP (upper) and cGMP (lower) by membrane fraction parasite lysate with either 
5 µM (red) or 200 nM (blue) of compound.  Zaprinast concentrations are 100 µM (red) and 1 µM 
(blue) due to the lower potency of the inhibitor.  Values are expressed as percent of uninhibited 
control.  Compounds that had IC50s lower than 250 nM in hypoxanthine incorporation assays 
are denoted by a star () and compounds with IC50s below 100 nM are denoted by two stars 
().  Due to time and financial constraints, the results presented represent single data points.  
The graph was capped at 100%. 
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Figure 5.15 Pfizer inhibitors: comparison between 3D7 and PDEα-KO parasites 
Hydrolysis of cAMP (left) and cGMP (right) by membrane fraction parasite lysate with either no 
inhibitor (lysate), 100 µM zaprinast or 5 µM of Pfizer inhibitor.   3D7 parasite PDE activity is 
shown in green and PDEα-KO activity is shown in blue.  Values are expressed as percent of 
uninhibited control.    The graph was capped at 100%.   
 
5.2.8 Phosphodiesterase activity of immunoprecipitated PfPDEβ-HA 
To further investigate both the cyclic nucleotide specificity of PDEβ and the specificity of the 
inhibitors, PDE assays on immunoprecipitated PfPDEβ-HA was performed.  Immunoprecipitation 
was performed as described in chapter 2.6.2.  However, for the initial test pulldown and western 
blot, a Nonidet P-40 based buffer and a RIPA buffer were used sequentially for extraction.  Figure 
5.16 shows the result of the western blot.  A band at about 133 kDa was successfully pulled 
down with the nonidet P-40 extraction.  The nonidet P-40 buffer was therefore used for further 
immunoprecipitations.  To prepare the bead sample for western blotting, the samples were 
boiled in reducing buffer for 10 minutes, however the majority of the sample remained bound 
to the beads (figure 5.16).  In a separate experiment, the PDEβ protein was eluted using a glycine 
buffer at acid pH.  This was tested by Westen blotting and PDE assay.  Very little protein or 
activity was eluted in this fraction and it was therefore decided to use the bead-protein complex 
in the PDE assay (data not shown).   
Two-fold serial dilutions were performed with the bead-protein complex, from 10 µl to 1.25 µl.  
Beads only was used as the negative control.  Each concentration was performed in duplicate 
and although the counts were not highly consistent, a dose-response with decreasing bead 
concentration could be observed.  The 30% hydrolysis dilution could not be determined as the 
highest concentration (10 µl) did not saturate the assay.  Therefore, 5 µl of the pulldown sample 
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was used for a further inhibitor assay as this concentration was within the linear range of the 
assay (figure 5.17).  The immunoprecipitation of PfPDEβ-HA has both cAMP and cGMP hydrolytic 
activity, confirming for the first time that PDEβ is a dual specific phosphodiesterase.   
A selection of the inhibitors was tested in a PDE inhibition assay.  Zaprinast was used at 100 µM 
concentration.  The Pfizer inhibitors were all used at a concentration of 100 nM, (lower than the 
previous screening assay).  As a negative control, the off target PF-05257670 inhibitor was 
included.  The five compounds that were previously most potent in the PDE assay were used, 
PF-01273175, PF-05184913, PF-05225388, PF-00394183 and PF-00388991.  Uninhibited lysate 
was used as a positive control.  As predicted, 100 µM zaprinast ablates cyclic nucleotide 
hydrolysis and PF-05257670 has no effect.  At 100 nM, PF-01273175 and PF-05184913 do not 
significantly inhibit PDEβ activity.  This could be likely because their IC50 is above 100 nM, which 
is likely looking at the data in figure 5.13 where a 5 µM concentration almost totally ablated PDE 
function whereas 200 nM only reduced the activity by about 60-70%.  However, the three 
remaining compounds do significantly inhibit PDEβ activity.  These compounds, PF-05225388, 
PF-00394183 and PF-00388991, were among the most potent in the parasite growth assays 
(IC50s of 11 nM, 62 nM and 20 nM, respectively).  The combined data indicates that these 
compounds are potent, on-target, highly PDEβ specific phosphodiesterase inhibitors.   
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Figure 5.16 Immunoprecipitation of PfPDEβ-HA 
Western blot showing the successful immunoprecipitation of PDEβ-HA with a nonidet P-40 
based buffer.  A protein migrating between 100 and 150 kDa (consistent with the predicted 
molecular weight of 133 kDa for PDEβ) was successfully isolated.  The blot was probed with rat 
anti-HA monoclonal antibody at 1:1000 dilution.   
 
 
 
Figure 5.17 Immunoprecipitation of PfPDEβ-HA has cAMP and cGMP hydrolysing activity that 
is dose-dependent  
Hydrolysis of cAMP (left) and cGMP (right) by immunoprecipitaed PfPDEβ-HA is displayed in 
combined counts per minute (CCPM), a relative measure of scintillation.  A dose-response was 
performed from 10 µl per well at two-fold serial dilutions.  The negative control represents anti-
HA affinity matrix alone (beads only).  5 µl was used for the subsequent experiments.  The assay 
was performed in duplicate and the error bars represent standard error of the mean.   
 
174 
 
 
Figure 5.18 Testing of selected inhibitors on immunoprecipitated PfPDEβ-HA  
Hydrolysis of cAMP (upper) and cGMP (lower) by immunoprecipitaed PfPDEβ-HA, in the 
presence of PDE inhibitors is displayed in combined counts per minute (CCPM), a relative 
measure of scintillation.  Zaprinast was used at 100 µM as a positive control and the Pfizer 
inhibitors were used at 100 nM.  The negative control represents anti-HA affinity matrix alone 
(beads only).  The assay was performed in duplicate and the error bars represent standard error 
of the mean.   
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5.2.9 Phosphodiesterase inhibitors kill at late schizont and ring stage parasites 
To investigate the timing of killing of phosphodiesterase inhibitors, a selection of the Pfizer 
compounds was added to synchronised asexual blood stage cultures at ring and trophozoite 
stages.  This was a very preliminary assay to visualise the death phenotype.  Concentrations of 
about four times the IC50 determined in the hypoxanthine incorporation assays were used.  
0.5% DMSO was used as a negative control.  For the first assay, shown in figure 5.19, inhibitors 
were added to ring stages (T=0).  Giemsa stained blood films were examined after 16 hours.  
Compounds PF-05225388, PF-00394183, PF-00388991 and zaprinast were tested.  The most 
potent PDEβ inhibitor, PF-05225388, is shown in the figure as a representative sample.  After 16 
hours, the DMSO treated parasites had progressed to trophozoites.  Parasites treated with 100 
μM zaprinast or 20 nM PF-05225388 appeared to have died at ring stages.  Parasites treated 
with PF-00394183 and PF-00388991 also resulted in parasite death at ring stages (not shown).  
For the second assay, shown in figure 5.20, inhibitors were added to trophozoite stages (T=0).  
Giemsa stained blood films were examined after 4 and 16 hours.  Compounds PF-05225388, PF-
00394183, PF-00388991 and zaprinast were tested.  The most potent PDEβ inhibitor, PF-
05225388, is shown in the figure as a representative sample.  After four hours all three samples 
had progressed to early-mid schizonts and looked healthy.  However after 16 hours, only the 
DMSO sample contained healthy, reinvaded parasites.  Two different phenotypes were present 
for the inhibitor treated samples.  Many of the parasites appeared to have ruptured, releasing 
merozoites that were unable to reinvade, resulting in a ‘burst schizont’ phenotype.  Some of the 
merozoites may have attached to RBCs and invaded.  These parasites then died at ring stages, 
as seen in figure 5.19.  For some of the parasites it was difficult to tell if they had managed to 
reinvade or if the merozoite was attached to the RBC surface.  Figure 5.20 shows an example of 
each of these phenotypes for the two compounds.  It was not possible to quantify the numbers 
of each of these phenotypes by Giemsa stained blood films because the burst schizonts made it 
difficult to count.  Further work will be necessary to investigate the stage of killing more 
thoroughly. 
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Figure 5.19 PDE inhibitors kill at ring stages 
Inhibitor (or DMSO) was added to ring stage parasites at T=0.  After 16 hours, DMSO parasites 
had developed into trophozoites.  Parasites in the presence of 100 μM zaprinast or 20 nM PF-
05225388 appeared to be dead.   
 
 
Figure 5.20 PDE inhibitors kill at ring and late schizont stages 
Inhibitor (or DMSO) was added to trophozoite stage parasites at T=0.  After 4 hours, all the 
samples contained healthy looking mid-schizonts.  After 16 hours, DMSO treated parasites had 
successfully reinvaded to form new rings.  Parasites in the presence of 100 μM zaprinast or 20 
nM PF-05225388 appeared to be dead.  All of the samples containing PDE inhibitors contained 
a mixture of what appeared to be burst schizonts and dead merozoites/rings. 
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5.3 Discussion 
As part of this project, fourteen potential PDE inhibitors were obtained from Pfizer.  Originally 
developed as a part of lead compound optimisation for various human PDE series, very little was 
known about the compounds.  In addition, some of the compounds provided were guanylyl 
cyclase inhibitors although it was not known which.  Additionally, eight commercially available 
PDEs were tested, including the previously characterised, broad spectrum PfPDE inhibitor 
zaprinast.  The current antimalarials artemisinin and chloroquine were used as positive controls.   
5.3.1 Hypoxanthine incorporation assays 
The first step that was taken in characterising the compounds for potency and specificity against 
the PfPDEs was with a parasite growth inhibition assay.  All 24 compounds were screened using 
hypoxanthine incorporation assays.  A standard hypoxanthine uptake assay is 48 hours long, 
however in some instances a 72 hour assay is preferred.  For the PDE inhibitors this was indeed 
the case.  A 72 hour growth inhibition assay was necessary to obtain reliable IC50 curves.  In 
addition to producing robust results, the necessity of a 72 hour assay may also indicate that the 
compounds are toxic at the schizont, merozoite or very early ring stages, targets that are less 
amenable to a 48 hour assay.  A late schizont stage target would be expected from the previously 
determined expression profile of PDEβ.  Microscopy of P. falciparum parasites in the presence 
of the inhibitors also indicates that the schizont and early ring stages are killed (figures 5.19 and 
5.20).  Detailed conclusions about inhibitor potency are discussed in more detail below.  
However it is important to note that the IC50 of zaprinast was consistent with previous studies 
(approximately 26 µM) and that a number of the Pfizer inhibitors were far more potent, with 
IC50s in the low nanomolar range.   
Wild-type parasites are predicted to express two different PDEs in asexual blood stages, PDEα 
and PDEβ.  As PDEα is non-essential it can be supposed that the death of the parasites results 
from inhibition of PDEβ, although antagonistic effects of inhibiting both PDEs cannot be 
discounted.  In an attempt to determine the IC50 of the compounds in hypoxanthine 
incorporation assays in the absence of PDEα, and to determine whether there is a difference 
between inhibiting PDE(s) in the WT and the PDEα-KO line, comparison IC50s were performed.  
Prior to this experiment, any selectivity of the Pfizer compounds was totally unknown.  As PDEα 
is not essential in asexual blood stage parasites there may be no difference in the IC50s between 
the two lines, especially if a compound inhibited both PDEs equally well and all cyclic nucleotide 
function was ablated.  However, if the compounds only inhibited PDEβ then a difference in IC50 
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may potentially be seen.  In one scenario, inhibition of PDEβ in WT parasites could only inhibit 
the cAMP signalling pathway as PDEα is still able to hydrolyse cGMP, a cAMP specific phenotype 
may be seen.  However inhibition of PDEβ in the absence of PDEα would remove all PDE function 
from the cell, resulting in a cGMP and cAMP phenotype.  The PDEs may also be distinct in 
function and a PDEβ specific death phenotype would be observed.  The five most potent 
compounds along with zaprinast, artemisinin and chloroquine were tested at a narrower 
concentration range than for the previous growth inhibition assays.  Artemisinin and 
chloroquine do not target the PfPDEs which should therefore result in a consistent IC50 between 
the different parasite lines.  Zaprinast is known to inhibit PDEα, and as it kill the parasite, 
presumably PDEβ as well.  It should also therefore result in comparable IC50s between the lines.  
The specificity of the Pfizer compounds was unknown.   
Unexpectedly, the hypoxanthine incorporation assay IC50s of some of the control compounds 
was different between the 3D7 and the PDEα-KO lines.  For artemisinin, chloroquine and 
zaprinast the IC50 was lower in the 3D7 line.  There was no difference between the IC50s of the 
Pfizer compounds.  When looking at the IC50 curves (figure 5.8), the differences were quite slight 
and could have been the result of variation between the replicates.  Additionally, the faster and 
higher growth rate of the PDEα could have resulted in the difference between the IC50s of the 
controls.  This could then mask any true difference in inhibition profile between the WT and 
PDEα-KO line.  Unfortunately this assay was performed before it was determined that 
compound PF-01273175 inhibits both PDEα and PDEβ as it could have been a useful addition to 
the PDEα-KO/3D7 comparison experiment.  Comparative hypoxanthine assays were not used 
further due to the complexity in assessing the results.  This assay would be well suited to analysis 
of IC50s of PDEβ in a PDEα conditional knockdown system as the stains used for comparison 
would be from the same (or one removed) generation rather than a distant parental line.  
Additionally, if a second PDEα-KO line was generated that did not have a growth rate phenotype 
(i.e. it is the result of an off target effect) then that would also be a good line to use in this assay 
system.   
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5.3.2 Phosphodiesterase activity assays 
A PDE assay had previously been developed for Plasmodium PDEs at LSHTM, however some of 
the reagents were no longer commercially available which necessitated the development of an 
alternative method.  A PDE assay kit is produced by Perkin Elmer, however the cost was 
prohibitively high.  A key element of the kit is the PDE specific scintillation proximity assay beads, 
which are also available separately from Perkin Elmer.  These beads were used to develop a PDE 
assay suitable for analysing PfPDEs.  PDEs are dependent on divalent cations as co-factors for 
activity.  Ross Cummings had previously analysed presence of metal ions in the assay buffer for 
optimal activity.  Magnesium, closely followed by manganese results in the highest activity level.  
Studies on PDEα have shown that Mn2+ gives the highest level of PDE activity (Wentzinger et al., 
2008; Yuasa et al., 2005).  It is possible that Mg2+ is the primary co-factor for PDEβ and Mn2+ is 
the co-factor for PDEα.  Due to time constraints, this could not be investigated in depth, but 
would be best with the PDEβ-HA pulldown.    
Initially this PDE assay was tested with parasite lysate and commercially available PDE enzyme, 
both of which showed high levels of activity which was effectively inhibited by zaprinast.  
Additionally, lysate that was boiled for five minutes at 95oC had no PDE activity, indicating that 
a protein (i.e. enzyme) is responsible for the activity.   
Previous studies, as well as transmembrane domain predictions have indicated that PfPDEs are 
located in the parasite membranes.  In chapter 4.2.1, PDEβ-HA located to the integral membrane 
fraction in a sequential solubility assay.  Sequential protein extractions on PDEβ-HA parasite 
lysates, were performed and analysed by PDE assay and western blotting.  The presence of the 
protein and the PDE activity in the sample strongly correlate.  This is further confirmation that 
PDEβ is an integral membrane protein.   
PDEβ was also successfully immunoprecipitated using an HA-affinity matrix.  A protein of 
approximately 136 kDa was observed by western blotting which correlated to PDE activity.  This 
sample had both cAMP and cGMP hydrolysing activity, confirming for the first time that PDEβ is 
a dual specific phosphodiesterase.   
The Pfizer compounds and zaprinast were also tested on both whole parasite lysates and the 
PDEβ-HA pulldown, initially on 3D7 parasites at two different concentrations.  What was most 
evident from this experiment was that the inhibition profile was very different for cAMP 
hydrolysis compared to cGMP hydrolysis.  Although the potency of specific compounds will be 
discussed below, the most active compounds significantly reduced cAMP hydrolysis.  These 
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same compounds tended to reduce cGMP hydrolysis but not to the same magnitude as the 
cAMP hydrolysis (about 50% inhibition shifting to over 90% inhibition, respectively).  As PDEα is 
cGMP specific and PDEβ is dual specific, the decrease in potency of the compounds (screening 
of inhibitors on native PDE activity, figure 5.13) for cGMP hydrolysis could be explained by 
residual PDEα activity if the inhibitors were specifically targeting PDEβ.  This hypothesis was 
tested by repeating the assay on the PDEα-KO parasite line.  As part of the study in which the 
PDEα-KO line was generated, the levels of cyclic nucleotide hydrolysis were measured compared 
to the parental (WT) line.  cGMP hydrolysis was found to be reduced by 20% and cAMP hydrolysis 
levels were unchanged (Wentzinger et al., 2008).  In this study, the PDEα-KO line and the 3D7 
line had very similar cAMP hydrolysis levels in the presence of the inhibitors.  This was expected 
as PDEα does not hydrolyse cAMP and PDEβ is predicted to be the only other PDE active in 
asexual parasites.  A key point is that the cGMP hydrolytic activity was substantially inhibited by 
the potent Pfizer compounds in the PDEα-KO line compared to the WT line.  In the PDEα-KO line, 
the levels of cGMP hydrolysis are highly similar to those seen in the cAMP hydrolysis experiment.  
The only compounds for which this was not the case were zaprinast and PF-01273175 where 
inhibition of cAMP and cGMP hydrolysis was not different for 3D7 parasite lysate or PDEα-KO 
lysate.  This is shown clearly in figure 5.15.  The conclusion of this assay is that some of the 
potent PDE inhibitors are specific to PDEβ and do not target PDEα.  These compounds are PF-
05225388, PF-00394183 and PF-00388991.  Zaprinast and PF-01273175 target both PDEβ and 
PDEα.  Compound PF-05184913 is less potent than the other PDEβ specific inhibitors, but is also 
likely to predominantly target PDEβ.  A further conclusion from these data is that two of the 
compounds that were highly potent in the hypoxanthine uptake assays, PF-05257670 and PF-
05197824 (IC50s of 7.5 nM and 140.5 nM, respectively), are not PDE inhibitors.  They are 
potentially some of the guanylyl cyclase inhibitors that were included in the panel of drugs, 
however this remains unknown (summary table 5.4, below).   
5.3.3 Overview of inhibitor potency 
During the course of the experiments, almost all details about the Pfizer compounds were 
unknown, including whether they were indeed PDE inhibitors, rather than guanylyl cyclase 
inhibitors.  Recently, the human PDE target of the five most potent, on-target inhibitors has been 
divulged.  PF-01273175 is a human PDE9 inhibitor, PF-05184913, PF-05225388, PF-00394183 
and PF-00388991 are human PDE5 inhibitors (see summary table 5.4).  Interestingly, zaprinast 
(IC50 of 26 µM), T0156 hydrochloride (IC50 of 22 µM) and dipyridamole (IC50 of 4.7 µM), three 
of the effective commercial compounds, are also PDE5 inhibitors.  Although EHNA hydrochloride 
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(IC50 of 2.8 µM), the most potent commercial compound in the growth inhibition assay, is an 
inhibitor of PDE2, its primary target in humans is adenosine deaminases.  P. falciparum also 
contains an adenosine deaminase (ADA) which catalyses the conversion of adenosine to inosine 
and is critical in the purine salvage pathway.  EHNA has been tested against PfADA, and was 
found to be weakly active against recombinant protein.  It was not however, tested in a growth 
inhibition assay (Ivanov and Matsumura, 2012).  It is possible that the primary target of EHNA is 
not a PDE, but another protein within the parasite, potentially PfADA.  A similar picture emerges 
with vinopocetine (IC50 of 60 µM), a human PDE1 inhibitor which also blocks voltage gated 
sodium channels.  A brief search for ‘voltage gated sodium channel’ on PlasmoDB and NCBI did 
not turn up any obvious annotated candidate genes in the P. falciparum genome, however it is 
possible that the growth inhibition occurs due to a PDE independent effect.  CP 80633, a human 
PDE4 inhibitor and BRL 50481, a human PDE7 inhibitor, did not affect parasite growth (IC50s 
over 200 µM).  In keeping with results by Ross Cummings, IBMX (a broad spectrum PDE inhibitor) 
had no effect on parasite proliferation.    
Mammalian PDE5 is a cGMP specific phosphodiesterase encoded by a single gene.  Three 
variants of PDE5A mRNA have been discovered, PDE5A1-PDE5A3, which differ at their N-termini.  
PDE5 contains two GAF domains, one of which, GAF-A binds with high affinity to cGMP.  GAF 
domains are allosteric regulation sites which, upon cGMP binding, promote cGMP hydrolysis 
(Maurice et al., 2014).  Several human PDEs contain these domains, PfPDEs do not.  PDE5 is 
phosphorylated by PKG at an N-terminal serine, upstream of the GAF domains.  Under certain 
conditions this site can also be phosphorylated by PKA.  This phosphorylation increases the 
affinity of cGMP binding to the GAF domain and it has been predicted that this mechanism is a 
feedback loop for prolonging the activation of PDE5 (Bender and Beavo, 2006).  Interestingly, in 
a recent quantitative phosphorylation proteome study, PDEβ was found to be phosphorylated 
in a cGMP-dependent manner at Serine 156 (Alam et al., 2014).  This could potentially result in 
a feedback mechanism similar to that seen in PDE5.   
PDE9 is notable as having the highest affinity for cGMP of all of the PDE families discovered so 
far.  Like PDE5, PDE9 exists as a single gene copy, but has complex mRNA processing with 19 
variants identified.  PDE9 contains no GAF domains, but does contain a Pat7 nuclear localisation 
domain.  Little is known about the function of PDE9 although a PDE9 inhibitor (PF-04447943) 
has undergone clinical trials as a treatment for Alzheimer’s disease, however no effect was 
reported on improvement of cognition, behaviour or global change (Schwam et al., 2014).  Like 
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the PfPDEs, PDE9 is insensitive to many of the common broad spectrum PDE inhibitors including 
caffeine and IBMX. 
  
IC50 in Growth 
inhibition Assay Probable PfPDE 
Target 
Human 
PDE 
Target   µM nM 
Zaprinast 25.9 25900 Broad PDE5 
PF-05257670 0.01 7.47 Off-target  
PF-01273175  0.14 143.00 PDEα and PDEβ PDE9 
PF-05184913 0.16 156.40 PDEβ PDE5 
PF-05225388 0.01 5.34 PDEβ PDE5 
PF-00394183 0.08 81.73 PDEβ PDE5 
PF-05197824 0.14 140.50 Off-target  
PF-00388991 0.03 33.86 PDEβ PDE5 
 
Table 5.4 An overview of the properties of the seven Pfizer compounds with the lowest IC50 
and zaprinast in vivo  
IC50s in micromolar and nanomolar of seven of the most potent Pfizer compound with their 
presumed PfPDE target and the human PDE target, if known.   
 
In summary, this project, along with previous studies, has highlighted differences between 
PfPDEs and human PDEs in terms of their inhibition profile.  Many widely studied broad 
spectrum PDE inhibitors are ineffective on PfPDEs.  Prior to this study, the most potent 
mammalian PDE inhibitor in terms of effects on the parasite was zaprinast with an IC50 value 35 
µM (Yuasa et al., 2005). However, the present study has identified 5 compounds which are about 
1000-fold more potent than this, representing a big step forward.  Four of these target human 
PDE5 and, looking at the PDE assay results, are highly PDEβ specific.  Additionally, a PDE9 
inhibitor was active against both PfPDEα and PfPDEβ.  This selectivity was unexpected and 
therefore the compounds will be valuable tools for future functional analysis, as well as 
promising lead compounds for future antimalarial drug discovery. 
A robust PDE assay has been developed for PfPDEs that is much simpler than those previously 
used, notably with less handling of radioisotopes.  The fundamental differences between human 
and Plasmodium PDEs indicates that selective inhibitors could be developed that selectively 
target the PfPDEs, resulting in compounds with a good safety profile.  This will be further 
discussed in chapter 7.   
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Chapter 6: Expression of recombinant PvPDEβ protein 
6.1 Introduction 
There have been several previous attempts to generate recombinant PfPDE proteins.  PDEα is 
currently the only active PfPDE successfully expressed so far (Wentzinger et al., 2008; Yuasa et 
al., 2005).  The predicted catalytic domain of PfPDEα was expressed in an E. coli based 
recombinant expression system. All of the other PfPDEs have been attempted in a variety of 
systems including E. coli and the baculovirus insect cell system with no success (Ross Cummings, 
Thesis; Pfizer, personal communication; Thomas Seebeck, University of Bern, personal 
communication).  The reasons for failure are unknown but there have been problems with 
solubility.  Also, often the catalytic domain only was expressed, it is possible that the TM 
domains or cryptic regulatory features within the rest of the protein are key to activity.  P. 
falciparum proteins are notoriously challenging to express.  Although the reasons for this are 
uncertain, it has been postulated that as a result of the AT rich codon bias, some tRNAs used by 
P. falciparum may be rare in heterologous systems,  and atypical signal peptides and export 
motifs contribute to poor recombinant expression (Birkholtz et al., 2008).  Also, the high AT 
content, repetitive amino acid stretches and bias towards unusual codons likely make both the 
presence of the DNA sequence and subsequent protein unstable in the expression host organism 
(Zenonos et al., 2014).  For these reasons, baculovirus expression of the closely related, and also 
significant from a public heath perspective (Anstey et al., 2012), P. vivax PDEβ (PVX_122885) will 
be attempted.  To our knowledge, expression of the P. vivax PDEβ gene had not been attempted.  
The sequence was recodonised to Spodoptera frugiperda codon usage.   
Baculovirus expression technology has been exploited for over 30 years (Bishop, 1990).  Protein 
expression within a eukaryotic S. frugiperda insect cell line allows complex proteins to be 
produced with a high yield and post-translationally modified (Kost et al., 2005; Miller, 1993).  
The major species of baculovirus used for recombinant protein expression is the dsDNA virus 
Autographa californica multiple nucleopolyhedrosis virus (AcMNPV).  AcMNPV is a lytic virus to 
both the insect cells in culture and its natural reservoir, larval stages of Lepidoptera (Blissard and 
Rohrmann, 1990).   The genome of AcMNPV has been manipulated to remove the polyhedrin 
gene.  Polyhedrin is expressed to very high levels in the natural infection cycle of AcMNPV, but 
is not essential for the growth of the virus in culture (Smith et al., 1983).  By insertion of genes 
into this locus by homologous recombination between the baculovirus genome and a plasmid 
transfer vector, the protein of interest can be expressed at high levels.  In order to remove all 
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the background, non-recombinant baculoviruses, a segment of an essential gene, orf1629, has 
also been deleted from the genome.  This gene is then added to the transfer vector, 
complementing the baculovirus genome and resulting in rescue of only the recombinant viruses 
(Zhao et al., 2003).   
The his-tagged full length PvPDEβ portion of this study was performed with help from Meredith 
Stewart (LSHTM), mistic-tagged full length PvPDEβ was expressed in collaboration with Avnish 
Patel (LSHTM).   
 
6.2 Results 
6.2.1 Expression of His-tagged full length PvPDEβ  
The synthetic gene of P. vixax PDEβ was purchased from GeneArt (Invitrogen).  The gene 
sequence was codon optimised for Spodoptera frugiperda, the baculovirus insect host cells, to 
maximise the production of recombinant protein from the system.  The PvPDEβ gene and the 
pRN16 plasmid were digested with BamHI and PstI restriction endonucleases and ligated using 
procedures described in Chapter 2.  Plasmid DNA was extracted from transformed colonies and 
analysed by restriction digest and sequencing to ensure the PDE insert was correct.  A C-terminal 
His-tag was also included to enable purification and analysis of the expressed protein.  Sf9 cells 
were transfected, and the virus amplified using the methods described in chapter 2.7.  The 
transgenic virus (AcPvPDEβ-6xHis) was cloned by plaque purification.  After a few rounds of viral 
passage to maximise the viral titre or the cloned viruses, IFAs were performed on the infected 
insect cells in order to visualise the expressed protein and to estimate which clones had the 
highest expression levels.  IFAs, using antibodies against the C-terminal 6x His-tag, were 
performed as described in chapter 2.7.6.  Two of the clones, clone 1 and clone 5, showed 
punctate fluorescence above the level of the negative control (uninfected Sf9 cells).  The 
fluorescence was mostly in 2-4 foci at the periphery of the infected insect cell.  Clone 5 appeared 
to have more expression of the protein as the staining was stronger.  This could be due to 
increased viral titre in the culture as the insect cells also appeared to have greater cytopathic 
effects (reduced cell numbers due to cell lysis and irregular shaped cells caused by virus 
replication) than the clone 1 Sf9 cells (and the uninfected insect cells), or the protein itself could 
be cytopathic as increased expression correlates with this phenotype (figure 6.1).    
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Figure 6.1 Sf9 insect cells positive for His-tagged expression of PvPDEβ 
IFAs on formaldehyde fixed Sf9 cells infected with virus clone 1 (middle), clone 5 (lower) or 
uninfected (upper), were performed and representative images are shown for each.  The insect 
cell nuclei were stained with DAPI, and the phase image is shown.  PvPDEβ was stained with 
mouse monoclonal anti-His antibody (1:3000).  The lower figure shows a cell at high 
magnification from the AcPvPDEβ-6xHis clone 5 infected cells showing two focal areas of 
fluorescence.   
 
SDS-PAGE and western blotting was performed on whole cell lysates of the infected insect cells 
to investigate whether the expressed protein was of the expected size.  Coomassie stained SDS-
PAGE of whole infected insect cell lysates did not give any obvious differences between 
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AcPvPDEβ-6xHis infected and wild type baculovirus infected cells (figure 6.2).  Western blotting 
was performed several times.  Initially a very weak signal was seen, roughly consistent with the 
expected size (135 kDa) (figure 6.2), however the signal decreased with subsequent virus 
passages.  Sf21 cells were also infected but gave no greater expression than the Sf9 cell line.     
 
 
Figure 6.2 Western blot and SDS-PAGE of insect cell lysates 
SDS-PAGE of whole infected cell lysate (left) showing AcPvPDEβ-6xHis (clones 1 and 5) compared 
to WT baculovirus infected cells.  western blot showing a time course assay for PvPDEβ-6xHis 
compared to Uninfected Sf9 cells.  The blot was probed with monoclonal mouse anti-His 
antibody at 1:3000.   
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6.2.2 Expression of Mistic-tagged full length PvPDEβ  
The diminishing of the signal from the His-tag by western blot was not accompanied by a 
decrease in viral titre of the infection efficiency.  It was postulated that the His-tag was unstable 
or difficult to detect with the antibody.  Without an antibody specific to the protein it was not 
possible to purify the protein.  To address the issue of low expression of this membrane protein, 
potentially due to cryptic translocation signals in an orthogonal system and instability of the His-
tag, a second construct was designed utilising a Mistic-tag and a more stable 10x His-tag.  A 
second reason for using a longer His-tag is that proteins sequestered in the membrane can 
sterically occlude binding between the tag and the affinity resin.   
Integral membrane proteins can be extremely difficult to express.  Membrane proteins have to 
be trafficked to the membrane which requires targeting signals that could be unrecognisable to 
the insect cell (or other expression system).   Often, membrane proteins are targeted to inculsion 
bodies instead which necessitates renaturation of the protein from misfolded insoluble deposits 
which has had limited success (Laage and Langosch, 2001).   
Mistic (Membrane Integrating Sequence for Translation of Integral membrane protein 
Constructs) is a 13 kDa (for sequence see appendix A5) integral membrane protein derived from 
Bacillius subtilis which is able to fold autonomously into cell membranes and drive the insertion 
of downstream peptides.  This process is independent of the cellular translocon machinery 
(Roosild et al., 2005).  The Mistic protein has been adapted to form a fusion tag that has been 
shown to dramatically increase yield and expression success of integral membrane proteins 
when expressed N-terminally to the gene of interest (Deniaud et al., 2011; Xu et al., 2013).   
The full length PvPDEβ was cloned into the pAcH10Mistic YMI plasmid, containing an dual N-
terminal 10x His-tag followed by the Mistic-tag and a glycine serine flexible linker of the 
sequence 2x(GGGS), using BamHI endonucleases, to generate AcPvPDEβ-Mistic.  Plasmid DNA 
was extracted from the transformed colonies and analysed by restriction digest and sequencing 
to ensure the PDE insert was correct and in frame.  Sf9 cells were transfected, and the virus 
amplified using the materials and methods described in chapter 2.7. 
SDS-PAGE and western blotting was performed on lysates of the infected insect cells to see if 
PvPDEβ-Mistic was successfully expressed and of the expected size.  Coomassie stained SDS-
PAGE of whole infected insect cell lysates did not give any obvious differences between 
AcPvPDEβ-Mistic infected and wild type baculovirus infected cells (data not shown).  Western 
blotting using mouse monoclonal anti-His antibody showed two strong bands that were absent 
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in the uninfected insect cells.  However these proteins were much smaller than expected at 
about 60 and 50 kDa; PvPDEβ with a 10x his tag and the Mistic tag is predicted to be about 151 
kDa (figure 6.3).  This protein was His-purified using the protocol described in chapter 2.7.8.  
Figure 6.3 shows the His-purified AcPvPDEβ-Mistic compared to lysates of uninfected insect 
cells.  Very strong bands are present at about 70 and 50 kDa.   
 
 
Figure 6.3 PvPDEβ-Mistic in whole cell lysate and His-purified 
Western blots of whole infected cell lysate (left) and His-purified PvPDEβ-Mistic (right).  
Uninfected Sf9 cells were used as a control for both experiments.  The blots were probed with 
monoclonal mouse anti-His antibody at 1:3000.   
 
To test whether the purified PvPDEβ-Mistic contained cyclic nucleotide hydrolysing activity, PDE 
assays were performed.   In addition to testing eluted protein, the nickel sepharose beads used 
in the purification were utilised to test for residual activity that could not be eluted.  Uninfected 
Sf9 cells, treated identically to the AcPvPDEβ-Mistic infected cells, were used as a negative 
control.  Hydrolysis of both cAMP and cGMP was measured.  Purified PvPDEβ-Mistic did not 
show any activity in either the bead sample or the eluted sample for cAMP or cGMP.  This was 
unsurprising as the His-tag is located at the N-terminal end of the protein and the catalytic 
domain of PvPDEβ is located at the C-terminus, it was unlikely that the expressed AcPvPDEβ-
Mistic could result in an active enzyme (see figure 6.4) as the recombinant protein must be C-
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terminally truncated.  Curiously, the uninfected Sf9 bead sample showed high cAMP-PDE 
activity.  This could be due to residual insect cell PDEs becoming trapped in the bead sample.  
This was not seen in the infected cell sample, possibly because the baculovirus efficiently shuts 
down many host cell functions, potentially including cell signalling (Du and Thiem, 1997).   
 
 
Figure 6.4 The PDE assay with His-purified PvPDEβ-Mistic was negative  
Hydrolysis of cAMP (left) and cGMP (right) by PvPDEβ-Mistic or Sf9 cells, purified using nickel 
sepharose beads.  Samples from the eluted fraction and the residual activity on the beads was 
tested.  Activity is displayed as combined counts per minute (CCPM), a relative measure of 
scintillation.  The assay was performed in duplicate and the error bars represent standard error 
of the mean.   
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6.3 Discussion  
Two different approaches were attempted in order to generate recombinant PvPDEβ, using a C-
terminal 6x His-tag and also an N-terminal 10x His-tag in conjunction with a Mistic tag.  
Unfortunately neither method resulted in a purified active enzyme.  The AcPvPDEβ-6xHis 
construct initially produced a protein of approximately the correct estimated molecular weight, 
however it could not be detected following subsequent viral passages and the expression level 
was low.  This could have been due to instability of the His-tag or removal of the tag by the host 
cell machinery, which made it impossible to purify the protein.  The second approach AcPvPDEβ-
Mistic, used a more stable 10x His-tag and a Mistic-tag to help traffic the protein to the cell 
membrane.  There are currently no published results which utilise the Mistic-tag for Plasmodium 
proteins but it has lead to successful expression of a number of proteins in other organisms that 
were previously challenging to express (Xu et al., 2013).  Although in this case AcPvPDEβ-Mistic 
resulted in a potentially truncated protein, the Mistic-tag may be useful for expressing other 
integral membrane Plasmodium proteins.   
One potential application of the purified PvPDEβ-Mistic could be in generation of an antibody.  
Expression of PvPDEβ-Mistic does not result in a full length protein, however if the protein was 
proven by mass spectrometry to contain ~50 kDa of PvPDEβ then it could be significantly more 
immunogenic than the antipeptide antibodies.  One potential complication could be whether a 
PvPDEβ antibody would cross-react with P. falciparum PDEβ orthologue, which is much more 
experimentally tractable species as P. vivax cannot be cultured in vitro.  This could also be used 
in conjunction with the PDEβ-HA tagged line to validate the localisation studies in chapter 3.  The 
most conserved part of the protein is the catalytic domain which is C-terminal and will not be 
present on the truncated PvPDEβ-Mistic as the His-tag used for purification is at the N-terminus.  
However, mass spectrometery would provide the sequence of the protein and it can be 
determined from these results whether it is worth using the PvPDEβ-Mistic to immunise animals.   
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Chapter 7: General discussion 
7.1 Overview of the project 
One of the aims of this project was to investigate the potential of asexual PfPDEs as targets for 
lead compound development as novel antimalarials.  Through collaboration with Pfizer, a panel 
of human PDE inhibitors was made available to aid this objective.  In addition to drug target 
validation, this project aimed to advance knowledge of the cell biology of phosphodiesterases 
in the asexual blood stages of P. falciparum.  Phosphodiesterase β was the main focus of this 
project due to its predicted essential nature.   
Prior to this study there was very little known about PfPDEβ. All previous attempts to knockout 
the gene have failed (David Baker, unpublished).  Previous difficulty with generating reagents 
such as PDEβ specific antibodies, epitope tagged lines, recombinant protein and specific 
inhibitors has prevented progress in studying this molecule.  This project has aimed to develop 
novel tools to aid the study of malaria parasite phosphodiesterases and the cyclic nucleotide 
signalling pathway.   
7.2 Conditional knockdown of PfPDEβ  
There are four PfPDEs, three of which can be knocked out in asexual blood stages.  For two of 
the PDEs, the reason they could be genetically removed in asexual blood stages is that they are 
mosquito stage specific.  PDEγ has a role in sporozoite formation and infectivity (Cathy Taylor, 
Thesis) and PDEδ is essential for gametogenesis in P. falciparum (Taylor et al., 2008) and 
ookinete formation and motility in P. berghei (Moon et al., 2009).  Therefore disruption of these 
genes had no effect on blood stage proliferation and selection of transgenic parasites.  PDEα, on 
the other hand, is predicted to be most highly expressed in late trophozoites and schizonts 
according to mRNA transcript data (López-Barragán et al., 2011), however removing the gene 
did not lead to any obvious phenotype in in vitro culture (Wentzinger et al., 2008).  There have 
been several attempts to knock out PDEβ in both P. falciparum (David Baker, unpublished) and 
P. berghei (Oliver Bilker, personal communication), none of which have been successful.  
Therefore one of the major aims of this study was to attempt to develop a conditional 
knockdown system for PDEβ.   
This project commenced before the initial development of the DiCre system and therefore, at 
the time, the DD-system was the only conditional knockdown system available to attempt.  PDEα 
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was also included in this experiment, primarily as a positive control as it is not essential.  Both 
the pPDEα-HA-DD and pPDEβ-HA-DD plasmids were successfully generated and used to 
transfect P. falciparum parasites.  Unfortunately, despite repeated attempts the PDEβ-HA-DD 
plasmid did not integrate into the parasite genome.  Southern blotting of the individual separate 
transfection experiments after four rounds of drug cycling indicated that the plasmid had 
formed stable episomes containing multiple copies of the plasmid.  This phenomenon has been 
reported previously, particularly in cases where the presence of the plasmid was detrimental to 
the health of the parasite (O’Donnell, 2001).  As the pdeβ locus was subsequently successfully 
epitope tagged with the HA-tag, it is possible that the DD-tag is in some way disadvantageous to 
the parasite, even in the absence of shield-1.  A PDEα-HA-DD cloned line was successfully 
produced, however the presence or absence of shield had no effect on parasite growth and the 
HA-tag could never be detected with an anti-HA antibody.  The reasons for this are unknown but 
it could be that the DD-tag is preventing appropriate expression or trafficking of PDEα.  Ablation 
of PDEα would not be detected as the protein is not essential in vitro and there is no specific 
antibody that could detect a change in expression compared to the parental line.  Regrettably, 
generation of conditionally regulated PDE-DD proteins was unsuccessful.   
Towards the end of this project, the DiCre system was adapted for use with P. falciparum.  Using 
this system, PDEβ became one of the first proteins to be targeted by conditional Cre-mediated 
genomic excision, in collaboration with Mike Blackman.  The first strategy tested involved 
excision of the 3’ UTR of pdeβ by inserting a pair of loxP sites at either end of this region.  This 
approach has been effectively applied to the conditional knockout of essential genes in T. gondii 
(Andenmatten et al., 2013).  Unfortunately, P. falciparum appears to be able to stabilise mRNA 
in this scenario, perhaps using cryptic polyadenylation functions in several genes tested (Mike 
Blackman, personal communication; Collins et al. 2013).  This also seems to be true for PDEβ as, 
although the plasmid integrated and expression of the HA tag could be detected, 3’ UTR excision 
does not lead to a decrease in the amount of protein expressed.  As a result, a second construct 
was generated that aimed to induce excision of a fragment of the gene by insertion of the 5’ 
loxP site into an intron within the predicted PDE catalytic domain.  This construct has been 
successfully generated and used to transfect a PreDiCre P. falciparum line, generated in the 
Blackman lab, which already contains the DiCre recombinase gene.  At the time of writing, the 
PDEβ-IntronLoxP parasite line was undergoing drug cycling in an attempt to create a stable, 
integrated line.  However, a positive IFA result with the HA antibody has indicated successful 
integration of the plasmid. Colleagues in the Baker lab are currently carrying out rapamycin-
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mediated cleavage and detecting excision using PCR as well as monitoring blood stages for any 
growth phenotype.  
Generating parasite lines with integrated plasmids has traditionally been extremely time 
consuming.  Very recently, there have been reports of major improvements in the ability to 
target specific areas of the P. falciparum genome using the CRISPR/Cas9 (clustered regularly 
interspaced short palindromic repeats) system.  Briefly, CRISPR/Cas is used by bacteria as an 
adaptive immune defence system and has been adapted as an efficient genome modification 
tool.  CRISPR RNAs (crRNAs), complexed with CRISPR associated (Cas) proteins result in double 
stranded DNA breaks of specific gene sequences.  For genome editing, single guide RNAs 
(sgRNAs) can target the Cas9 protein to a particular locus of interest, lead to double strand DNA 
breaks, allowing insertion of a linearised plasmid using host cell repair machinery (Hsu et al., 
2014; Mali et al., 2013).  For P. falciparum this technique can generate stable parasite lines in a 
much shorter time frame than previously used methods as linear DNA can be transfected, 
eliminating the need for time consuming drug cycling (Ghorbal et al., 2014).  This system will be 
extremely useful in generating new parasite lines to study all aspects of P. falciparum, including 
further characterisation of the PfPDEs.  The following discussion sections include potential 
future work to continue this project, the CRISPR/Cas9 system could potentially be utilised to 
create many more transgenic parasite lines.  Additionally, if the current PDEβ-IntronLoxP proves 
inefficient, CRISPR/Cas9 could be used to insert a LoxP site into a different region of PDEβ, or in 
the 5’ non-coding region upstream of the gene to remove the entire gene.   
7.3 Temporal and spatial expression of PfPDEβ 
Despite not leading to a conditional knockdown of PDEβ, the attempt to create rapamycin 
induced 3’ UTR removal did result in a PDEβ-HA stable parasite line.  In this line the PDEβ protein 
could be detected using monoclonal anti-HA antibodies.   
Prior to this study, most of the knowledge of PDEβ was based on what could be inferred from 
the gene sequence.  For temporal expression,  mRNA transcript data suggested that the levels 
of PDEβ peak in late trophozoites and schizonts (López-Barragán et al. 2011; Ross Cummings, 
Thesis).  Additionally, Ross Cummings performed PDE assays on parasite lysates at different life 
cycle stages.  He found that in asexual blood stages, both cAMP and cGMP PDE activity peaked 
in schizonts.  Late ring stages and late trophozoites also had significant levels of PDE activity, 
with early trophozoites containing least cyclic nucleotide hydrolytic activity.  In general the level 
of cGMP-PDE activity was higher than cAMP-PDE activity and this was most pronounced in 
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schizont and late ring stages.  Work during this project has confirmed that PDEβ is most highly 
expressed in schizonts (figure 4.2).  Signal obtained in immunofluorescence assays indicated that 
mid-trophozoites contain the highest levels of PDEβ protein, with levels decreasing in very late 
schizonts (figure 4.3).  It would also be beneficial to perform further western blots on tightly 
synchronised PDEβ-HA parasites over a greater number of time points, particularly around the 
schizont stages to further investigate the apparent decrease in PDEβ protein expression in very 
late schizonts.  If possible it would also be interesting to perform western blotting on merozoite 
stages.  As ring stages contain cyclic nucleotide hydrolytic activity and PDEβ-HA has not been 
detected in this stage, it is possible that PDEα is the major PDE at this stage.  This would also fit 
with the observation that cGMP-PDE activity is predominant at this stage as PDEα has been 
shown to be cGMP specific.  To fully dissect the temporal expression of the asexual PfPDEs, it 
will be necessary to generate a PDEα-tagged line and/or a PDEα specific antibody.  A very 
preliminary experiment looking at the stage specificity of Pfizer PDE inhibitor induced killing of 
P. falciparum in vitro has implied that addition of the drugs to ring stages or schizont stages leads 
to rapid death of the parasites.  Addition of the drugs to trophozoites does not result in death 
of the parasites until later in the cycle (figure 5.20).  This would fit with the PDE activity data, 
however the lack of PDEβ detected in ring stages is surprising considering this result.  From 
mRNA transcript data, none of the four PDEs are predicted to be expressed in ring stages.  
Potentially the highly PDEβ specific Pfizer inhibitors such as PF-05225388, PF-00394183 or PF-
00388991 on both the 3D7 and PDEα-KO lines at different life cycle stages could be used to 
determine which PDE is predominantly responsible for this activity.  It is also important to 
consider the possibility that there may be off target effects of the inhibitors.   
Before this study, PDEβ was assumed to be an integral membrane protein on the basis of six 
predicted transmembrane domains in its deduced amino acid sequence and due to the fact that 
all previous studies have identified PfPDE activity in the membrane fraction of parasite lysates 
only (Yuasa et al. 2005; Wentzinger et al. 2008; Ross Cummings, Thesis).  This has been 
confirmed by solubility assays during this project (figure 4.1), as well as PDE assays on 
sequentially solubilised parasite lysate fractions (figure 5.11).     
The PDEβ-HA tagged line was also used to determine spatial expression.  Prior to this study, the 
only implied subcellular location of PDEβ was the bioinformatics prediction that the catalytic 
domain projected into the PV lumen, using hidden Markov topography (Gould and de Koning, 
2011).  Through colocalisation studies in this project, this seems to be incorrect and that PDEβ 
colocalises with markers of the endoplasmic reticulum (ER).  Three lines of evidence point 
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towards PDEβ being located in the ER.  Firstly, PDEβ-HA strongly colocalises with the ER marker 
BiP (figure 4.4).  This is consistent in all life cycle stages tested which also implies that PDEβ does 
not change location throughout the P. falciparum asexual blood stage life cycle but remains 
within the ER.  Interestingly, PDEβ-HA does not colocalise with ERD2, suggesting that its function 
is ER-specific and it is not trafficked through the Golgi.  Secondly, PDEβ-HA partially colocalises 
with MSP1 before it becomes merozoite surface associated, presumably as it is trafficked 
through the ER.  Thirdly, PDEβ-HA colocalises with ER-Tracker, a commercial ER stain.  This signal 
was very weak as the stain is predominantly for use with live cell staining.  It would be extremely 
useful to produce a PDEβ-GFP tag to enable live cell studies of PDEβ.  It has been known for 
proteins to be mislocalised to the endoplasmic reticulum as a result of C-terminal epitope 
tagging.  In mammalian cells, a KDEL (lysine-aspartic acid-glutamic acid-leucine) motif is 
important for retention of certain proteins within the ER (Cancino et al., 2013).  In P. falciparum, 
a SDEL (serine-aspartic acid-glutamic acid-leucine) motif has been shown to play a homologous 
role, and indeed PfBiP contains this sequence at its C-terminus (Kumar et al., 1991).  However, 
this seems to be more important for soluble proteins, plasmepsin V, an integral membrane 
protein that is also localised to the ER does not contain the SDEL sequence (PlasmoDB).  PfPDEβ 
also does not contain the SDEL motif.  ER retention of membrane proteins appears to be more 
complex, with several different mechanisms proposed such as lysine-lysine-X-X sequence at the 
C-terminus (Jackson et al., 1990) or the retention factor p11 with the sequence 
(histidine/lysine)-X-lysine-X-X-X (Renigunta et al., 2006).  Additionally, multi-spanning 
transmembrane proteins often use the first TM domain in place of the signal peptide (Rapoport, 
2007).  No ER integral membrane retention factors have been described for P. falciparum.  It 
cannot be fully ruled out that PDEβ-HA is being mislocalised to the ER, however as it is an 
essential protein, it must be able to perform appropriate functions in the ER as the parasites do 
not have a growth phenotype.  One possibility is that a portion of PDEβ is being targeted to the 
appropriate subcellular localisation and the HA-tag is cleaved (resulting in no signal at the 
appropriate localisation).  To conclusively prove that PfPDEβ is an ER resident protein, a PDEβ 
specific antibody would need to be generated.  Assuming that PfPDEβ is localised to the ER, it 
would also be interesting to determine whether the catalytic domain projects into the cytoplasm 
or the ER lumen.  This could be determined by immunogold labelling electron microscopy.  As 
future work it would also be very interesting to generate a PDEα-HA tagged line, (potentially in 
combination with a DiCre mediated conditional knockdown system) to determine the temporal 
and spatial localisation of PDEα.   
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A major feature of cyclic nucleotide signalling pathways in mammalian systems is the presence 
of signalosomes, complexes of signalling associated molecules that are spatially organised to 
result in maximum efficiency of the response.  In mammalian systems, PKA signalling molecules, 
including PDEs, are often complexed with A-kinase anchoring proteins (AKAPs) and PKG 
signalling with PKG interacting partner (GKIP) proteins (see chapter 1.10.2).  In P. falciparum, 
only one putative PfAKAP (PF3D7_0512900) protein has been identified on the basis of sequence 
homology.  PfAKAP antipeptide antibodies (through collaboration with Anaïs Merckx) were 
tested in dual staining IFAs with PDEβ-HA and no colocalisation was observed.  Dual staining IFAs 
were also performed with the commercial PKG antibody on PDEβ-HA, unfortunately the signal 
was too weak to infer any colocalisation.  However, previous work in the group had identified 
partial overlap between PfPKG and the ER marker PfBiP.  It is therefore likely that this association 
would hold with PKG and PDEβ-HA.  However preliminary data using immunoprecipitation and 
subsequent western blotting of PDEβ-HA did not co-precipitate PKG (Oriana Kreutzfeld, LSHTM, 
MSc Project).  It would be worthwhile to perform colocalisations and co-immunoprecipitations 
with other known cyclic nucleotide signalling protein such as PKA regulatory and catalytic 
domains, and the cyclases to try to identify potential signalosomes in P. falciparum.  
Interestingly, a study into the Rab GTPases, important regulators of vesicular trafficking, 
reported that the catalytic domain of PKA (PKA-C) is recruited to PfRab5A+ and PfRab7+ vesicles.  
The authors suggested that these Rab proteins may act as pseudo-AKAP proteins (Rached et al., 
2012).  A comparison may also be drawn to mammalian Rab4 and Rab11A which are able to bind 
D-AKAP2 and recruit PKA to endosomes, where it regulates transferrin receptor recycling (Eggers 
et al., 2009).    
An emerging role of cyclic nucleotide signalling in malaria parasites is in calcium release or 
mobalisation, which in itself has a link with the endoplasmic reticulum.  As mentioned in chapter 
1.10.1, calcium ions are important secondary signalling molecules.  The ER is thought to be one 
of the major Ca2+ stores within the parasite cell (Passos and Garcia, 1997).  IP3 signalling leads to 
release of Ca2+ from the ER, resulting in a rise in the cytosolic calcium concentration (Ma et al., 
2000).  As discussed in chapter 1.12, there are many overlaps between cyclic nucleotide and 
calcium signalling including, but not limited to; microneme secretion in sporozoites (Mota et al., 
2002), motility in merozoite (Lasonder et al., 2012) and ookinete (Moon et al., 2009) stages, 
gametocyte activation (McRobert et al., 2008), egress in schizont stages (Dvorin et al., 2010; 
Taylor et al., 2010) and phosphoinositide metabolism (Brochet et al., 2014).  One potential 
function of PDEβ in these instances could be to keep cyclic nucleotide levels low to prevent 
inappropriate calcium release from the ER.   
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In one particular example, a recent study by Collins et al. into PKG mediated merozoite secretory 
organelle discharge and egress, found that addition of zaprinast (a PDE inhibitor) to very late 
stage schizonts, lead to discharge of the secretory organelles and resulted in premature egress 
of the merozoites.  Usually, BAPTA-AM (a calcium chelator), prevents merozoite egress.  Notably 
in this study, this egress block could be overcome by addition of 75 µM of zaprinast.  The authors 
hypothesised that stimulation of PfPKG by zaprinast (through inhibition of PDE activity and 
elevation of cGMP levels) may lead to increased levels of calcium signalling, resulting in egress 
(Collins et al. 2013).  Much more work is necessary before the precise roles of PDEα and PDEβ 
can be elucidated in egress, however the characterisation of highly specific PDEβ inhibitors 
should be able to help pinpoint whether this phenotype is PDEβ specific.   
7.4 Biochemical properties of PfPDEβ 
One of the major aims of this project was to determine the cyclic nucleotide specificity of PDEβ.  
It was previously assumed to be a dual specific PDE on the basis that PDEα is cGMP specific 
(Yuasa et al., 2005), and that in a PDEα-KO line, both cAMP- and cGMP-PDE activity was present 
(Wentzinger et al., 2008).  As PDEβ is the only other predicted asexual blood stage PDE, it was 
assumed that it was able to hydrolyse both cyclic nucleotides in the absence of PDEα.  In 2004, 
Zhang et al, proposed a mechanism for cyclic nucleotide selectivity by the mammalian PDEs.  An 
invariant glutamine was identified as key to detection of the purine moiety in the cyclic 
nucleotide.  The surrounding residues anchor the glutamine in a different orientation for cAMP 
than cGMP, and in dual specific PDEs, a nearby histidine residue allowed the glutamine to shift 
between the two conformations.  This was termed the ‘glutamine switch’ (Zhang et al., 2004).  
However this has been shown to be significantly more complex than previously thought, and not 
all the PDE families conform to this theory (Ke et al., 2011).  As part of his thesis (2005), Ross 
Cummings modelled the active site of PDEβ (and PDEδ) using the Deep View Swiss-PdbViewer 
(v3.7).  Using this he proposed that PDEβ was dual specific as the invariant glutamine (Q1052 in 
PfPDEβ) would be able to rotate freely, as proposed by Zhang et al.  Ross Cummings also 
proposed that PDEδ was a cGMP specific PDE using this modelling method, which was later 
confirmed by Taylor et al. in 2008.  The current study has provided the first direct evidence that 
PDE beta has dual specificity using immunoprecipitated PDEβ-HA in a PDE activity assay.  PDEβ-
HA is able to hydrolyse both cAMP and cGMP.  With this enzyme it will now be possible to 
determine the specific kinetic properties of PDEβ including specific substrate affinity by 
determining the Km (the Michaelis constant, the substrate concentration at which the reaction 
rate is at half-maximum) of cAMP and cGMP hydrolysis.   A further point to note is that for future 
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PDE assays it would be highly useful to perform a Bradford assay on the samples to be able to 
equate the amount of protein to the PDE activity.  This will be particularly important when 
calculating the kinetic constants.    
PDEs are dependent on two divalent metal cofactors.  All PDEs are predicted to contain a tightly 
bound Zn2+ ion, coordinated by conserved histidines and aspartates (Wang et al., 2005).  This ion 
has been described as structurally important and essential for enzyme function (Conti and 
Beavo, 2007).  The second metal ion binds less tightly to the enzyme, several divalent cations 
are able to support catalysis in vitro, but it is predicted that manganese or magnesium are usually 
the relevant physiological ion (Houslay et al., 1997).  One possible explanation for lower affinity 
binding is the presence of five water molecules that coordinate this ion with other residues (Xu 
et al., 2000).  Ross Cummings found that Mg2+ supported the highest level of PDE activity in 
asexual blood stage parasite lysates of 3D7.  Interestingly recombinant PDEα shows greatest 
activity when supplemented with Mn2+ (Yuasa et al., 2005).  It is possible that Mn2+ is the most 
potent activator of PDEα and Mg2+ is for PDEβ.  This could explain the discrepancy between 
recombinant PDEα enzyme and parasite lysate metal ion dependent activity.  With the 
immunoprecipitated PDEβ-HA is should be possible to determine if this is the case by 
supplementing the buffer with different metal ions.   
7.5 PfPDEα 
PDEα was not the main focus of this project, however to fully understand the role of 
phosphodiesterases in the context of the cyclic nucleotide signalling pathways in malaria it is 
essential to gain a better understanding of all the PDEs.  PDEα is not essential in asexual blood 
stage culture as it has been successfully knocked out.  This PDEα-KO line has a subtle growth 
phenotype.  Wentzinger et al., noted that ring stages appear earlier after synchronisation than 
for the parental line.  This study also showed that the line reaches a higher parasitaemia, more 
quickly than all other parasite lines tested.  This phenomenon was discussed in greater detail in 
chapter 3.3.2.  However the phenotype is interesting and needs further investigation to validate 
that it is PDEα specific.  For future work it would be important to generate a second PDEα-KO 
line.  Even if this line does not have a growth phenotype it would be extremely interesting to 
also put PDEβ under DiCre conditional knockout control (if possible) to create a line that would 
have no asexual PDEs when excision is induced.  It would also be important to generate an 
antibody against PfPDEα.  Ideally a PDEα specific antibody would also be produced.  As a 
recombinant catalytic domain of PDEα can be expressed it should be possible to use this to 
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generate an antibody.  However it would also be useful to create an HA- or GFP-tagged line, 
although the HA tag could not be detected in the PDEα-HA-DD line the reasons for this were 
unknown.  It could be that the DD tag was preventing expression of the protein.  An HA- or GFP-
tag alone could feasibly be less detrimental to the parasite.  Other potential ways to investigate 
the growth rate phenotype of PDEα-KO would be to complement the gene or perform whole 
genome sequencing of the parasite compared to WT.  Even if the phenotype is not PDEα specific, 
whole genome sequencing would be informative to determine what is different compared to 
the WT and may point towards another gene that is responsible.  It could also determine the 
reason why PDEα-KO does not produce gametocytes.   
Additionally any future transgenic studies should be performed on gametocyte producing lines 
to confirm that PDEα does not have a role in gametocytogenesis.  It would also be worthwhile 
to create a P. berghei knockout to confirm that PDEα is truly indispensable and not an artefact 
of culture conditions.  A P. berghei knockout could also determine if PDEα has a function in any 
mosquito or liver stages of the lifecycle.    
7.6 PfPDEβ as a target for antimalarial drug discovery 
One approach for drug development for infectious diseases has relied on targeting proteins or 
pathways that are absent in their mammalian host, this is called the ‘silver bullet’ paradigm.  
Eukaryotic parasites such as Plasmodium spp. are genetically similar and metabolic pathways 
are highly related to those of the human host.  This can make drug development according to 
the silver bullet theory challenging.  However, the field is shifting towards more of an ‘inverted 
silver bullet’ approach.  Established drug targets in humans are explored and the current drugs 
repurposed through rational drug design to become highly specific for the pathogen and not the 
host.  Phosphodiesterases represent a potential avenue to explore in the context of 
antimalarials.  Additionally, PDEs in members of the kinetoplastid family such as Trypanosoma 
brucei, the protozoan causative agent of African sleeping sickness, are currently being explored 
as potential drug targets (Amata et al., 2014; Jansen et al., 2013).    
Phosphodiesterases are established drug targets for many human diseases.  Despite the large 
number of members of the PDE family in mammalian cells, PDE inhibitors can be highly specific 
for their target.  There is therefore the potential to develop inhibitors that are exclusively specific 
for the PfPDEs.  Two PfPDEs are essential at key stages of the parasite life cycle that have the 
potential to be targeted with antimalarials.  PfPDEβ, as explored in this project, is essential for 
asexual blood stage growth, the cause of clinical pathology of malaria.  PfPDEδ is essential for 
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transmission to the mosquito.  Compound that target these enzymes have the potential to 
prevent clinical disease and block onward transmission.   
This project has demonstrated that specific PDEβ inhibitors are lethal to the parasite in vitro with 
IC50s comparable to current clinically available drugs such as chloroquine and artemisinin.  This 
is a first important step in validating phosphodiesterase inhibitors as potential antimalarials.  The 
compounds PF-01273175, PF-05184913, PF-05225388, PF-00394183 and PF-00388991 should 
be taken forward as lead compounds for further medicinal chemistry development.  Animal 
studies using P. berghei infected mice are an essential step to test the validity of these 
compounds as effective drugs.  Bioavailabilty, amongst other complex factors in the setting of 
infection of whole organisms may be limiting.  If the compounds are not active in mice then 
there would be several other experiments to attempt.  It is possible that the compounds are 
highly specific for PfPDEβ and are less active against P. berghei PDEβ.  To combat this a P. berghei 
strain could be modified to replace the PbPDEβ with PfPDEβ.  It would also be beneficial to 
perform pharmacokinetic studies on the compounds to determine absorption and half life rates 
to ensure that the drug is available to the parasite long enough for drug activity.  If the 
pharmacokinetics are unfavourable, a chemistry programme could be carried out to improve 
this whilst retaining potency against P. falciparum in vivo. 
Of the 14 PF- compounds provided by Pfizer, seven have IC50s of less than 160 nM against the 
parasite.  Of these, five were shown to be potent inhibitors of PDE activity within the parasite.  
It is likely that the other two compounds are guanylyl cyclase inhibitors and also have the 
potential to be useful in future studies on the cyclic nucleotide signalling pathways.  Three of 
the compounds, PF-05225388, PF-00394183 and PF-00388991, which are based on the human 
PDE5 inhibitor series, have PDEβ specific activity and are active against the parasite at IC50s of 
between 5 and 82 nM.  Compound PF-05225388 is over 5000 times more potent than zaprinast 
against the parasite.    
In summary, this project has demonstrated that PfPDEβ represents a novel target for 
antimalarial drug development.  Inhibitors exist within current human drug libraries that are 
highly potent and specific for PfPDEβ.  These compounds not only inhibit enzyme activity but 
also kill the parasite at concentrations comparable to those of current antimalarials.  The 
pathways that PfPDEβ is involved with are essential for parasite survival.  The results of this 
thesis are to be used in an application to the Tres Cantos Open lab to explore GSK compound 
libraries for PDEβ inhibitors.  In addition, this study has also begun to develop the tools necessary 
for further study of the role of the PfPDEs in the context of malaria infection, such as the PDEβ-
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HA tagged line which can provide active enzyme for an effective PDE activity assay developed 
for this project.  Previously little was known about the biology of PfPDEβ but this study has 
confirmed its dual specific cyclic nucleotide activity and tentatively identified its subcellular 
location as the endoplasmic reticulum.  Work to generate a conditional knockdown of PfPDEβ is 
ongoing as the detailed biology of this essential drug target still largely remains elusive, however 
this study has paved the way for future insights.     
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Appendix 2: Antipeptide antibodies 
PDEα 
MMDTKVDQTIQPKFYVDKKLSKSFDNKLDEDIFNYPFKKESFLKSEKFSFEHTKDSLWKCIKEK
AKKKSDMEYFNCVNNLCCKFICTIRKYVKYFLYLKDSSYEIYNINLYNNNNMNIINNKNITNNK
NITNNINNSFSNDYINYNHNYNHLNNSSSSKHNNYNVNNIDEKNIKNDYNTYHNIYEQIFFKYN
PSFYEYLMFTLMKKLIHYKNYIFNKTKKINNSYNNNDIKNIDGFLIFQNINFEEIFLNTFYSSF
PFKLFLHSLYMIFICFIYFVVLYFMLLKKIYTHPFIFHLSVLKFLFDIIFFLSFILYPLFLRLK
RIDKIIYSSYISSYIFVCVTFLYSFIIFKCSSYSVKMNSNTYQNNFVFQNMLFLLINIIYICIF
CFLKNYMILYSFLYNCRFSIFCILFIFLYYYLFFSLDFYRIIHLPLDNFFFPFLCFLFFSFLFI
FKIIMSLYYEYVYEKKYRILFVKKNNLIEKRITKRKNTNINNAYFTKYFSIDNTIPTSPIEDIL
NNFKHILETINIIEENPNHNLTTNIMKIKEKIKNCDNILRTKNINQVQIGKYRKFEKVYNIWCL
DKMYLNYPLNQEETKSFLSNSLNRISFNSFSNMHSLLSSKFQEHYNDIYDWNGNIENIYKANTF
ISIGYKLLYPLGVLEANFDKEKLKKFLFRICSYYNDIPYHTSLHAAQVAHFSKSMLFMLDMNHK
ISAIDEFCLHISSLCHDTGHPGLNNYFLINSENNLALTYNDNSVLENYHCSLLFKTLKNPNYNI
FEHYPYHIFISCKKNIIKAILSTDMKNHFEYISDFRTSKEFIDYDNLSNDQIWQIFCLILKASD
IGHSTLEWNKHLEWTLKINEEFYLQGLLEKSLNIQNSFLCDINTMNKLALSQIDFLKHLCIPLF
NELNYICKNNDVYTHCIQPIENNIERWESHKNDNQNLGLHEKYKEENLLSKLELIKFE 
 
Sequence Length: 954 amino acids 
 
 Peptide Sequence Sample Number 
CGGSDFRTSKEFIDYDNLSND 4608 4609 
CGGESHKNDNQNLGLHEKYKEENLLSK 4668 4669 
 
 
PDEβ 
MGKVEDFEEHNKNSNQDIEKNVGNRRRSNSNTINDQNENINKNKAIVTKKSFIMNLLRNKEKTK
VEQNDDNIVENMNERKNSLKDMSLISDNVEKDNKVKKKNSYLKNLNILGKTKSIEFSFPSNILN
NARKNIQEIDEESPLTSNSLRTYKEGISEDNRQNQRNADNNSLNWSTSNINTECNSEFSNIEVK
VLKTEKSNSVKLKDNIIDIPNDKNKKELQEINIKNTNKDSYKNLYLKVRNSISFNDNIKIDDEN
KNDKNNIIDNYNNYDDINSSNEITIDGLNHDDNIKKIDNINNFDNKHDDNLQDHHQNHVHHTFR
SSRKSLGNIKSNNTNIKLNNDKNFDTNINKRSILEKYFYDIWKRNITIKKEIYSLSSKNPPNPL
KSTFADACQNESSEKELLKKIPLKFNDDSIESLYVLNLNNWISSRMIIIGIVMLILSFIIWPLT
TWSLKTSTWGRETYIIILFHTLMAINTLILIFFIIIGSTELCKYSECMSYVLFSLMVALWGLWN
IAIGLTLEYNPNLSEMPTTTYELEMIYVLTYIYGFLPLVIIDIFFPSRTKYNWIIHLIFIFLNS
SSIILVGSAKPDFVPEIYVVFRILAYTTLCIFLYIGSYTSELQIRYVFYNLLVAGYKLDKIESD
MKNKTSNKKISTGIEDLINMLKECTKVILELENETDTNFNVHTKTSYCSNILEQCLSTLTKSDN
LYNIDYNVLENPENKKFIEAYVSKSKSNFAGEEVPKGVDFKLNKSFSNNDCISTDKVDLDKKQI
KKFLKQINISQLTKMIQFIDNKLLSDWDFNCLTYFDESEYPFFDINLSLICTIDHNIPINIIIN
FLCFVEKQYNNVPYHNTIHATMVTQKFFCLAKKLGIYDDLEYKIKLVMFISGICHDIGHPGYNN
LFFVNSLHPLSIIYNDISVLENYHASITFKILQLNQCNILKNFSEKDFRMMRSYIIELILSTDM
KHHFEIISKFRIRRENEDFDYIKNSDDLLILTKMIIKSADISHGSVSWSEHYCWCQRVLSEFYT
QGDEELKNKMPLSPLCDRTKHNEVCKSQITFLKFVVMPLFEELSHIDNNKFIKSFCLKRLNSNC
IMWDTLMKEEKTIEVYDPAAVKLKDKKKKKVDKKKKSYIDLTLFFIKNVSD 
 
Sequence Length: 1139 amino acids 
 
 Peptide Sequence Sample Number 
CGGRIRRENEDFDYIKNS 4608 4609 
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Appendix 3: Negative control IFAs 
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Appendix 4: Results of the 48 hour hypoxanthine incorporation assays 
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Appendix 5: Sequence of the Mistic-tag 
 
A 5.1 DNA sequence of the 10x His-tag followed by the Mistic-tag and a glycine serine linker 
with a TEV cleavage site 
ATGCACCACCATCATCATCACCATCATCACCATGGTACCATGTTTTGTACATTTTTTGAAAAAC
ATCACCGGAAGTGGGACATACTGTTAGAAAAAAGCACGGGTGTGATGGAAGCTATGAAAGTGAC
GAGTGAGGAAAAGGAACAGCTGAGCACAGCAATCGACCGAATGAATGAAGGACTGGACGCGTTT
ATCCAGCTGTATAATGAATCGGAAATTGATGAACCGCTTATTCAGCTTGATGATGATACAGCCG
AGTTAATGAAGCAGGCCCGAGATATGTACGGCCAGGAAAAGCTAAATGAGAAATTAAATACAAT
TATTAAACAGATTTTATCCATCTCAGTATCTGAAGAAGGAGAAAAAGAAGGTACCGGCGGAGGC
TCGGGCGGCGGCTCAGAAAACTTGTACTTTCAAGGATCC 
 
 
A 5.2 Amino acid sequence of the 10x His-tag followed by the Mistic-tag and a glycine serine 
linker with a TEV cleavage site 
MHHHHHHHHHHGTMFCTFFEKHHRKWDILLEKSTGVMEAMKVTSEEKEQLSTAIDRMNEGLDAF
IQLYNESEIDEPLIQLDDDTAELMKQARDMYGQEKLNEKLNTIIKQILSISVSEEGEKEGTGGG
SGGGSENLYFQGS  
 
10x His-tag – shown in bold 
Mistic-tag – shown highlighted 
Glycine serine linker – shown underlined 
 
Theoretical pI/Mw: 5.26 / 16.1KDa 
 
 
 
